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Abstract
CD59 is a GPI-anchored protein found in membrane microdomains known as lipid 
rafts. It is a complement regulator protein, which blocks the formation of the 
membrane attack complex by inhibiting binding of C9 to the C5-8 complex. Human 
CD59 has also been described as a co-stimulator of T cell activation. The aim of this 
project was to analyze the role of CD59 on T cell activation in vivo. For this purpose, 
anti-viral CD4+ T cell responses were analyzed in mice deficient in the mouse 
analogue of CD59; CD59a. Infection with recombinant vaccinia virus (rVV) and 
influenza virus, resulted in stronger virus-specific CD4+ T cell responses in Cd59a -/- 
mice compared to WT mice. This effect, which indicates that CD59a downmodulates 
antigen-specific T cell activity, was found to be complement independent. Experiments 
were performed to investigate the effect of CD59 expression on human CD4+ T cells. 
Blocking CD59 increased proliferation of the cells in vitro indicating that CD59 might 
similarly downmodulate human CD4+ T cell activity. Using mouse T cells, 
mechanisms underlying the effect of CD59a on CD4+ T cell activity were investigated. 
Results of these studies indicated that downmodulation of T cell activity through 
CD59a requires engagement of CD59a with a ligand expressed on APCs.
To assess the biological consequences of CD59a deficiency, the extent of 
immunopathology induced following infection with influenza virus was compared in 
WT and Cd59a-/- mice. Immunopathology was exacerbated in Cd59a-/- mice, 
correlating with increased numbers of neutrophils and CD4+ T cells in infected lungs. 
When complement was inhibited, lung-infiltrating neutrophils in Cd59a-/- mice were 
much reduced while numbers of infiltrating-CD4+ T cell remained unchanged. These 
results demonstrate that CD59a is more than a regulator of complement but can in fact, 
alter both the innate and adaptive immune responses using both complement 
dependent and independent mechanisms.
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Chapter 1- Introduction
1.1. The Complement System
Complement is an arm of the innate immune system, providing a rapid and efficient 
means for opsonising or killing pathogens and triggering inflammation. The 
complement system is made up of a large number of distinct plasma proteins produced 
mainly by hepatocytes but also by different tissues and cells including macrophages 
and gut epithelial cells. These proteins are activated by a variety of agents and their 
activation proceeds in a cascade fashion leading to lysis. In this way, the activation of 
a small number of complement proteins at the start of the pathway is highly amplified 
by successive enzymatic reaction, resulting in the rapid generation of a large 
complement response.
Complement activation can be divided into three pathways classical, alternative 
and lectin pathway. These pathways depend on different molecules for their initiation, 
but they converge in the last steps of the cascade (membrane-attack complex; MAC).
The classical pathway is activated by antibody opsonization of pathogens 
(binding of antibodies to specific epitopes of surface proteins) and is therefore linked 
to the adaptive immune system. This pathway is initiated by the binding of C lq to a 
specific part of the antibody molecule. Clq is part of the Cl complex, which 
comprises a single Clq molecule bound to two molecules each of C lr and C ls 
(Schumaker et al., 1976). Upon Clq binding to an antibody-antigen complex, the
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homologous C lr and C ls subcomponents are converted into catalytically active 
species to generate an active serine protease triggering the first step of the classical 
pathway of complement activation (Rivas et al., 1994). Then, C ls cleaves C4 to 
produce C4b, which binds covalently to the surface of the pathogen (Muller-Eberhard 
and Lepow, 1965). The formation of an active C4b site creates the binding site for C2. 
Cleavage of C2 by C ls results in the formation of a large fragment, C2a, that becomes 
firmly associated with C4b and a smaller fragment C2b. The complex, C4b2a, remains 
on the surface of the pathogen as the C3 convertase of the classical pathway (Figure 
1.1 A).
The lectin pathway is initiated by a component which is a serum lectin, Mannan 
Binding Lectin, MBL, which binds pathogen surface molecules containing mannose 
residues. MBL in the lectin pathway is equivalent to Clq in the classical complement 
pathway (Lu et al., 1990). When the MBL complex binds to a pathogen surface, 
MASP-1 and MASP-2 (MBL-associated serine proteases; equivalent to C lr and C ls of 
the classical pathway) are activated to cleave C4 and C2 and form C4b2a, the C3 
convertase (Thiel et al., 1997; Weis et al., 1992)(Figure 1.1 A). In contrast, the 
alternative pathway is initiated by spontaneous hydrolysis of C3. C3 has been shown to 
contain a thioester bond which reacts with almost anything that exposes -OH or -NH2 
groups, by spontaneously "ticking over"(Hostetter et al., 1982; Lachmann and Hughes- 
Jones, 1984; Pangbum and Muller-Eberhard, 1980). In this arm of complement, 
spontaneous low-level cleavage of C3 converts inactive native C3 to a functionally
i
active C3b-like molecule referred to as C3(H20) which, in the presence of Mg , binds 
the plasma protein factor B, that is subsequently cleaved by factor D, leading to the 
generation of a distinct C3 convertase designated C3b,Bb (Fearon and Austen, 1975a).
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The resulting C3 convertase is stabilized by the binding of properdin (P) that increases 
the half-life of this convertase (Fearon and Austen, 1975b)(Figure 1 .IB). All three 
pathways converge at the enzyme activity of the C3 convertase. The function of the 
initial C3 convertase is to produce nascent C3b and to deposit C3b on the surface of 
surrounding particles. Alternatively C3b can become bound to C3 convertase resulting 
in formation of C5 convertase (C4b2a3b for classical pathway or C3bBbC3b for 
alternative pathway) which cleaves C5 into C5a and C5b, the first known as the most 
potent of the anaphylatoxins (Daha et al., 1976; Hugli and Muller-Eberhard, 1978; 
Medicus et al., 1976).
One of the important effects of complement activation is the assembly of the 
terminal components of complement to form the MAC. The MAC constitutes a 
supramolecular organisation where one molecule each of C5b, C6 , Cl, and C8  form 
C5b-8 that catalyzes the polymerization of C9 to form the MAC (Tschopp et al., 1982). 
This structure inserts into target membranes and causes cell lysis (Hu et al., 1981; 
Podack et al., 1982) (Figure 1.1C).
Activation of the complement cascade leads to the fragmentation of C3, C4 
and C5 releasing low-molecular-weight peptides, C3a, C4a, and C5a with 
anaphylatoxin activity (Bokisch et al., 1969; Gorski et a l, 1979). Anaphylatoxins are 
biologically active peptides that are defined functionally by their actions on small 
blood vessels, smooth muscle, mast cells, and peripheral blood leukocytes. They bind 
to specific receptors and induce the release of vasoactive amines such as histamine 
from mast cells and basophils, and lysosomal enzymes from granulocytes (particularly
17
C3a and C5a) (Johnson et al., 1975; Schulman et al., 1988). C5a is the most active 
followed by C3a and finally C4a with approximately 500-fold less activity than C3a 
(Gorski et al., 1981). In addition, complement activation can significantly enhance the 
immune response by antigen opsonization. Antigen bound C3d, iC3b and C4b can be 
recognized by receptors on a variety of cells such as macrophages, monocytes, B 
lymphocytes, neutrophils, erythrocytes and platelets (Schreiber, 1984). Therefore, C3b 
and C4b serve as a bridge between the antigen and the phagocytic/responder cell.
1.2. Complement Regulation
Due to the propensity of the system to tick over, to undergo rapid and extensive 
amplification once triggered and to damage bystander cells because active components 
‘drift’ away from activating sites, self cells have evolved an armoury of proteins which 
protect membranes from damage by homologous complement. Some of these are 
soluble, plasma proteins, whereas others are expressed on cell membranes.
Complement regulatory proteins (CReg) serve to protect host tissue against the 
potentially destructive effects of complement The CReg comprise three structurally 
and functionally distinct families of proteins which collectively control the classical, 
alternative and lectin C pathways: the serine protease inhibitors (SERPINs), the 
“regulators of complement activation” (RCA) family, and CD59. SERPINs include the 
Cl inhibitor (Clinh). Clinh binds the active enzyme Clr:Cls, and causes it to 
dissociate from Clq, which remains bound to the pathogen. In this way, Clinh limits 
the time during which active C ls is able to cleave C4 and C2.
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The RCA family includes factor H (fH), C4b binding protein (C4bp), decay 
accelerating factor (DAF; CD55), membrane co-factor protein (MCP; CD46) and 
complement receptor 1 (CR1; CD35) (Holers and Kotzin, 1985; Hourcade et al.,
1989). In common with all members of the RCA family, they contain a structural 
module comprising approximately 60 amino acids, termed the short consensus repeat 
(SCR) (Barlow et al., 1991). CD46 and CD55 each have four of these modules, the 
C3b-binding and functional activities of the proteins reside in this region (Liszewski et 
al., 1991; Nicholson-Weller and Wang, 1994; Reid and Day, 1989) (Figure 1.2). On 
cell membranes, CD55 regulates complement by binding to the C3 convertases, C4b2a 
(classical pathway) and C3bBb (alternative pathway), accelerating their decay (decay 
accelerating activity) thereby interfering with both the classical and alternative arms of 
the complement cascade (Figure ID) (Fujita et al., 1987; Medof et al., 1984). CD46 
binds to either C3b or C4b enabling a plasma serine protease, factor I (fl), to 
proteolytically cleave the active component and irreversibly inactivate the enzymes 
(co-factor activity) (Liszewski and Atkinson, 1996; Seya and Nagasawa, 1981). CD55 
is also expressed in rodents where it performs a similar CReg function (Harris et al., 
1999; Hinchliffe et al., 1998; Spicer et al., 1995); in contrast, CD46 is only expressed 
in rodent testis and is not present in other tissues or circulating cells (Miwa et al.,
1998; Mizuno et al., 2005). Instead, rodents have another membrane CReg, 
complement receptor related protein-y (Crry), which is expressed on blood cells and in 
most tissues (Funabashi K, 1994; Li et al., 1993). Crry is also built from a ‘string’ of 
SCR domains and can perform the functions of both CD55 and CD46 i.e. it promotes 
decay of the convertase enzymes and acts as a cofactor for factor I-mediated cleavage 
of C3b and C4b (Kim et a l, 1995; Quigg et al., 1995). CR1 exhibits decay 
accelerating activity and co-factor activity (Iida and Nussenzweig, 1983)(Figure 1.1D).
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Figure 1.1. Complement Activation and Regulation.
Diagram of the complement activation pathways. (A) The classical pathway is 
activated by antibody. Binding of Cl to antibody leads to cleavage of C4 and 
deposition of C4b on the membrane. C2 associates with C4b and is cleaved and 
activated by Cl to form the C3 convertase. As with the alternative pathway, multiple 
molecules of C3b are cleaved to form the C5 convertase. The lectin pathway is 
identical to the classical pathway except that it is initiated by mannan-binding lectin 
(MBL) binding to carbohydrate moieties, this activates the MASPs (MBL-associated 
serine proteases) which cleave C4 and C2 in a manner similar to C l. (B) The 
alternative pathway ticks over spontaneously in plasma resulting in C3b-like molecules 
or C3b which can deposit on cell membranes. C3b binds factor B which is cleaved 
and activated by fD to form the C3 convertase. C3b can associate with the initiating 
enzyme to form the C5 convertase. The C5 convertase cleaves multiple molecules of 
C5 to C5a and C5b, initiating the terminal pathway. (C) The activation pathways 
converge at the point of C5 cleavage. C5b remains associated with the C5 convertase 
where it binds C6  and Cl. The C5b67 complex releases from the convertase and binds 
loosely to the membrane, it rapidly binds C8  forming the C5b678 complex. C9 binds 
to the complex and poymerises to form the MAC. (D) Regulation of the activation and 
terminal pathways is brought about through the actions of the membrane associated 
CReg: CD46, CD55 and CD59. CD55 has decay accelerating activity and acts by 
binding the C3 and C5 convertases of all activation pathways (the classical pathway 
C3 convertase is illustrated here). Binding of CD55 accelerates the decay of the 
enzyme by promoting release of the enzyme subunit Bb or C2a. By dissociating the 
enzymes it prevents amplification of the cascade by further C3 cleavage and enzyme 
formation. CD46 has cofactor activity, it binds C3b or C4b and enables a plasma 
serine protease, factor I, to cleave and inactivate the protein. CD59 regulates the 
terminal pathway by binding the C5b678 complex preventing C9 polymerisation and 
pore formation.
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Figure 1.2. Structure and Function of CReg
CD35 (CR1), CD46, CD55 and Crry are members of the RCA family and contain a 
structural module termed the short consensus repeat (SCR). Crry is only present in 
rodents and is formed of 5 SCR domains in mice and 7 SCR domains in rat. CD59 is a 
small highly glycosylated molecule and, like CD55, is attached to the membrane via a 
GPI-anchor.
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Whilst several proteins collaborate to regulate the activation arms of the 
complement cascade, only one membrane CReg, CD59, inhibits the terminal pathway 
(Davies et a l , 1989). CD59 is a small, globular glycoprotein (approx. 20kDa), which 
is associated with the plasma membrane through a glycosyl phosphatidylinositol (GPI) 
anchor (Figure 2). It is found in both humans and rodent and is expressed on all 
circulating cells and most tissues (Meri and Lachmann, 1991; Nose et al., 1990). It 
blocks formation of the lytic membrane attack complex (MAC) by binding C8  within 
the C5b-8 complex, preventing unfolding and polymerisation of the final component, 
C9 (Meri et a l , 1990). (Figure 1.1D). Mice have a duplication of the CD59 gene, 
resulting in two isoforms of CD59 (Qian et a l , 2000). The first described, now termed 
CD59a, is widely distributed, while the more recently described CD59b is found 
primarily in the testis and its role in complement regulation is unclear 
(Baalasubramanian et a l , 2004; Harris et a l , 2003).
The importance of CReg in protecting host cells from complement attack is 
illustrated by the consequences of CReg deficiency in humans. Patients with 
Paroxysmal Nocturnal Haemoglobinuria (PNH) exhibit a deficiency in CD55 and 
CD59 on clonal populations of erythrocytes, platelets and other circulating cells as a 
result of stem cell mutations in the phosphatidylinositol glycan-class A (PIG-A) gene 
essential for GPI anchor synthesis (Takeda J, 1993). The disease is characterized by 
complement-mediated haemolysis, venous thrombosis, and bone marrow failure 
(Takeda J, 1993). In rodents, the protective role of CReg is best illustrated by 
deficiency of Crry. First, Crry is crucial for embryonic development since its 
deficiency result in embryonic lethality (Xu et a l , 2000); second, Crry deficient
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erythrocytes are subject to rapid elimination from the circulation in normal mice 
despite expression of CD55 and CD59, demonstrating that Crry is indispensable for 
protecting mouse erythrocytes from spontaneous complement attack (Molina et al., 
2002)
1.3. Alternative Roles for CReg
A growing body of evidence indicates that CReg are not just regulators of complement 
and there is an ever-expanding and diverse list of roles that these proteins play. Roles 
include acting as pathogen receptors, influencing neutrophil migration and promoting 
cell proliferation, signal transduction and LPS-induced activation of various cell types 
(Cattaneo, 2004; Davis et al., 1988b; Harris and Morgan, 2004; Heine H, 2003; 
Lawrence et al., 2003; Morgan et al., 1993; Yamamoto et al., 2003). There is also 
striking evidence that CReg, most notably CD46, play a part in fertilisation and 
reproduction (Kitamura et al., 1997; Riley-Vargas et a l, 2004). Recently, much 
attention has focussed on the effect of CReg on the activation of antigen-specific T cell 
responses. These observations, summarised below, imply that CReg, sometimes in 
collaboration with the complement system, play key roles in regulating the adaptive 
immune system.
1.3.1. Cross-Linking CReg on T Cells Triggers Cell Activation
Membrane CReg have been implicated in T cell activation almost since their 
discovery. Several groups demonstrated in early papers that antibody cross-linking of 
either CD55 or CD59 on human lymphocytes in association with stimulation through 
the T cell receptor or with phorbol esters, induced re-organization of the cytoskeleton
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(Harder and Simons, 1999; Kammer, 1988), cell proliferation (Davis et a l, 1988a; 
Korty et al., 1991), enhanced tyrosine phosphorylation through p56,ckand calcium 
mobilisation (Stefanova et al., 1991b; Stefanova, 1991; Tosello et al., 1998). More 
recently, studies have shown that antibody ligation of Crry in rodent or CD46 in 
human promotes tyrosine phosphorylation and cell proliferation of primary T cells 
stimulated with CD3-specific antibodies (Antic Stankovic et al., 2004 ; Arsenovic- 
Ranin et al., 2000; Wang et a l, 2000; Zaffran et a l, 2001). Both Crry and CD46 are 
transmembrane proteins and, upon ligation with antibody, signals may be transmitted 
directly via their cytoplasmic tails. Antibody cross-linking of CD46 on primary human 
T cells induced activation of Vav and Rac, phosphorylation of the adaptor proteins 
pl20CBL and LAT, and phosphorylation of extracellular signal-related kinase mitogen- 
activated protein kinase (Erk MAPK) (Astier et al., 2000; Zaffran et al., 2001). 
Collectively, these observations, all derived from antibody cross-linking studies have 
prompted more detailed analyses of the effect of individual CReg ligated by natural 
ligands on T cell activity. These are discussed in detail below.
1.3.2. Roles of CD46 in T Cell Function
Several recent publications and reviews have highlighted a role for CD46 in 
modulation of T cell activity (Kemper et al., 2005; Riley-Vargas et al., 2004). CD46 is 
expressed in most human cells as various isoforms derived from alternative splicing of 
one gene (Post et al., 1991). The isoforms differ in the length of the membrane- 
proximal Ser-Thr rich region, the extent of glycosylation and in the cytoplasmic tail. 
Two different tails are utilised, termed CYT-1 and CYT-2. Both contain signalling 
motifs and associate with intracellular kinases (Wang et al., 2000; Wong et al., 1997b).
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Interactions between CD46 and its ligands or antibodies induce signalling events that 
differ according to the cytoplasmic tail. An early in vitro study by Wang et al. 
suggested that CYT-2 was tyrosine phosphorylated by the src kinase lck upon cross- 
linking on Jurkat cells expressing both forms of CD46 (Wang et al., 2000). 
Subsequently, an elegant study by Marie and colleagues utilising transgenic mice 
expressing human CD46 with either CYT-1 or CYT-2, showed that cross-linking the 
different cytoplasmic tails in vivo could have dramatically different effects on 
inflammatory responses in a contact hypersensitivity (CHS) model (Marie et al.,
2002). Just prior to sensitisation with DNFB, CD46 was cross-linked in vivo using 
recombinant vesicular stomatatis virus (VSV) expressing the measles virus 
hemagglutinin, a natural CD46 ligand. Inflammatory responses were monitored 
following a second challenge with DNFB some days later. CD4+ T cells expressing the 
CYT-1 isoform showed strong proliferative responses with increased IL-10 production 
resulting in decreased generation of specific CD8 + T cells and a weak contact 
hypersensitivity reaction. In contrast, engagement of the CYT-2 isoform on CD4+ T 
cells resulted in decreased cell proliferation and IL-10 production, strong CD8 + T cell 
responses and increased inflammation. These results show that the effects of CD46 
ligation are dictated by the isoform involved. Kemper et al. later demonstrated an 
immunomodulatory effect of CD46 on human T cells (Kemper et al., 2003). Here, 
simultaneous engagement of CD4+ T cells with CD3 and CD46-specific antibodies in 
the presence of IL-2 triggered the induction of T cells exhibiting the characteristics of 
T regulatory 1-type cells (Trl Cells). These cells secreted high amounts of IL-10 and 
inhibited the proliferation of conventional CD4+ T cells. Human T cells express both 
CD46 isoforms but the contribution of the different cytoplasmic tails is unexplored in 
this work. Later studies revealed that CD46-induced Trl cells expressed high levels of
granzyme B and perforin and were capable of killing autologous targets cells 
(Grossman et a l, 2004). Collectively, these observations have led to the suggestion 
that these Trl cells may impinge upon other immune responses either through cell 
lysis or through the immunosuppressive effects of IL-10. Importantly, these and other 
studies also showed that triggering with a physiologically relevant ligand, such as C3b 
dimers or pathogens, induced the same phenotype (Kemper et al., 2003; Price et al., 
2005).
1.3.3. Crry as a Modulator of T Cells in Rodents
As noted above, CD46 expression in rodents is restricted to testis and its complement 
regulatory function is taken over by a broadly expressed rodent-specific CReg, Crry. 
Like CD46, Crry may also impinge upon T cell activation. Experiments performed by 
Femandez-Centeno and colleagues demonstrated that concurrent antibody ligation of 
Crry and CD3 promoted activation of mouse CD4+ T cells and skewed the CD4+ T cell 
response towards production of the Th2 cytokine, IL-4, rather than IFNy (Thl 
cytokine) (Femandez-Centeno et al., 2000). Arsenovic-Ranin et al. showed that co­
incubation of rat thymocytes with Crry- and CD3-specific antibodies enhanced 
thymocyte proliferation, IL-2R expression and IL-2 release (Arsenovic-Ranin et al., 
2000). No studies utilising natural ligands to cross-link Crry have been reported and, 
because deficiency of Crry results in embryonic lethality, it has not been possible to 
study the influence of Crry on T cell responses using Crry-deficient animals. 
Nevertheless, the data obtained thus far indicate that engagement of Crry, like CD46 in 
humans, may downmodulate T cell responses by inducing production of Th2 
cytokines.
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1.3.4. Roles of CD55 and CD59 in Human T Cell Activation
CD55 and CD59 are GPI-anchored glycoproteins expressed in all circulating cells and 
most tissues. As discussed above, antibody cross-linking of either CD55 or CD59 
influences T cell activation despite the fact that these proteins lack a cytoplasmic 
domain. Like other GPI anchored proteins, CD55 and CD59 are found predominantly 
in membrane microdomains called glycosphingolipid-enriched microdomains (GEMs) 
or lipid rafts. Lipid rafts are structures within the plasma membrane enriched in 
cholesterol and containing palmitoylated transmembrane adaptor proteins such as LAT 
(linker for activation of T cells) and PAG (phosphoprotein associated with 
glycosphingolipid-enriched microdomains), and a multitude of intracellular signalling 
molecules including Src family kinases and G-proteins (Rodgers, 2005; Viola et a l , 
1999). The signalling capacity of GPI-anchored proteins requires interaction with these 
raft-associated signalling molecules since disruption of lipid rafts causes loss of 
signalling capacity (Stefanova et al., 1991a). Since antibody cross-linking is likely to 
induce a different type of response to engagement with a natural ligand, these types of 
experiments do not indicate that CD55 and/or CD59 modulate T cell activation under 
physiological conditions. Signalling through CD55 following binding of complement 
components or complexes has yet to be demonstrated; however, ligation of CD55 on 
intestinal epithelial cells by E. coli adhesin has been shown to result in dramatic 
cytoskeletal F-actin rearrangements accompanied by recruitment of signal transduction 
molecules, indicating that a natural ligand can also mediate an effect on the cell 
through CD55 (Peiffer et al., 1998). For CD59, the natural complement-derived ligand 
is the forming MAC. As well as its lytic activity, it has been reported that MAC 
deposition can result in stimulation of IL-1 production and DNA synthesis in 
glomerular mesangial cells and to initiate Ca2+ flux and stimulate procoagulant activity
of platelets (Couser et al., 2001; Lovett et a l, 1987; Sims et al., 1988). No relevant 
non-complement ligands for CD59 have yet been described.
1.3.5. Studies of CD55 Utilising Knockout Mice
Two genes for CD55 have been characterised in mice (named Dafl and Daf2). Dafl is 
GPI-anchored, widely distributed and is the human homologue of CD55, whereas Daf2 
lacks a GPI anchor, possesses a transmembrane domain and its expression is restricted 
to testis and spleen (Lin et al., 2001; Spicer et al., 1995). Mice deficient in Dafl have 
been engineered and used to examine the influence of these proteins on T cell activity 
in vitro and in vivo.
Two recent studies describe T cell responses in CD55-deficient (Dafl-/-) mice. 
The first study by Liu et al. showed that recall responses measured using spleen cells 
from mice immunised with OVA or an MHC class II restricted MOG-derived peptide 
were more vigorous in Dafl-/- mice compared to control mice (Liu et al., 2005). T 
cells from the Dafl-/- mice produced more IFNy and IL-2 upon antigen re-stimulation 
than their wild-type (WT) counterparts, whereas production of the immunosuppressive 
cytokine IL-10 was reduced. This hyper-responsiveness of T cells from the Dafl -/- 
mice was due to lack of CD55 on the T cells themselves since antigen presenting cells 
(APCs) purified from Dafl-/- mice stimulated T cells to produce IFNy to the same 
degree as those purified from Dafl+/+ mice. The more vigorous response observed in 
Dafl-/- T cells was not due to a global increase in sensitivity of the T cells to antigen 
stimulation since no difference was observed in the response of Dafl-/- and Dafl+/+ T 
cells to stimulation with superantigen. A key finding was that the enhanced production
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of IL-2 and IFNy by Dafl-/- T cells after re-stimulation with antigen was largely 
dependent upon a functional complement system since the effect was lost when Dafl - 
/- mice were back-crossed onto C3-deficient (C3-/-) mice in which complement 
activity is effectively abolished. A residual, complement-independent effect of Dafl 
deficiency on T cell function was suggested by the observation that T cell responses 
were more vigorous in C3-/-Dafl -/- mice compared to C3-/-Dafl +/+ mice. The 
complement-independent effect was minor and unlikely to be of physiological 
relevance, as shown by studies in a T cell-driven experimental autoimmune 
encephalomyelitis (EAE) model. Here disease was exacerbated in Dafl-/- mice, but 
not in Dafl-/-C3-/- mice. Importantly, the increased T cell activity upon antigen re­
stimulation in vitro was lost in Dafl-/- mice after neutralisation of C5 using C5- 
blocking antibodies in vivo. This finding implies that complement products 
downstream of C5, i.e. the anaphylatoxin C5a or the MAC, are responsible for the 
observed phenotype in the Dafl-/- mice.
Heeger et al. independently reported similar findings in a different line of 
Dafl-/- mice (Heeger et al., 2005). In this study, the authors observed that Dafl-/- 
spleen cells proliferated more vigorously following in vitro stimulation with allogeneic 
cells and more spleen cells purified from female mice immunised with the male 
antigen (HYDby) produced IFNy upon restimulation in vitro. In addition, Dafl-/- 
female mice rejected male skin grafts more efficiently than their WT counterparts and 
exhibited more HY-specific T cell activity as measured in IFNy ELISpot assays.
Liu et al. showed that the effects of Dafl deficiency on T cell activity are lost 
when complement activity is removed, either by back-crossing to C3-/- mice or by
31
inhibition of C5 (Liu et a l , 2005). Heeger et al reported similar findings, though in 
these experiments, neutralisation of C5 only partially abrogated the effect of Dafl - 
deficiency (Heeger et al., 2005). They also showed that T cell responses were partially 
normalized in Dafl -/-Factor D-/- mice, thereby indicating that the alternative pathway 
of complement activation contributes to the influence of Dafl on T cell activity.
Overall, complement activation plays a critical role in T cell modulation by Dafl. 
Complement components not only mediate immune defence against foreign pathogens, 
but also modulate diverse processes, such as cell survival, growth, and differentiation 
in various tissues (Mastellos and Lambris, 2002). Complement has been shown to be 
critical for liver regeneration after acute toxic challenge. Local production of C3a and 
C5a induce, through interaction with their receptors, downstream activation of the 
latent transcription factors NF-kB and STAT-3 necessary for hepatocyte regeneration 
(Markiewski et al., 2004; Strey et al., 2003). In addition, synthesis of factor D, B and 
C3 by adipose cells and consequent activation of the alternative pathway of 
complement, has been related with adipose cell metabolism (Choy et al., 1992). In the 
absence of Dafl, exacerbated complement activation result in generation of several 
proteolytic fragments with biological activity such as C3a, C3b and C5a (Figure 1.3). 
Indeed, in vitro activation of T cells induce the release of complement components of 
the alternative pathway C3, factor B and D (Heeger et a l, 2005). The direct 
mechanism with which complement drives T cell activation remains unclear. 
Neutralization of C5 abrogates Dafl-/- phenotype suggesting a role for C5a and/or 
MAC. C5a, a potent anaphylatoxin, is known to promote and perpetuate inflammatory 
reactions by facilitating chemotaxis of neutrophils, eosinophils, monocytes, 
macrophages and lymphocytes and by inducing mast cells, neutrophils and
macrophages to release inflammatory cytokines such as IL-12, TNFa and IL-6 
(reviewed in Guo and Ward, 2005). C5a may therefore indirectly influence T cell 
function through promotion of inflammation and creating a favourable environment for 
the activation of antigen-specific T cells. Although expression of C5aR on murine T 
cells has not yet been described, virus-specific T cell responses are impaired in mice 
treated with a peptide antagonist of C5aR (Kim et al., 2004a). Neutralization of C5 
also disrupts the formation of the MAC. MAC has also been implicated in T cell 
activation on human T cell lines (Murray and Robbins, 1998). Neutralisation of C5 did 
not completely abrogate the effect of Dafl-deficiency in some of the experiments 
described above, and it is possible that C3a and/or C3b might play a role. C3a 
molecule, another anaphylatoxin, has a wide spectrum of pro-inflammatory effects and 
C3aR is expressed by activated T cells (reviewed in Muller-Eberhard, 1988; Werfel et 
a l , 2000). Kerekes et al. showed that deposition of C3b on APCs facilitates T cell 
proliferation through improving cell-to-cell contact between APC and cognate T cell 
(Kerekes et al., 1998). Although T cells express a variety of C3 receptors, including 
the C3b receptor, CR1, a systematic study of the effects of complement fragments on T 
cell activity has not yet been performed (reviewed in Wagner and Hansch, 2006). Also 
worthy of consideration is the possibility that a complement-independent component 
may contribute to the hyperactivity of Dafl-/- T cells since C3-deficient Dafl-/- T 
cells displayed enhanced responses to recall antigens compared to those purified from 
C3-/- mice (Liu et al., 2005). It is possible that CD55 binds to an as yet unidentified 
ligand on APCs, which directly or indirectly, downmodulates T cell activation.
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Figure 1.3. Complement Activation in Dafl-/- Mice
(A) Complement ticks over spontaneously in plasma resulting in low level production 
of C3b. In WT animals, in which expression of CRegs is normal, levels of active 
complement are low and tick-over amplification is kept in check. In inflammatory 
sites, activation of the complement cascade and production of active mediators is 
increased. These products (C3b, C3a, C5b, C5a and MAC) might have stimulatory 
effects on both APCs and T cells, resulting in enhanced T cell activation and 
proliferation (red arrow). (B) In Dafl-/- mice, when C regulation is deficient, 
complement tick over is more efficient, there is enhanced cleavage of C3 to C3b, 
particularly at sites of inflammation or infection, and complement amplifies more 
readily on cell membranes. Enhanced complement activation, production of active 
mediators and subsequent cell stimulation occurs in the absence of CD55 resulting in 
the hyper-responsive phenotype seen in the Dafl-/- mice. Solid black arrows indicate 
cleavage events and/or progression of the C cascade; dashed black arrows indicate 
putative binding of activation products to receptors (only C3b, C3b, C5a and MAC are 
shown here).
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One known non-complement ligand for CD55 is CD97, a transmembrane 
protein and member of the EGF (Epidermal Growth Factor)-TM7 family with an 
extended extracellular region containing a variable number of EGF-like domains. It is 
constitutively expressed on granulocytes, monocytes and DCs and is rapidly 
upregulated in lymphocytes upon activation. CD55 binds CD97 with low affinity and a 
rapid off rate. The physiological significance is still unknown but it has been suggested 
that the interaction facilitates cell adhesion. Ex-vivo incubation with mAbs to CD97 
delayed neutrophil recruitment to the colon in an experimental model of colitis 
(Leemans et a l, 2004). However, Heeger et al. found no effect of antibody blocking of 
CD97 on modulation of T cell responses (Heeger et a l, 2005).
1.4. GPI-anchored Proteins and T Cell Activation
1.4.1. Roles of GPI-anchored Proteins in T Cell Activation In Vitro
As discussed above, the way in which a GPI-anchored protein such as CD55 
influences T cell activation is unclear. Although the studies described above strongly 
support a role for complement components, there is also evidence that CD55 can 
modulate T cell activation in a complement-independent fashion. It is interesting that 
GPI-anchored proteins other than CReg have been shown to modulate T cell activity in 
man and rodents implying that the effect of CReg on T cell activation is not 
inextricably linked to the complement system (Gonzalez-Cabrero et a l, 1999; Gunter 
et a l, 1984; Kroczek et a l, 1986; Malek et a l, 1986; Reiser, 1990; Thompson et a l, 
1989).
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Thy-1 was the first GPI-anchored protein described to induce T cell activation 
(Gunter et a l, 1984; Kroczek et a l, 1986). Thy-1 exists in two allotypic forms, Thy- 
1.1 and Thy-1.2, and is expressed by thymocytes, T cells and brain tissue in mice. Thy- 
1 specific antibodies have been shown to stimulate T cell activation, measured by
^  I
proliferation, IL-2 production, IL-2R expression and Ca mobilization, directly or 
indirectly after cross-linking Thy 1-specific antibodies in the presence of PMA 
(Kroczek et a l, 1986). Similar observations have been made with other GPI-anchored 
proteins. These include Ly-6 (Malek et a l, 1986), Qa-2 (Hahn and Soloski, 1989; 
Robinson et a l, 1989), CD48 (Maschek et a l, 1993; Reiser, 1990), CD73 (Massaia et 
a l, 1990; Thompson et a l, 1989) and as described above, CD55 and CD59 (Korty et 
a l, 1991; Shenoy-Scaria, 1992). Ly-6 comprises a family of cell surface proteins of 
unknown function found in mouse lymphocytes. Studies show that antibody cross- 
linking of Ly6 with Fc receptors expressed on APCs or secondary antibodies, results in 
IL-2 production, IL-2R expression and T cell proliferation (Malek et a l, 1986). Qa-2 
is a non-classical mouse MHC class I molecule expressed at high levels on T cells. 
Unlike the classical class I molecules, H-2 K, D and L, Qa-2 lacks a transmembrane 
domain and is attached to the cell membrane by a GPI-anchor. Antibody cross-linking 
of the Qa-2 antigen but not H-2 antigens induced T cell proliferation in the presence of 
PMA (Hahn and Soloski, 1989; Robinson et a l, 1989). The GPI-anchored protein 
CD48 (formerly known as sgp-60) is expressed on lymphocytes, macrophages and 
DCs. Antibody cross-linking of CD48 results in T cell proliferation, IL-2 production
^  I •  •  •  •and Ca mobilisation following stimulation with CD3 specific antibodies and PMA 
(Maschek et a l, 1993; Reiser, 1990).
1.4.2. Roles of GPI Anchored Proteins in T Cell Activation In Vivo
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The role of GPI-anchored proteins in T cell activation is illustrated in mice deficient in 
specific GPI-anchored proteins. In the case of Thy-1- and CD48- deficient mice, T 
cells, stimulated with allogeneic cells or CD3-specific antibodies tended to proliferate 
less well than their WT counterparts. Reduced proliferation was accompanied by 
reduced tyrosine phosphorylation and Ca2+ influx compared to T cells from WT mice 
(Beissert et al., 1998; Gonzalez-Cabrero et a l, 1999). Different results were obtained 
in a similar study using Ly6A-deficient mice (Stanford et al., 1997). Splenocytes from 
the knockout mice exhibited enhanced T cell proliferation compared to WT mice after 
stimulation with allogeneic splenocytes, CD3-specific antibodies, KLH or ConA. The 
ability to generate allogeneic CTL responses was also tested with no significant 
distinction observed between the different groups of mice. In support of the premise 
that GPI-anchored proteins modulate T cell activity is the observation that T cell 
proliferation is enhanced in lymphocytes lacking GPI-anchored proteins (Hazenbos et 
a l , 2004). The effects of different GPI-anchored proteins on T cell activation are 
summarised in Table 1.1.
1.4.3. Modulation of T Cell Responses -  A General Role for GPI Anchored 
Proteins?
Overall there is a general consensus that GPI-anchored proteins modulate T cell 
activation but the specific influence of each of the different proteins remains 
controversial. In general, cross-linked antibodies to GPI-anchored proteins induce T 
cell activation but studies of T cells from mice lacking certain GPI-anchored proteins 
have revealed that the proteins may positively (Thy-1 and CD48) or negatively (CD55 
and Ly6A) modulate T cell activation in vivo. Despite the lack of a cytoplasmic 
signalling domain, these proteins are, as described above, believed to facilitate
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GPI
Protein
Target Stimulation Effect Reference
Thyl.l Mouse T cells Antibody cross-linking + PMA Proliferation and Ca++ influx Kroczek et al., 1986
Mouse T cells 
(Thyl.l -/- mice)
Allogeneic cells or mAbs to CD3 Thy 1.1 -/- T cells exhibit decreased 
proliferation, Ca++ influx and Tyr 
phosphorylation
Beissert et al., 1998
Ly6 Mouse T cells Antibody cross-linking + PMA or mAb to CD3 Proliferation, IL-2 release and IL2-R 
expression Ca++ influx
Malek etal., 1986 
Stanford etal., 1997
Mouse CD4+T cells 
(Ly6 -/- mice)
Allogeneic cells or mAbs to CD3 or ConA or 
KLH antigen
Ly6-/- T cells exhibit increased 
proliferation
Stanford et al., 1997
Qa-2 mouse T cells Antibody cross-linking + PMA Proliferation Hahn and Soloski, 1989; 
Robinson et al., 1989
CD48 Mouse CD4 + T 
cells
Antibody cross-linking + PMA Proliferation Maschek et a l , 1993
Mouse T cells Fab to CD48+ mAb to CD3 + PMA or ConA Inhibition o f cell proliferation, IL-2 
release, Ca++ flux
Reiser, 1990
Mouse CD4+T cells 
(CD48-/- mice)
Allogeneic cells, PHA, ConA or mAbs to CD3 CD48 -/- T cells exhibit decreased 
proliferation
Reiser, 1990
CD73 Human T cells Antibody cross-linking + PMA Proliferation, IL-2 release and IL2-R 
expression
Thompson etal., 1989
Table 1.1. Effect of GPI-anchored Proteins in T Cell Activation
Data was obtained either from antibody cross-linking experiments or using T cells 
purified from genetically modified mice lacking individual GPI-anchored proteins.
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intracellular signalling through association with tyrosine kinases in lipid rafts. The 
diverse effects of different GPI-anchored proteins may reflect the composition of 
proteins and signalling molecules present in the raft that they occupy. Thus, the 
presence of distinct groups of proteins within rafts allows specific molecules to interact 
in response to a given stimulus and influence the biological outcome.
1.5. Studies of CD59 In Vivo
I
Ligation of CD59 on human lymphocytes induced Ca flux, IL-2 release and cell 
proliferation suggesting a role of positive modulation of T cell activation. This effect 
was attributed to the recruitment of signalling molecules in particular Src kinase family 
members. However, as discussed previously for other GPI-anchored proteins, 
interaction of these proteins with their natural ligand under physiological 
circumstances does not always correlate with in vitro antibody cross-linking findings. 
Indeed results of the detailed studies of murine CD55 using Dafl-/- mice did not 
support those previously obtained in vitro using human T cells. Whereas, antibody 
cross-linking of CD55 promotes T cell activation, mice genetically deficient for CD55 
(Dafl) exhibited enhanced T cell responses. Whether this observation reflects a 
species difference or the difference between antibody cross-linking and engagement 
with more natural ligands remains to be elucidated.
For activation, naive CD4+ T cells require the engagement not only of their TCR 
with MHC peptide complexes (signal 1), but also a costimulatory receptor, such as 
CD28 with ligands such as B7.1 (signal 2) (Dubey et a l , 1996; Harding et al., 1992; 
Horgan et a l, 1990). In addition, several other interactions between the T cell and the
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APC are known to influence T cell activation either positively or negatively, 
presumably altering the threshold of signals required for activation to occur (reviewed 
in Kroczek et a l , 2004; Leibson, 2004)). It appears that GPI-anchored proteins, 
including CReg, can perform this function. To further our understanding of the effect 
of CReg on modulation of T cell activity in vivo, this thesis describes a study of the 
effect of the murine CReg, CD59a on T cell activity. To achieve this goal, mice 
lacking CD59a were studied. Antigen-specific T cell activity was measured following 
infection of mice with recombinant vaccinia virus (Model 1) and infection with 
influenza virus (Model 2). Use of these models, described in detail below, allow the 
effect of CD59a on both antigen-specific CD4+ and CD8+ T cells to be studied. In 
addition, the models allow an examination of whether modulation of T cell activity 
through expression of CReg alters the course and/or pathogenesis of virus infection.
1.6. Model 1: Vaccinia Virus
1.6.1. The Virus
Vaccinia virus (VV) is a member of the poxvirus family, a complex family of viruses 
containing a large double-stranded DNA genomes. VV contains approximately 200 
genes which can be subdivided into three temporally distinct classes termed early, 
intermediate, and late (Johnson et al., 1993; Moss, 1990). Early genes are transcribed 
immediately after infection by enzymes and transcription factors contained within the 
infecting virion, while late and intermediate genes are transcribed only after the start of 
viral DNA replication (Moss, 1990). The genes located in the central region of the 
genome are highly conserved and encode enzymes, transcriptional factors and
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structural proteins necessary for virus replication. The VV genome also contains more 
variable genes that are in general non-essential for virus replication but which affect 
the immune response of the host (Perkus et al., 1991). Indeed, VV have unique 
strategies for evasion of the host immune response (McFadden et al., 1995) reviewed 
in (Alcami and Smith, 1995; Spriggs, 1996) and are the only virus family known to 
produce secreted versions of receptors for cytokines such as TNF, IL-lp, IFN-cx/p, and 
IFN-y that bind cytokines with high affinity blocking their activity.
Viral particle formation is a complex process occurring in the cytoplasm of 
infected cells which results in the formation of two infectious forms of the virus 
termed intracellular mature virus (IMV) and intracellular enveloped virus (IEV). 
Initially, the viral genome is surrounded by crescents which extend to form spherical 
IMV. Some IMV particles become wrapped by membranes derived from the 
intermediate compartment to form an IEV(Sodeik et al., 1993). VV is thought to leave 
the cell by fusion of the outer IEV membrane with the plasma membrane, to give rise 
to the extracellular enveloped virus (EEV) (Morgan, 1976).
1.6.2. Immune Response to W
VV can cause either localized, self-limited infection or more generalized infection. VV 
has a broad cellular tropism and infects cells of many different mammalian species 
(Buller and Palumbo, 1991). It has been shown to infect multiple organs in the host 
such as skin, liver, lung and ovaries. It has also been shown to infect human DCs, NK 
cells, monocytes/macrophages, B cells and activated T cells but not resting T cells 
(Chahroudi et a l , 2005; Kirwan et al., 2005). This suggests that the cell surface
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receptor for VV is ubiquitously expressed and highly conserved; however, no receptor 
for VV has been reported.
VV is a potent inducer of IFN and nitric oxide synthase (iNOS) production by 
macrophages (Harris et a l , 1995; Karupiah et a l, 1993). Also, several cytokines have 
been shown to play an important role in host defences against VV infection. Some 
cytokines contribute to increased virulence, as with IL-4, whereas others have a 
protective role against VV infection, as IFN-y, TNF-a, IL-12 and IL-18 (Gherardi et 
al., 2003; Gherardi et al., 1999; Ramshaw et al., 1997; Sharma et al., 1996).
VV elicits strong and long-lasting CD4+ and CD8+ T-lymphocyte responses, as 
well as humoral immune responses (Amara et al., 2004; Combadiere et a l, 2004; 
Demkowicz et al., 1996; Eichner, 2003; Harrington et al., 2002). During acute 
infection, CD4+ T cell-dependent Ab response play an important role in virus clearance 
(Xu et a l, 2004b). VV infection of CD4- or IgM-deficient mice resulted in increased 
levels of virus titres compared to WT and virus was controlled by the action of CD8+ T 
cells. The activity of CD8+ T cells appears to be independent of perforin- or Fas- 
dependent cytotoxicity and be mediated by nonlytic T cell-dependent soluble 
mediators such as cytokines (IFN-y) (Kagi et al., 1995).
1.6.3. Recombinant W
VV are commonly used for the generation of live recombinant viruses with the 
capacity to express multiple genes (Mackett et al., 1982). VV can accept as much as 25
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kb of foreign DNA, making it useful for expressing large eukaryotic and prokaryotic 
genes.
VV are attractive as vaccine vectors for the treatment of different diseases. 
Attenuated and host range-restricted VV that undergo limited replication in human and 
other mammalian cell lines, such as modified vaccinia virus Ankara (MVA) and 
canarypox, have been developed as vaccine vectors for use in humans. These poxvirus 
vectors are less pathogenic and have been shown to be safe for use in humans and to 
induce protective immunity in animal models (Belyakov et al., 2003; Moss, 1996; 
Paoletti, 1996).
1.6.4 Usefulness of r W  for The Study of the Effect of CD59a on T Cell Activity In
Vivo
As described above VV can be readily used as a viral vector for the expression of 
foreign proteins. An rVV expressing the glycoprotein (GP) of lymphocytic 
choriomeningitis virus (LCMV) has been described previously (Bachmann et al.,
1994). The usefulness of this rVV (rVVG2) is that the GP of LCMV contains well 
characterised peptide epitopes presented by H-2b MHC class I and class II molecules 
that are presented to CD8+ and CD4+ T cells respectively. Since Cd59a -I- mice were 
generated on a B6 background, use of rVVGP allows comparison of both CD4+ and 
CD8+ T cell responses to be measured and compared to those observed in control B6 
mice. In addition, the main site of rVV replication in female mice is known to be the
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ovaries. Thus, use of this model also facilitates measurement of T cell responses at the 
site of infection and allows any effects on control of virus infection to be monitored.
1.7. Influenza A Virus
1.7.1. The Virus
Influenza virus is an enveloped RNA virus from the Orthomyxoviridiae family 
measuring 80 to 120 nanometers in diameter. There are three strains of influenza virus, 
A, B, and C, each characterized by the antigenic properties of its internal, non­
glycosylated components. Influenza A and B are the strains that cause epidemic human 
disease whereas type C virus is associated with minor symptoms. Influenza A viruses 
can be further categorized into subtypes on the basis of two surface antigens present in 
the lipid bilayer: hemagglutinin and neuraminidase.
The core of the viral particle consists of ribonucleoproteins surrounded by a lipid 
bilayer that contains two types of glycoproteins; neuraminidase (NA), that facilitates 
release of viral progeny from infected cells, and haemagglutinin (HA), which is 
responsible for binding the virus to red blood cells and other host cells. It is now 
recognized as the crucial antigen recognised by the host’s immune system. The 
influenza A genome consists of eight separate pieces of single-stranded RNA 
(McGeoch et a l, 1976), a feature which increases the potential for genetic 
reassortment and may contribute to development of new influenza virus variants and 
antigenic drift (Bush et a l, 1999; Ghedin et a l, 2005).
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The genome encodes for 10 proteins: Haemagglutinin (3 distinct 
hemagglutinins, HI, H2, and H3); Neuramidase (2 different neuraminidases N 1 and 
N2 have been found in human viruses); Nucleoprotein (NP); two matrix proteins (M); 
two non-structural proteins (NS1 and NS2) and three polymerases (PB1, PB2 and PA) 
(Ghedin et al., 2005).
1.7.2. Replication Cycle
Influenza virus infects the epithelial cells of the respiratory tract. Sialic acid on the 
host cell interacts with the HA (Weis et a l , 1988) on the surface of the viral particle 
that is taken into the cell by endocytosis. In the low pH environment of the endosome, 
the ribonucleoprotein complex (RNP) is released into the cytoplasm, from where it is 
transported into the nucleus. Influenza mRNA synthesis is initiated by the RNA 
polymerase complex. Using host cell machinery, new viral proteins are translated from 
transcribed mRNA in the cytoplasm. New viral RNA is encased in the capsid protein, 
and together with new matrix protein is then transported to sites at the cell surface 
where envelope HA and NA components have been incorporated into the cell 
membrane. Within a few hours of infection, 100 or more incomplete virions can be 
detected at the periphery of the cytoplasm. Progeny virions are formed and released by 
budding (Figure 1.4).
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Figure 1.4. Influenza A Virus Replication
Initially, HA binds to sialic acid receptors on the host cell membrane. The virus is 
endocytosed, and then moved into an endosome where the low pH frees the virus 
nuclear material to enter the nucleus of the host cell and replicate. At the nucleus, host 
mRNA provides the primer for viral mRNA from which new viral proteins are 
synthesized. The viral mRNA is synthesized and moves into the cytoplasm for protein 
synthesis. Newly synthesized polymerases, NP,NS1 and NS2 are transported into the 
nucleus while HA, NA and M2 migrate to the cell membrane to await budding. After 
new viral RNA and proteins have been synthesized. The proteins and RNA segments 
group together in the nucleus of the host cell to form new nucleocapsids. The new 
nucleocapsids then migrate to the cell membrane and merge with the new matrix and 
glycoproteins.
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1.7.3. Pathogenesis
Influenza infection is spread by direct person-to-person contact. Infection begins in the 
upper respiratory tract by inhalation of droplets emanating from the respiratory tract of 
an infected individual. Infection of epithelial cells induces cell death, in part due to the 
direct effects of the virus on the cell, and also possibly due to the cytotoxic effects of 
interferon a/p. Cell death at later times may also result from the actions of cytotoxic T 
cells. As a result, the efficiency of ciliary clearance is reduced, leading to impaired 
function of the mucus elevator. The infection usually lasts for around a week and is 
characterized by high fever, myalgia, headache and severe malaise, sore throat and 
rhinitis. Most people recover in two to three weeks but infection can lead to severe 
complications in very young or elderly people or people with medical conditions such 
as lung disease, diabetes and cancer (Eccles, 2005; Stein et al., 2005).
Epidemics of influenza typically occur during the winter months. In the UK, 
influenza infections have been responsible for an average of approximately 13000 
deaths in February 2005 ('http://www.hpa.org.uk/infections/topics az/influenza). the 
influenza A/Wellington/l/2004(H3N2)-like virus being the dominant circulating strain. 
Influenza viruses can also cause pandemics, during which rates of illness and death 
from influenza-related complications increase worldwide. In 1918-9 the “Spanish Flu” 
influenza A (H1N1) killed up to 50 million people worldwide and nearly half of those 
who died were young, healthy adults. The “Spanish Flu” appears to have an avian 
origin. In 1957 and 1968 two other influenza pandemics generated approximately 1-2 
million and 700,000 death respectively and were caused by viruses containing a
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combination of genes from a human influenza virus and an avian influenza virus
(http://www.cdc.gov/flu/pandemic).
1.7.4. Innate Immune Responses to Influenza Virus
The innate as well as the adaptive immune response is important for controlling 
influenza infection (Fujisawa et al., 1987; Garcia-Sastre et a l, 1998). The successful 
generation of the innate response is also necessary for a proper transition to and 
development of the adaptive response.
Infected epithelial cells and macrophages in the lung respond to virus infection 
by deploying a complex network of signalling molecules that initiate and then amplify 
the production of a number of cytokines and chemokines. Experiments performed in 
vitro using influenza-infected human epithelial cells showed that infection resulted in 
the rapid induction of M IP-la, MIP-lp, TNF-a, IL-6 and IL-8 gene expression 
(Adachi et a l, 1997; Arndt et a l, 2002; Tong et al., 2003). Influenza A virus-infected 
human monocytes/macrophages secrete M IP-la, MIP-IB, RANTES, MCP-1, MCP-3, 
MIP-3a, and IP-10 (Bussfeld et a l, 1998; Matikainen et a l, 2000; Sprenger et al.,
1996). Secretion of these cytokines and chemokines contribute to the recruitment of 
neutrophils and mononuclear cells, and virus clearance. IL-8 recruits primarily 
neutrophils and stimulates their degranulation and adhesion (Storgaard et al., 1997) 
whereas MIP-la, MIP-IB, and MCP-1 recruit primarily monocytes/macrophages 
(Menten et a l, 1999; Rollins, 1992). TNF-a exerts powerful anti-influenza virus 
activity. Seo and colleagues demonstrated that TNF-a has a direct anti-influenza 
effect by inhibiting virus replication (Seo and Webster, 2002). Influenza viruses also
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efficiently induce secretion of interferons (type I and II), which represent a major 
component of the innate antiviral immune response (Garcia-Sastre et al., 1998). Both 
types of IFN upregulate the expression of MHC class I and II molecules and activate 
NK cells (Welsh et a l , 1991). IFN-a/p (Type I) not only have a direct anti-virus effect 
but also promote the survival of lymphocytes. IFN-y (Type II) induces macrophages 
activation. The importance of these cytokines in controlling virus infection was 
demonstrated in a recent study which showed that as a mechanism of escape from the 
host innate response, the influenza virus protein, NS1, can attenuate the host response 
mediated by IFN-cx/p and TNF-a (Garcia-Sastre et al., 1998; Seo et al., 2002).
It has recently been suggested that NK cells are also involved in control of 
influenza infection (He et al., 2004; Liu et al., 2004; Siren et al., 2004). Infected cells 
rapidly activate NK cells resulting in production of IFN-y and the activation of 
macrophages and DCs. Activation of NK cells can occur following a direct interaction 
between the Nkp46 receptor on NK cells and HA on virus-infected cells (Mandelboim 
et a l, 2001; Siren et al., 2004) and by macrophage-derived IFN-a (Siren et al., 2004).
1.7.5. Adaptive Immune Responses to Influenza Virus
The early innate immune response to influenza virus is not sufficient to control and 
clear the virus. The adequate clearance of the virus requires a complex interplay 
between cytotoxic T cells, neutralizing antibodies and CD4+ T cell help and the 
importance of each arm of the adaptive immune system depends upon the strain of 
influenza virus in question.
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Influenza vims infects epithelial cells and monocytes/ macrophages of the 
airways and these infected cells are able to process and present antigen to 
lymphocytes. With an adequate immune response, the vims is controlled within 7-10 
days mainly by cytotoxic CD8+ T cells. In a mouse model using a standard laboratory 
strain of influenza virus, CD8+ T cells have been shown to be primed, activated and 
expanded in the draining lymph node 3-4 days after infection (Lawrence and Braciale, 
2004; Tripp et al., 1995a) and subsequently migrate to the lung at day 5-7. CD8+ T 
cells exert their effector functions at this site, producing antiviral cytokines and lysing 
target cells by mechanism involving perforin and Fas (Topham et al., 1997). The 
importance of virus-specific CD8+ T cells is demonstrated by the observation that 132- 
microglobulin-negative mice, which are devoid of MHC class I-restricted T cells, 
showed a delay in vims clearance (Eichelberger et al., 1991). Although these mice still 
recover from the infection, infection with a more pathogenic strain of influenza caused 
death of p2-microglobulin-negative mice (Bender et a l, 1992).
Less is known about the role of CD4+ T cells in influenza infection. During 
primary influenza infection, removal of CD4+ T cells had no effect on vims clearance 
(Allan et al., 1990). However, two later studies showed a diminished clonal expansion 
of influenza-specific CD8+ CTL in CD4-deficient MHC class II-/-  mice (Riberdy et 
al., 2000; Tripp et al., 1995b). The importance of CD4+ T cells became more evident 
in the absence of B cells. In Ig-/- jiMT mice, the absence of the CD4+ T cell population 
was associated with diminished recmitment of virus-specific CD8+ T cells to the lung, 
delayed vims clearance, and increased morbidity (Mozdzanowska et al., 2000; Riberdy 
et al., 2000).
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B cells are responsible for the generation of neutralizing antibodies to external 
viral coat proteins (Gerhard et a l, 1997). Control of virus infection appears to depend 
on the generation of Th-dependent antibodies since B cells or CD4+ T helper cells 
alone are unable to protect the host from influenza infection (Mozdzanowska et a l ,
1997). In the absence of B cells, mice survive virus infection but require an intact 
CD4+ and CD8+ T cell response (Epstein et a l, 1995; Epstein et a l, 1998; 
Mozdzanowska et a l, 1997). Together, the evidence indicates that either a T helper- 
dependent antibody response or a CD8+ cytotoxic T (Tc) cell response can 
independently resolve the infection but they act more efficiently in combination. The 
immune response to influenza virus is summarized in Figure 1.5.
1.7.6. Influenza-induced Immunopathology
Although mounting an adequate immune response is crucial for virus clearance, over- 
exuberant infiltration of immune cells into the lung can result in tissue damage and 
pathology (Moskophidis and Kioussis, 1998; Singer et a l, 1972). Several investigators 
have observed that infection of mice with influenza virus leads to a dose-dependent 
decrease in locomotor activity, body weight, body temperature and survival, which 
correlates with the extent of immune activity and involves cells of both the innate and 
adaptive immune system (Conn et a l, 1995; Enelow et a l, 1998; Wong et a l, 1997a). 
Indeed, treatment of influenza-infected mice with cyclophosphamide resulted in 
decreased mortality despite higher and more persistent virus titres in treated compared 
to untreated mice (Singer et a l, 1972). This finding was attributed to the 
immunosuppressive effect of cyclophosphamide which resulted in a less extensive 
cellular infiltration in the lungs of the infected mice.
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Figure 1.5. Immune Responses to Influenza Virus
Macrophages and epithelial cells release different cytokines and chemokines in response 
to influenza virus infection. TNF-a has a direct anti-virus effect while release of IL-8, 
MCP-1 and M IP-la/p induce recruitment of monocytes, macrophages and neutrophils 
forming the first line of defence to influenza virus. Infected cells also present viral 
antigens that will be recognized by T cells initiating the adaptive response and 
antibodies that control virus entry to the cell.
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The inflammatory sequelae associated with influenza infection appear to be 
multi-factorial. Shortly after infection, neutrophils and eosinophils migrate to the lungs 
leading to disruption of the airways and contributing to airway occlusion (Enelow et 
al., 1998; Singer et al., 1972; Wells et al., 1981). T cells have also been shown to 
contribute to influenza-induced pathology, a process influenced by the type of T cell 
recruited to the lung. While a Thl response to influenza virus is associated with 
reduced lung pathology and successful virus clearance, a Th2 response does not confer 
protection and leads to massive eosinophilic infiltration and increased injury (Graham 
et al., 1994; Hussell et al., 2001; Wiley et al., 2001; Xu et a l , 2004a). Release of pro- 
inflammatory cytokines and chemokines by infected and immune cells is also 
implicated in influenza-induced pathology through their direct effects on the lung 
tissue and through their ability to promote further recruitment of inflammatory cells to 
the site of infection (Kroczek et a l, 2004; Leibson, 2004; Schmitz et al., 2005).
The complement system plays an important role during the very earliest events 
of host defence against an invading pathogen. Indeed, complement components have 
been shown to contribute to virus-specific immune responses in the lung and to lung 
injury (Abe et al., 2001; Czermak et al., 1998; Kim et al., 2004b; Kopf et al., 2002; 
Krug et al., 2001). C3a and C5a can act as chemoattractants of neutrophils (Martin et 
al., 1997; reviewd in Guo and Ward, 2005) and blockade of C5a and C3a in an allergic 
asthma model was shown to dramatically decrease neutrophil recruitment to the 
airways (Baelder et al., 2005; Karp et al., 2001). Complement also influences the 
activity of influenza-specific T cells. Mice deficient in complement component C3 
displayed reduced influenza-virus specific T cell responses in the lungs of infected 
mice, implying that components of the complement system play a role in T cell
activation and/or recruitment. Collectively, these studies imply that the complement 
system is likely to impinge on the extent of cellular infiltration into the lungs of 
influenza-infected mice and therefore on immunopathology. It is therefore reasonable 
to hypothesise that CReg, including CD59a, play an important role in limiting 
immunopathology by limiting the activation of complement. This hypothesis was 
tested as described in Chapter 4.
1.8. Objectives
CD59 acts as a Creg protein inhibiting the formation of the MAC and, therefore, 
regulating cell lysis mediated by complement. However, several studies suggest that 
CD59 also plays a role in T cell activation. Cross-linking of CD59 with specific 
antibodies on human T cells promotes T cell activation measured by Ca2+ flux, IL-2 
production and cell proliferation. The way in which a GPI-anchored protein such as 
CD59a, with no cytoplasmic tail, influences T cell activation is unclear. Several 
studies suggest that this activation may proceed through association with src-family 
tyrosine kinases resulting in tyrosine phosphorylation of intracellular substrates. The 
physiological significance of these findings had not been investigated and it is possible 
that antibody cross-linking of human CD59 in vitro might not reflect CD59 
engagement under more physiological circumstances. Thus, the first aim of this study 
was to investigate the effect of CD59 on T cells in vivo. To achieve this objective, I 
utilised CD59a deficient mice, which were infected with either recombinant vaccinia 
viruses or with influenza virus. The effect of CD59a on T cell activity in vivo was
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therefore assessed by comparing anti-viral T cell responses in wild-type (WT) and 
CD59a -/- mice. These experiments are desribed in Chapters 3 and 4.
Under conditions of sustained complement activation such as tissue injury or 
pathogen infection, T cells are constantly exposed to potentially immunostimulatory 
complement fragments that affect T cell responses. It is possible therefore that as a 
complement regulator protein, CD59 could modulate T cell activation indirectly by 
modulating the extent of complement activation. With this in mind, experiments were 
performed to determine the extent to which modulation of T cell responses by CD59a 
were due to the indirect effects of CD59 on complement activation. This work, 
described in Chapters 3 and 4, was also carried out in the context of the virus models 
mentioned above. The findings of the studies described above prompted a closer 
analysis of the effect of CD59a on T cell activity. This work is discussed in Chapter 5.
CRegs, as explained above, have been shown to activate human T cells upon 
antibody ligation. A more detailed analysis of the effect of CD59 expression on the 
activity of human T cells was also therefore analysed. This work is described in 
Chapter 6.
In summary therefore, the work presented in this thesis describes an 
investigation of the effect of the CReg, CD59, on T cell activation following virus 
infection of CD59a-deficient mice. Subsequently, this study explored the mechanisms 
through which CD59a might affect T cell activation and finally, experiments were 
performed to validate the findings obtained in mice using human T cells.
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Chapter 2- Materials and Methods
2.1. Mice
C57BL/6 (H-2b) mice (WT) were obtained from Harlan (Oxford, UK). B6.129- 
Cd59atmlBpm (Cd59a-/-) mice were generated as previously described (Holt et al., 2001) 
and back-crossed onto the C57BL/6 background for 8 generations. Cd59a-/- mice were 
intercrossed with the B6.129S4-C3tmlCrr(C3-/-)rnice (Wessels et al., 1995) also on the 
C57BL/6 background. Cd59a-/- mice on the Balb/c background were kindly provided 
by Professor Marina Botto, (Imperial College, London). During experimental 
procedures mice were housed in Scantainers. Experiments were performed in 
compliance with Home Office regulations.
2.2. Cell Culture
2.2.1. Cell Lines
Yac-1 cells (TIB-160;American Type Culture Collection, Rockville, M D), T cells and 
V8E cells, a mouse CD4+T cell hybridoma (Oxenius, 1997) ( kindly provided by Dr 
Annette Oxenius, University of Zurich, Switzerland), were maintained in RPMI 
medium supplemented with 10% fetal calf serum (FCS), penicillin-streptomycin, L- 
glutamine, non-essential amino-acids (Life Technologies, Grand Island, NY) and 50 
pM of 2p-mercaptoethanol (2p-ME) (Sigma-Aldrich, St Louis, MO) (R10). In the 
case of V8E cells transfected with CD59a, hygromycin B (Life Technologies, Grand 
Island, NY) was added to the media at a final concentration of 0.3mg/ml in order to
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maintain expression of CD59. TK- cells were maintained in DMEM medium 
supplemented with 10% FCS, penicillin-streptomycin and L-glutamine (Life 
Technologies, Grand Island, NY) (DIO).
2.2.2. Dendritic Cells
Dendritic cells (DCs) were prepared from bone marrow cells that were collected by 
removing the femurs of mice, cutting off the ends of the bones, and flushing out the 
bone marrow with RPMI 1640 medium injected with a syringe. Cells were centrifuged 
at 1500 rpm for 5 min, resuspended in 12 ml of RIO and incubated 30 min at 37°C in 
10 cm tissue dish. Non-adherent and loosely adherent cells were recovered, 
resuspended in 50 ml of medium and incubated for 6  days in medium supplemented 
with 10% FCS, 200 U/ml recombinant mouse Granulocyte Macrophage-Colony 
Stimulating Factor (rmGM-CSF; Peprotech, Rocky Hill, NJ) in a 24 multiwell plate. 
On day 3 of culture, floating cells were gently removed, and fresh medium was added. 
For DC maturation, 2pg/ml of LPS (Sigma Chemical Co., St. Louis, MO) or 50 
HAU/ml of influenza virus was added to the wells at day 5. On day 6  of culture, non­
adherent and loosely adherent DC cells were removed for analysis and for cell 
proliferation. DC purity was evaluated with CD1 lc staining by flow cytometry 
(>90%).
2.2.3. PBMCs
Peripheral blood mononuclear cells (PBMCs) from healthy donors were collected in 
heparin and separated by density centrifugation. 15-20 ml of blood was layered onto 
20 ml of Ficoll-Hypaque solution (Pharmacia Biotech, Alameda, CA) and centrifuged 
at 2000 rpm for 20 min. After centrifugation, the PBMC interface was aspirated and
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washed two times in RPMI 1640 medium. The PBMCs were then used for CD4+ T cell 
purification by positive MACS MicroBeads selection (Miltenyi Biotech, Bergisch- 
Gladbach, Germany) according to the manufacturer’s instructions. Cells were cultured 
in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% heat- 
inactivated autologous serum, penicillin-streptomycin, L-glutamine, non-essential 
amino-acids and 50 pM of 2p-ME (Sigma-Aldrich, St Louis, MO).
2.3. Cell Transfection
2.3.1. Electroporation Protocol
V8 E cells were resuspended at 4xl06 cells in 500 pi of RPMI medium without FCS. 
Cells were mixed with 10 pg of plasmid containing the Cd59a gene or control vector 
(pDR2A EFla; gift of Dr Anegon, INSERM U437, Nantes, France) in a 0.4 cm 
cuvette for 15 min on ice and then electroporated at 274v, 950 pF using the Bio-Rad 
Genepulser with capacitance extender. The cuvette was then placed on ice for an 
additional 5 min and cells were transferred into a sterile flask and cultured for 24 hours 
in 10 ml fresh RPMI containing 10% FCS. Cells were washed once in PBS and 
resuspended in selection medium (R10 and 600 pg/ml hygromycin B; Life 
Technologies). After 2 weeks all of the nontransfected control cells had died. 
Transfected cells were then maintained in RPMI containing 10% FCS and 300 pg/ml 
hygromycin B.
2.3.2. Lipofectamine Protocol
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A plasmid containing FLAG-FasL was obtained from Professor Gavin Screaton 
(Imperial College, London). 293T cells were transfected with the plasmid using 
Lipofectamine (Life Technologies, Grand Island, NY) according to the manufacturer’s 
instructions. Cells were cultured in serum free medium supplemented with penicillin 
and streptomycin for 5 days at 37°C. Conditioned medium from 293T cells transiently 
transfected with FLAG-FasL expression vector was collected, aliquoted and used for 
induction of T cell apoptosis.
2.4. Induction of Apoptosis
Apoptosis was induced with FLAG-FasL (sFasL) in the presence of FLAG M2- 
specific antibodies to aggregate FasL. Optimal concentration of sFasL conditioned 
media was first tested on Jurkat cells. Splenocytes or purified CD4+ T cells were 
treated with increasing amounts of sFasL in the presence of 5 pg/ml anti-FLAG 
antibody (Sigma-Aldrich, St Louis, MO). The cells were incubated for 24 hours at 
37°C before assessing final cell viability using annexin/ PI staining (BD PharMingen, 
San Diego,CA) by flow cytometry.
2.5. Fluorescence Staining
2.5.1. Antibodies
The mAbs to CD28 (37.58) and CD3 (500A2) were purchased from Leinco 
Technologies. Anti-CD4Cy5, anti-CD8-Cy5, anti-F4/80-Cy5 mAbs were purchased 
from Caltag Laboratories (Burlingame,CA). Anti-Fas, anti-MHC-II, anti-IFNy-FITC,
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anti-CD25-PE, anti-TCR-PE, anti-CD8 6 -FITC, anti-Grl-PerCPCy5.5, anti-CDl lc- 
APC, anti-CDl lb-FITC, anti-NKl.l-PE, anti-B220-FITC mAbs were purchased from 
BD PharMingen (San Diego,CA). Donkey anti-mouse-PE and donkey anti-goat-FITC 
were purchased from Jackson laboratories (Bar Harbor, ME). Antibodies to human 
CD45RO-Cy5, CD45RA-Cy5, CCR7-PE, CCR5-FITC and CD69-FITC were 
purchased from BD PharMingen (San Diego,CA). Isotype controls antibodies rat 
IgGl, rat-IgGl-biotin, rat IgG2a-FITC were purchased from Caltag Laboratories 
(Burlingame,CA) and rat IgG2a-PE, rat IgG-Cy5, mouse IgG-FITC, mouse IgG2a-PE, 
mouse IgG2a-PECy5.5, mouse IgGl-PE, mouse IgG2b-Cy5 were purchased from BD 
PharMingen (San Diego,CA). The mAbs specific for mouse CD59a (mCD59.1) and 
human CD59 (HC1 and MEM-43) were obtained from hybridomas produced in the 
laboratory (Harris et al., 2003). For cross-linking experiments, F(ab) ’2 rabbit anti-rat 
IgG was purchased from Serotec (Oxford, UK). Influenza-specific CD8 + T cells were 
identified using PE-labelled MHC class I tetramer (H-2Db) loaded with the 
immunodominant peptide np6 8  (ASNENMDAM) from the influenza nucleoprotein.
2.5.2. Extracellular Staining
Cells were incubated with 0.5pg/ml of antibody in FACS buffer (PBS + 2%FSC + 
2mM EDTA) for 30 min at 4°C. In cases where directly labelled antibodies were not 
used, secondary stains with immunoglobulin-specific antibodies were performed. After 
2 washes with FACS buffer, cells were fixed with FACS Fix buffer (PBS + 2%FSC + 
2mM EDTA + 2% formalin) and analysed by flow cytometry (FACS-CALIBUR®; 
Beckton Dickinson, CA). For CFSE (carboxyfluorescein diacetate succinimidyl ester) 
staining (Molecular Probes, Eugene, OR), cells were washed with PBS and incubated
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for 10 min at 37°C with 0.5 pM CFSE. The reaction was stopped with FBS and cells 
washed twice with PBS.
2.5.3. Intracellular Staining
Intracellular cytokine staining was performed by incubating lymphocytes for 4 hr at 
37°C in the presence of ionomycin (1 pg/ml), PMA (20ng/ml) and monensin (3pM) 
(Sigma-Aldrich, St Louis, MO). Cell surface staining was performed as described 
before followed by intracellular staining, performed using CytoFix/CytoPerm Kit (BD, 
Pharmingen, San Diego,CA) according to the manufacturer’s instructions. Cells were 
resuspended in FACS buffer and analysed by flow cytometry (FACS-CALIBUR®; 
Beckton Dickinson, CA).
2.6. Cytokine Enzyme-linked Immunosorbant Assay (ELISA)
IL-2 from culture supernatants was quantified using murine IL-2 ELISA development 
Kit (Peprotech, Rocky Hill, NJ). 96 MW plates were coated with 100 pi of capture 
antibody in PBS overnight (ON) at 4°C. After 3 washes in PBS containing 0.05% 
Tween-20, plate were blocked with 200 pi of PBS with 10% FCS for 1 hour at RT. 
Samples and serial dilutions of the standard were incubated for 2 hours at RT. After 5 
washes with PBS containing 0.05% Tween-20, plates were further incubated with pre­
mixed biotinylated IL-2-specific antibodies and avidin-HRP. Antibody binding was 
detected using OPD substrate (DAKO; Hamburg, Germany) and the absorbance read 
at a wavelength of 480 nm in a plate reader (MRX II; Dynex Technologies, 
Billinghurst, U.K).
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2.7. Immunoprecipitation and Western Blotting
Immunoprecipitation was performed as previously described (Baalasubramanian et al., 
2004). Lysates of mouse CD4+ or CD8 + T cells were incubated with 10 pg of mouse 
mAb against CD59a (mCD59.4) (Harris et al., 2003) and 50 pi of protein A-Sepharose 
beads for 2 h at 4°C .The immunoprecipitates were washed in lysis buffer and boiled in 
non-reducing SDS-PAGE sample buffer. Beads were removed by centrifugation, 
supernatants resolved on non-reducing 12% SDS-PAGE, and transferred to a PVDF 
membrane (Amersham Pharmacia Biotech, Freiburg, Germany). The membrane was 
blocked in 5% non-fat milk in PBS for 1 hour at room temperature (RT) and probed 
with the CD59a-specific mAb mCD59.1, ON at 4°C. The membrane was washed three 
times with 0.5% Tween in PBS. The membrane was subsequently incubated with 
secondary antibody Donkey-anti mouse-HRP (1:10000 Jackson Laboratories, Bar 
Harbor, ME) for 2 hours RT, washed in 0.5% Tween PBS . Protein bands were 
detected with ECL Advance Western Blot detection reagent (Amersham Pharmacia 
Biotech, Freiburg, Germany) used according to the manufacturers instructions.
2.8. Exogenous Incorporation of GPI-CD59a
Mouse CD59a was purified from EL4 cells using an immimoaffrnity column by Dr B. 
Sivasankar as previously described (Stefanova and Horejsi, 1991). 5xl06 CD4+ T cells 
were incubated with 5 pg/ml of GPI-CD59a for 20 min at 37°C to permit incorporation 
via the GPI anchor. Cells then were washed and incubated for another 2 hours to allow 
incorporation into lipid rafts (van den Berg et al., 1995).
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2.9. CD59a Cross-linking
V8 E, a mouse CD4+ T cell hybridoma known to be negative for mCD59a expression 
by FACS, was transfected with mCD59a as described above (Harris et al., 2003). 
Purified CD4+ T cells from Cd59a-/- or WT mice or V8 E cells, untransfected or 
transfected with CD59a, were incubated with mCD59.1 or isotype control mAb for 15 
min at 4°C. After two washes in RPMI, cells were plated at 105 cells/well in triplicate 
in a 96 MW plate. Where appropriate, 5pg/ml of F(ab’)2 rabbit anti-rat antibody 
(Serotec, Oxford, UK) was added to the wells. Cells were activated with 0.5 ng/ml of 
PMA and incubated at 37°C. After 18 hrs, supernatant was taken and IL-2 release 
analysed by ELISA performed according to the manufacturer’s instructions (BD, 
Pharmingen, San Diego,CA). For human CD59 cross-linking, purified CD4+ T cells 
(105/well) were incubated with HC1 or MEM43 antibodies for 15 min at 4°C, washed 
and cross-linked with polyclonal rabbit serum to mouse immunoglobulins.
2.10. Complement Assay
2.10.1. Complement Inhibition
For inhibition of complement activity in vitro, 1 pg/ml of recombinant human soluble 
CR1 (sCRl; gift of T Cell Sciences) was added to each well of a 96 MW plate. Cell 
proliferation was assayed after 3 days by thymidine incorporation. For in vivo 
inhibition, mice were injected i.v. daily with 20mg/kg of sCRl.
2.10.2. In Vitro Mouse Complement Haemolytic Activity
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To test complement inhibition, mice were bled every day and serum was tested for 
complement haemolytic activity using rabbit erythrocytes (RbE) sensitized with mouse 
anti-rabbit antiserum. RbE were washed twice in PBS, centrifuged at 2000 g  for 
10 min and resuspended with 1/200 dilution of mouse anti-rabbit serum for 30 min at 
RT. Red cells were washed, resuspended at 2% (v/v) in complement fixation diluent 
(CFD; OXOID Limited, Hampshire, UK) and aliquoted into the wells of a 96-well 
plate (0.1 mL/well) in triplicate. Serial dilutions of the test or control sera were 
incubated with the RbE (100 pl/well) at 37°C for 30 minutes. Hemolysis was 
measured by absorbance at 415nm ([A415 (sample)- A415 (min)]/[A415 (max) - A415 
(min)]) xlOO. Haemolytic activity in samples was tested 24 hours post-treatment.
2.10.3. In Vitro Complement Lysis Assay on Human Erythrocytes
Erythrocytes (E) from healthy donors were washed two times in PBS, centrifuged at 
2000 g  for 10 min and resuspended at 2% (v/v) in CFD. E were sensitized with 
polyclonal anti-CD55 antibody (100 pi) for 30 min at RT, washed, resuspended at 2% 
(v/v) in CFD, aliquoted into the wells of a 96-well plate (0.1 mL/well) in triplicate. 
When applicable, CD59-specific antibodies were added to the wells (10 pg/ml). E 
were then incubated at 37°C for 30 minutes with 0.1 mL dilutions of human serum in 
CFD and subsequently centrifuged at 800 g  for 5 min. The supernatants were 
transferred into a fresh flat-bottom 96-well plate and their absorbance at 415 nm was 
measured. Percentage of lysis for individual wells was calculated from the following 
formula: % lysis = ([A415 (sample-A415 (min)]/[A415 (max) - A415 (min)])xl00
2.10.4. Measurement of lutravascular Haemolysis and Haemoglobinuria
65
Mouse blood (200 pi) was collected into tubes containing 10 pi of 0.5 M EDTA to 
prevent clotting. Plasma was prepared by centrifugation at 5000 rpm for 10 min at 4°C 
in a micro-centrifuge, carefully removed and diluted 1:10 in 0.942 M Na2CC>3. To 
determined haemoglobin concentration in plasma samples, absorbance was measured 
at 380 nm, 415 nm and 450 nm in a spectrophotometer. The haemoglobin 
concentration in grams per liter was calculated from the following formula: cHb = 1.65 
x A415 - 0.93 x A380 -  0.73x A450. Urine haemoglobin levels from freshly collected 
samples were estimated by measuring the absorbance at 414 nm in a 96 multiwell plate 
( 1 0 0  pi).
2.11. Antibody Fab Fragment Generation and Purification
Purified MEM43 and HC1 antibodies, both IgG2a subclass, were resuspended in PBS 
pH 7.0 and 2mM EDTA and incubated with papain (Fluka, St Louis, MO) at an 
enzyme:IgG ratio of 1:25 (w/w) for different times at 37°C. The Fc fragment was 
removed using a HiTrap protein A HP column (Amersham Pharmacia Biotech, 
Freiburg, Germany). The column was equilibrated in PBS pH 7.0 and the antibody 
sample was applied using a syringe. The column was washed with PBS until material 
no longer appeared in the effluent (measured by OD 280 nm). The Fc fragment was 
eluted in 0.1 M citric acid buffer pH 3. Fab fragment purity was analysed on a 10% 
SDS gel.
2.12. Preparation of Virus Stocks
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2.12.1. r W
Recombinant vaccinia virus expressing the glycoprotein (rVVG2) of lymphocytic 
choriomeningitis virus (LCMV) has been previously described (Bachmann et a l, 
1994). rVVG2 was expanded in TK- cells. A confluent monolayer of TK- cells was 
infected with 107 pfu/ml in 5ml of VDM media (DMEM + 10% FCS + 0.05% BSA) 
for 2 h at 37°C and incubated for another 48 hours in DIO. The cell were subsequently 
harvested and subjected to three ffeeze-thaw cycles. Virus titres were subsequently 
measured by plaque assay.
2.12.2. Influenza Virus
Recombinant influenza A virus strain E61-13-H17 (HI 7; H3N2) amplified in 
embryonated chicken eggs, was obtained from the National Institute for Medical 
Research, London. The virus was titrated from allontoic fluid by performing a 
haemagglutination assay. Chicken red blood cells collected in Alsever’s solution 
(Harlan Sera-Lab, Oxford, UK), were washed three times in PBS, centrifuged for 10 
min at 1800 rpm and re-suspended in PBS to obtain a 1% suspension. 50 pi of virus 
dilutions were added to a V 96-multiwell plate and 25 pi of 1% red blood cells were 
added to each well. The plate was incubated at RT for 45 min. The last well to show 
complete haemagglutination (a hazy film of red blood cells) was considered to contain 
1 HA unit in 50 pi of sample.
2.13. Virus Titres
rW G P titres were determined in the ovaries of mice at day 3 and 8 post infection. 
Ovaries were homogenized and incubated into a monolayer of TK- cells as described
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previously (Gallimore, 1998). TK- cells in a 24 multiwell plate were infected with 200 
pi of various dilutions of the ovary homogenate for 2 hours at 37°C. The wells were 
overlaid with 1ml of DIO and incubated for a further 24 hours before staining with 
Giemsa. Virus titres were calculated after counting the number of plaques in one or 
more of the wells.
Influenza virus titres were determined by ELISA. Lungs were harvested at day 3 
and 8 post infection, homogenised, centrifuged at 2000 g and the supernatants used to 
infect Madine Darby Canine Kidney (MDCK) cells in a 96 multiwell plate. After 48 
hours incubation at 37°C, the supernatants were removed by aspiration and cells were 
incubated with influenza-specific antibody (Serotec, Oxford, UK), followed by anti- 
mouse-HRP (1:5000; Jackson Laboratories, Bar Harbor, ME) for 1 hour at RT. 
Antibody binding was detected using OPD substrate (DAKO; Hamburg, Germany) 
and read at 480 nm. A positive control calibration curve was constructed using 
dilutions of the titrated virus stock instead of lung homogenate.
2.14. Virus Infection and Determination of Anti-Virus Response
2.14.1. rW G2
Mice were inoculated via intra-peritoneal (i.p.) injection with 50 pi of rVVG2 at 108 
PFU/ml. At day 3 and 8 after infection, ovaries were harvested for virus titres and 
immuho-staining and spleens were harvested for NK assays, CTL assays and CD4+ T 
cell proliferation assays. For measurement of memory anti-virus responses, spleens
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were harvested approximately 6 weeks after infection and CTL assays and CD4+ T cell 
proliferation assays were performed (Figure 2.1).
2.14.2. Influenza Virus
Mice were infected intra-nasally (i.n.) with 20 HAU of Influenza virus HI 7 in 20 pi of 
PBS. At day 3 and 8 after infection, perfused-lungs were harvested for virus titres, 
histology and immuno-staining and spleens were harvested for NK assays, CTL assays 
and CD4+ T cell proliferation assays. For measurement of memory anti-virus 
responses, spleens were harvested approximately 6 weeks after infection and CTL 
assays and CD4+ T cell proliferation assays were performed (Figure 2.2).
2.15. T Cell Proliferation
2.15.1. Polyclonal Stimulation
CD4+ or CD8+ T cells from single cell suspensions of splenocytes were purified by 
positive MACS MicroBead selection (Miltenyi Biotec, Bergisch-Gladbach, Germany) 
according to the manufacturer’s instructions. Purity of T cells was analysed by flow 
cytometry (> 90%). For APCs, spleen cells were panT depleted (dynabeads, Dynal, 
Inc., Lake Success, N.Y.) and irradiated with 2400 cGy. CD4+ or CD8+ T cells (2xl04 
cells) were incubated with 105 APCs and 1 pg/ml of anti-CD3 mAb in a 96 multiwell 
plate. Cell proliferation was assessed by thymidine incorporation or CFSE FACS 
analysis at day 3. For anti-CD28 and anti-CD3 antibody stimulation, 105 CD4+ T cells 
were incubated in a 96 multiwell plate with 2 pg/ml of anti-CD28 and 2 pg/ml of anti- 
CD3 antibodies (Leinco Technologies, St. Louis, MO).
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2.15.2. Suppression Assays using CD4+CD25+ T Cells
CD4+CD25' and CD4+CD25+ T cells from single cell suspensions of splenocytes were 
purified using a Treg purification Kit (Miltenyi, Biotec, Bergisch-Gladbach, Germany) 
according to the manufacturer’s instructions. Purified CD4+CD25' T cells (2xl04 cells) 
were incubated with 105 irradiated APCs and 1 pg/ml of anti-CD3 mAb in a 96 
multiwell plate and CD4+CD25+ T cells were added to the wells in 1:1 or 1: 5 ratios 
when applicable. Cell proliferation was assessed by thymidine incorporation at day 3.
2.15.3. Adoptive Transfer of Fluorescently Labelled Cells
Purified CD4+ T cells from naive Cd59a-/- or WT mice, were then labelled with 
fluorescent dyes, either PKH26 (red) or PKH67 (green) respectively (Sigma-Aldrich, 
St Louis, MO) according to the manufacturer's instructions. The cells were transferred 
to Rag-/- recipient mice by i.v. injection. One day later, the mice were challenged i.n. 
with 20 HAU of influenza virus. After an additional 3 days, the mice were sacrificed, 
and their lungs were perfused and infiltrated cells analyzed by flow cytometry.
2.15.4. Virus-specific T Cell Proliferation
Vaccinia specific CD4+ T cell proliferation assays were performed by incubating 105 
CD4+T cells with 6xl05 irradiated splenocytes and 2.5 pg/ml of PI 3 
(GLNGPDIYKGVYQFKSVEFD) (LCMV-GP, I-Ab) or P61 
(SGEGWPYIACRTSWGRAWE) (LCMV-NP, I-Ab) peptide (EMC 
Microcollections, Tuebingen, Germany). For Influenza virus-specific CD4+ T cell 
proliferation splenocytes were incubated with UV-inactivated virus. UV inactivation
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Figure 2.2. Experimental Protocol. Influenza Virus
was carried out by incubating the virus for 20 min under a LF-106.5 UV lamp (UVltec 
Limited, Cambridge, UK). Influenza virus-pulsed DCs were also used as 
APCs.Immature DCs were incubated with influenza virus (50HAU/ml) and, in some 
conditions, with purified CD4+ T cells and incubated for 24 hours to allow maturation. 
Cells were incubated for 6 days and thymidine was added for the last 18 hours.
2.16. Killing Assay
2.16.1. CTL Assay
Spleen cells (4xl06 cells) were stimulated in vitro with lxlO6 gp33 (KAVYNFATM, 
(EMC Microcollections, Tuebingen, Germany) (LCMV-GP, Db) peptide-loaded (1 O'5 
M), irradiated splenocytes in a 24 multiwell plate and IL-2 was added at day 2. After 
one week, cells were re-stimulated with lxlO6 peptide-pulsed irrradiated splenocytes 
and IL-2 10 U/ml. Five days after restimulation, cells from 6 wells were collected, 
centrifuged at 1500 rpm and three-fold dilutions of the cell suspensions were made in 
RPMI medium containing 10% FCS in 96 MW plate. Cells were incubated with 51Cr- 
labelled, gp33 peptide-loaded B16 cells (10-4 cells/well) for 4 h at 37°C. For minimal 
and maximal lysis, splenocytes were incubated with medium or lysed with Triton 
X I00 respectively. rVVG2-specific CTL activity was measured by 51Cr release with 
the formula %lysis = ([counts sample -counts min]/[counts max -  counts min] )xl00.
2.16.2. NK Assay
Three-fold dilutions of Spleen cells (lx l 06) were incubated with 51Cr labelled Yac-1 
cells (lxlO4) in 96 multiwell plates for 5 h at 37°C. For minimal and maximal lysis,
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splenocytes were incubated with medium or lysed with Triton X I00 respectively.
Lysis was measured by 51Cr release using the formula %lysis = ([counts sample -  
counts min]/[counts max -  counts min] )xl00
2.17. Histology
Lungs were perfused with PBS and fixed in Zinc fixative (0.1M TrisHCl (pH 7.4) with 
0.05% Ca acetate, 0.5% Zn acetate and 0.5% Zn chloride) (Beckstead, JH 1994). The 
lungs were then embedded in paraffin wax and 5 pM sections were stained with 
Hematoxylin and Eosin (H&E). Briefly, cells were stained with hematoxylin (deep 
blue cells nuclei) and counter-stained with eosin (pink cytoplasm).
2.18. Statistic
All experiments were performed at least twice. Statistical significance (p<0.05) was 
evaluated using the student t test, 2 tailed assumed unequal variance, 95% confidence 
interval with the GraphPad Prism softward program. The Mann-Whitney U test was 
used to determine statistical differences in lungs-histological score between groups.
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Chapter 3- Murine CD59a Modulates Antiviral CD4+ T Cell 
Activity in a Complement-independent Manner
3.1. Introduction
Several groups have suggested that CD59 acts as a costimulatory molecule for T cell 
activation. Monoclonal antibody-mediated cross-linking of CD59 on PMA-treated 
human T cells resulted in enhanced proliferation, CD25 expression and IL-2 
production (Deckert et al., 1995; Korty et al., 1991). Other GPI-anchored proteins 
have also been implicated in modulation of T cell activation (Hahn and Soloski, 1989; 
Kroczek et al., 1986; Malek et al., 1986; Marmor et al., 1999 ; Maschek et al., 1993; 
Reiser, 1990; Robinson et al., 1989; Stefanova and Horejsi, 1991; Thompson et al., 
1989). However, studies performed in vivo using different GPI-anchored protein- 
deficient mice showed contradictory results (Gonzalez-Cabrero et al., 1999; Hazenbos 
et al., 2004; Heeger et al., 2005; Liu et al., 2005; Stanford et a l, 1997). This raised the 
question whether antibody cross-linking of CD59 on T cells mimics binding of CD59 
to its natural ligand and whether CD59 acts as a costimulator of T cell activation in 
vivo.
In order to explore the role of CD59 in T cell activation in vivo, we examined T 
cell function in mice deficient in the species analogue, CD59a (Holt et al., 2001). 
Cd59a-/- mice are healthy, fertile with a mild phenotype. Although mice are not 
anaemic, low levels of haemoglobulin can be detected in serum and urine indicating 
some spontaneous intravascular haemolysis. It has also been described that Cd59a-/-
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mice develop, in experimental models, more severe arthritis, ischemia-reperfusion 
injury, allergic encephalomyelitis and nephrotoxic nephritis than Cd59a +/+ 
counterparts (Mead et a l, 2004; Tumberg et al., 2004; Tumberg et a l, 2003; Williams 
et a l, 2004). In this chapter, T cell activity was compared in CD59a-deficient (Cd59a- 
/-) and WT mice following infection of mice with recombinant vaccinia virus (rVV).
For this study, we used a rVV expressing the glycoprotein (GP) of lymphocytic 
choriomeningitis virus (rW G2). rW G 2 contains several MHC-restricted peptide 
epitopes recognized by T cells in WT mice. One peptide, gp33, derived from the GP, is 
presented by the MHC class I molecule, H-2-Db and is recognized by CD8+ T cells 
(Whitton et a l, 1988), while another epitope, p i3, is presented by the MHC class II 
molecule H2-I-Abto CD4+T cells (Oxenius et a l, 1999). Infection of mice with 
rVVG2 therefore allowed analyses of both CD4+ and CD8+ virus-specific T cell 
response. In this Chapter, T cell responses to rW G 2 were measured and compared in 
WT and Cd59 -/- mice.
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3.2. Results
3.2.1 Cross-linking using Anti-CD59 mAb
Previous studies indicate that human CD59 acts as an accessory molecule for T cell 
activation (Deckert et al., 1995; Korty et al., 1991). Cross-linking of CD59 enhanced 
proliferation and IL-2 production on the Jurkat T cell line treated with PMA. In order 
to confirm this finding in the mouse system, purified splenic CD4+ T cells were 
stimulated with PMA, CD59a-specific mAb and cross-linking anti-Ig. CD59a cross- 
linking on mouse CD4+ T cell did not induce IL-2 production (Figure 3.1 A). Since this 
may be due to the low level of CD59a on mouse lymphocytes (as assessed by FACS 
(Harris et al., 2003) CD59a was overexpressed in a murine CD4+ T cell hybridoma 
(V8E) (Oxenius et al., 1999). Transfected cells expressed CD59a (Figure 3.1C) and, 
when stimulated with PMA, cross-linking of CD59a yielded enhanced IL2 production 
in comparison to untransfected cells subjected to the same stimuli (Figure 3.IB). These 
data indicate that when CD59a is expressed at a sufficient level on murine T cells, 
cross-linking CD59a does enhance IL2 production in a manner similar to that 
described for human T cells.
3.2.2. Mouse T Cells Express CD59a
The laboratory has previously shown that CD59a is broadly distributed while the 
second form of CD59 in the mouse, CD59b, is expressed only in testis (Harris et al., 
2003). In these studies it was reported that lymphocytes did not express CD59a as 
assessed by flow cytometry. More sensitive methods were therefore employed to
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Figure 3.1. CD59a Cross-linking Induces Secretion of IL-2
Expression of CD59a inVE8 and VE8-CD59a cells was detected by flow cytometry 
(B). Purified CD4+ splenic T cells from WT and Cd59a-/- mice (A) or VE8 and VE8- 
CD59a cells (C) were incubated with mCD59.1 mAb followed by an anti-Ig Ab. After 
18 hrs, IL-2 production was detected by ELISA. Values shown are mean ± SD. The 
results are representative of two experiments. Statistical significance (*) was evaluated 
using Student’s T test (p<0.001).
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determine whether primary murine CD4+ and CD8+ T cells express CD59a. CD59a 
expression was detectable by RT-PCR (data not shown) and immunoprecipitation 
followed by western blotting (Figure 3.2A) in both CD4+ and CD8+ T cells from WT 
but not Cd59a-/- mice.
3.2.3. Immune Responses in Cd59a -/- Mice Following Infection with 
Recombinant Vaccinia Virus
In order to determine whether CD59a plays any role in modulation of murine T cell 
activation in vivo, CD4+ and CD8+ T cell responses were compared in WT and Cd59a - 
/- mice after infection with a rVV expressing the glycoprotein (rVVG2) of LCMV 
(Whitton et al., 1988). CTL assays were performed to analyse the antiviral-activity of 
CD8+ T cells. Spleen cells harvested at day 8 and 6 weeks post-infection were 
stimulated in vitro using peptide-pulsed APCs. After a five-day culture period, CTL 
activity was measured against target cells pulsed with gp33. As shown in Figures 3.2B 
and D, no significant difference in CTL activity was observed between groups of mice 
at either of the time-points tested. CD8+T cells also exhibited similar gp3 3-specific 
proliferative responses as assessed by thymidine incorporation at day 8 post-infection 
(Figure 3.2C). Virus-specific CD4+T cell proliferation assays were also performed at 
the same time-points. As shown in Figures 2E and F, stronger proliferative responses 
to the specific peptide, p i3, were observed in Cd59a -/- mice compared to WT mice 
whilst no differences were observed in background proliferation to an irrelevant 
peptide p61, derived from the nucleoprotein of LCMV (Oxenius et al., 1999).
3.2.4. Cd59a-/- Mice have Unaltered NK Cytotoxicity
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Figure 3.2. rW G P  Specific CD8+T Cell Activity and CD4+T Cell Proliferation
CD59a expression was analyzed from immunoprecipitates of purified CD4+ T and 
CD8+ T cells from WT and control T cells from Cd59a-/- mice. Expression was 
detected using specific antibodies in a western blot (A). CD8+ T cell cytotoxic activity 
(B) and CD8+ T cell proliferation (C) was analyzed at day 8 after rW G P  infection. 
Memory CD8+ T cell cytotoxic activity was detected at day 42 after rW G P  infection 
(D). CD4+ T cells purified from rVVGP infected mice were tested for proliferation 
against peptides p61 and p i3, 8 (E) and 42 (F) days post-infection. Cell proliferation 
was measured by 3H-Thymidine incorporation at day 6. Mice were analyzed 
individually and values shown are the mean ± SEM (n= 3 mice/group). The results are 
representative of three independent experiments. Statistical significance was evaluated 
using Student’s T test
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Recently, it has been shown that antibody activation of CD59 enhances NK 
cytotoxicity (Marcenaro et a l, 2003). NK cells are critical components in innate 
immunity. Downregulation of MHC class I molecules in human cells by VV sensitizes 
the cells to lysis by NK cells (Kirwan et a l, 2005). Also, vaccinia infection of 
macrophages induces release of IL-18 that subsequently activates NK cells (Gherardi 
et a l, 2003; Tanaka-Kataoka et a l, 1999). To test the effect of CD59 deficiency on 
NK activity, mice were infected with rW G 2 and NK activity in splenocytes was 
measured against YAC- cells at day 3 after infection. Infected mice exhibited increased 
NK lytic activity compared to non-infected mice; however, no significant difference 
was observed between Cd59-/- and WT mice (Figure 3.3).
3.2.5. Immune Responses in Ovaries and Virus Titres
In order to determine whether the enhanced proliferation of GP-specific CD4+ T cells 
observed following in vitro stimulation reflected a stronger anti-viral CD4+ T cell 
response in vivo, numbers of CD4+ T cells at the site of rVVG2 infection (ovary) were 
compared in WT and Cd59a -/- mice at day 8 after infection. Higher numbers of 
infiltrating CD4+ T cells (Figure 3.4A and C) and IFNy-producing CD4+ T cells 
(Figure 3.4B and D) were observed in the ovaries of Cd59a -/- mice compared to WT 
mice. The same analysis was performed for ovary-infiltrating CD8+ T cells (Figures 
3.4E and F). Slightly higher numbers of CD8+ T cells were observed in the ovaries of 
Cd59a-/- mice compared to WT mice. This difference was not statistically significant 
and may reflect enhanced helper CD4+ T cell activity in the Cd59a -/- mice rather than 
a direct effect of CD59a on CD8+ T activity. To test whether the higher level of CD4+
T cell activity in the ovaries of Cd59a -/- mice was due to poorer control of virus in
81
NK
day 340 n
30-
- I  2 0 -
10 -
200 66 22 8
Cd59a-/-
WT
naive Cd59a-/- 
naive WT
E:T
Figure 3.3. Cd59a-/- Mice Have Unaltered NK Cytotoxicity
NK cytotoxic activity was analyzed at day 3 after rVVG2 infection. Spleen cells were 
incubated with YAC-1 and cell lysis was measured by 5ICr release.
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Figure 3.4. Increased Numbers of Ovary-infiltrating CD4+ T Cells in Cd59a-/- 
Mice
Ovary-infiltrating lymphocytes were stained for intracellular IFN-y, CD4 and CD8 
expression at day 8 post-infection and analyzed by FACS. CD4+ and CD8+ IFN-y 
producing cells were gated as shown in A and B respectively. Total numbers of 
infiltrating and IFN-y producing CD4+ are shown in C and D respectively and total 
numbers of infiltrating and IFN-y CD8+ T cells are shown in E and F respectively. 
Each symbol represents an individual mouse and similar data was observed in two 
independent experiments. Mean titres are also indicated in each graph. Statistical 
significance was evaluated using Student’s t test.
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Figure 3.5. CD59a-/- Mice Control rW G2 Infection More Effectively Compared 
to WT Mice
Virus titres in the ovaries of infected mice were determined at day 3 and at day 8 post­
infection. Virus clearance was more effective in Cd59a-/- mice compared with WT 
mice at day 3. No significant difference was detected at day 8 post-infection.
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these mice, vims titres were compared in both groups of mice at days 3 and 8 post­
infection. Vims titres were found to be significantly lower in Cd59a -/- mice compared 
to WT mice at day 3 post-infection, whereas both groups of mice had controlled the 
infection by day 8 (Figure 3.5). These data indicate that the more robust CD4+ T cell 
response observed in Cd59a -/- mice does not reflect an inability to clear the vims 
efficiently but may rather contribute to more rapid control of the infection.
3.2.6. Analysis of CD4+ T Cell Proliferation In Vitro
Proliferation of T cells from WT mice and Cd59a -/- mice was compared following in 
vitro stimulation with CD3-specific mAbs and APCs (T-depleted spleen cells). While 
no difference was observed in the proliferative behaviour of CD8+ T cells (Figure 
3.6A), CD4+ T cells from Cd59a -/- mice exhibited more proliferation in vitro 
compared to T cells from WT mice (a 2.5-fold increase; Figure 3.6B). The increase in 
proliferation of CD4+ T cells from Cd59a-/- mice compared to WT mice was only 
apparent when CD3-specific mAb and APCs were used for in vitro stimulation and not 
when CD3- and CD28-specific antibodies were used (compare Figures 3.6B and C). 
However, it was possible that strong stimulation with CD3- and CD28-specific 
antibodies could override the effect of CD59. To address this question, CD4+ T cells 
from Cd59a-/- and WT mice were stimulated with different concentrations of CD3- 
and CD28-specific antibodies. No difference in CD4+ T cell proliferation between 
groups was observed at any of the concentrations tested (Figure 3.7).
To determine whether CD59a expression on APCs affected proliferation of the 
responding T cells, CD4+ T cells were incubated with APCs from either WT or Cd59a 
-/- mice. CD4+ T cell proliferation was not influenced by the presence or absence of
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Figure 3.6. In vitro Proliferation Assays
Purified CD4+ or CD8+ T cells (>90%) were CFSE labeled and incubated with anti- 
CD3 mAb and APCs (A and B) or anti-CD28 mAb (C). Calculation of the number of 
mitotic events was performed as previously described (Yamazaki et a l 2003). One 
representative result of at least three independent experiments is shown. Values 
indicating mitotic events are the means of three experiments ± SD. To confirm that 
lack of CD59a expression was responsible for enhanced proliferation of T cells from 
Cd59a-/- mice, lymphocytes were incubated with GPI-anchored CD59a (CD59a-GPI) 
before the proliferation assay (E). Incorporation of CD59a-GPI on CD4+ T cells was 
confirmed by immunostaining (D).Values shown represent the mean ± SD. The 
experiment was performed on three separate occasions. Statistical analysis was 
performed by the Student’s T test.
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Figure 3.7. Enhanced CD4+T Cell Proliferation Requires The Presence 
of APCs.
Purified CD4+ T cells from Cd59a-/- or WT mice were stimulated with different 
concentration of CD3- and CD28-specific antibodies. Proliferation was measured by 
3H-Thymidine incorporation. One representative result of two independent 
experiments is shown. Values shown represent the mean ± SD.
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Figure 3.8. Effect of CD59a Expression on APCs
Purified CD4+ T cells were CFSE labeled and incubated with anti-CD3 mAb and 
APCs from Cd59a-/- or WT mice. One representative result of two independent 
experiments is shown.
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CD59a on APCs indicating that the difference in proliferation of CD4+ T cells from 
WT and Cd59a -/- mice is due to expression of CD59a on the T cells (Figure 3.8). 
Indeed, incorporation of GPI-anchored CD59a into CD4+ T cells from Cd59a -/- mice 
(Figure 3.6D) caused a reduction in proliferation to levels the same as cells purified 
from WT mice (Figure 3.6E). Together, these data imply that expression of CD59a on 
T cells down-modulates CD4+ T cell proliferation and requires the presence of APCs 
to exert this effect.
3.2.7. Analyses of CD4+T Cell Activation in WT and CD59a-/- T Cells
To determine whether CD59a deficiency affects early events of CD4+ T cell activation 
such as cytokine production, we measured IL-2 levels in CD4+ T cell cultures upon 
stimulation with CD3-specific antibodies and APCs (Figure 3.9). CD4+ T cell culture 
supernatants from Cd59a-/- mice showed a modest increase in IL-2 levels after 4 hours 
of stimulation compared to culture supernatants from WT T cells (Figure 3.9A). The 
difference became more significant after 18 hours of stimulation (Figure 3.9B). Higher 
levels of secreted IL-2 could reflect greater numbers of activated cells in cultures of 
CD59a-/- T cells. To address this question, we analyzed IL-2 production on a per cell 
basis by intracellular staining. CD4+ T cells from Cd59a-/- mice secreted more IL-2 
per cell compared to WT T cells as determined by mean fluorescence (MF; Figure 
3.9C). These data demonstrate a consistent correlation between the degree of IL-2 
production and proliferative responses observed in CD4+ T cells from Cd59a-/- and 
WT mice.
In order to further analyse T cell activation events, expression of markers 
associated with T cell activation was compared in WT and CD59a -/- CD4+ T cells.
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Figure 3.9. Increased Release of IL-2 in T cells From Cd59a-/- Mice Upon 
Activation
Purified CD4+T cells were activated with CD3-specific antibodies in the presence of 
APCs. Supernatants were taken at 4 (A) and 18 (B) hr after activation and IL-2 was 
detected by ELISA. Levels of IL-2 produced per cell were analyzed by intracellular 
staining of cells after 18 hr of activation (C). Markers were set using isotype staining 
controls.
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Stimulation of T cells results in a number of biochemical and morphological changes 
that can be tracked by expression of different cell markers. A hallmark of T cell 
activation is the ligation-induced down-modulation of the TCR:CD3 complex (Boyer 
et al., 1991; Lauritsen et al., 1998; Telerman et a l , 1987) . This process is easily seen 
by staining with TCR-specific antibodies within the first 5 hours of T cell activation. 
TCR downregulation is followed by upregulation of the activation marker CD25 24-48 
hours after stimulation (Biselli et al., 1992; Caruso et al., 1997; Viola and 
Lanzavecchia, 1996). Around three days after stimulation, T cells upregulate 
expression of the death receptor Fas, an event that increases the susceptibility of the 
cells to activation induced cell death (AICD). TCR expression was reduced to a greater 
extent on CD59a -/- T cells than WT T cells, an effect that was apparent as early as 1 
hour post-stimulation (Figure 3.10). No significant difference was observed in 
expression of CD25 or Fas between the two groups of mice (Figure 3.11).
3.2.8. Role of Complement in CD59a Modulation of T Cell Activation
The function of CD59a as a CReg is well described. The absence of CD59a allows
formation of the MAC and renders the cell more susceptible to complement-mediated
cell lysis. As described above, expression of CD59a appears to modulate T cell
activity. To test the possibility that C activation and formation of the MAC mediates
this effect, CD4+ T cells purified from both WT and Cd59a-/- mice were stimulated
with CD3-specific antibodies and APCs in the presence and absence of a soluble
inhibitor of complement (sCRl). sCRl blocks activation of the classical and the
alternative pathways of complement by binding C3b and C4b and mediating
proteolytic degradation of these molecules (Kalli and Fearon, 1994). Inhibition of*
complement in vitro did not affect the proliferative response of Cd59a-/- T cells
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Figure 3.10. TCR Down-regulation Upon Activation
Purified CD4+T cells were activated with CD3-specific antibodies in the presence of 
APCs (n=3). Lymphocyte activation was analyzed by down-regulation of TCR at 
different time points. (A) represent a representative histogram for each group. Table in 
(B) shows the MF of TCR expression on CD4+ T cells. Values shown represent the 
mean ± SD.
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Figure 3.11. CD4+T Cell Activation
Purified CD4+T cells were activated with CD3-specific antibodies in the presence of 
APCs. Lymphocyte activation was analyzed by expression of CD25 and Fas every 24 
hr for the period of 3 days.
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indicating that the enhanced proliferation was complement independent (Figure 
3.12A). To determine whether this was also true in vivo, mice infected with rVVG2 
were injected daily with sCRl. Treatment of mice with sCRl was shown to efficiently 
inhibit complement activity (more than 85% inhibition) throughout the course of the 
experiment. Glycoprotein-specific CD4+ T cell responses were measured 9 days after 
infection and no difference was observed in virus-specific proliferative responses 
induced in the presence or absence of complement inhibition (Figure 3.12B). To 
confirm this result, Cd59a-/-mice were intercrossed with C3-/- mice and then infected 
with rVVG2. Virus-specific CD4+ T cell response were enhanced equally in Cd59a-/- 
and Cd59a-/- C3-/- mice compared to WT and C3-/- mice (Figure 3.12C). These data 
demonstrate that the enhanced proliferation of Cd59a-/- CD4+ T cells is complement 
independent.
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Figure 3.12. Role of C in CD4+ T cell proliferation
Complement was inhibited in vitro with sCRl (i.v.) in assays where CD4+ T cells were 
stimulated with CD3-specific mAb and APCs (A). Data is representative of two 
experiments and values are shown as mean ± SD. C was inhibited in vivo by 
administration of sCRl to mice for the first 9 days of infection with rW G P  (B). In 
vivo experiments were repeated with Cd59a'/_C3‘‘ mice (C). Mice were individually 
analyzed and the values shown indicate the mean ± SEM (n= 3 mice/group). The 
results were analyzed statistically by Student's t test
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3.3. Discussion
Although the function of CD59 as a complement regulator protein is well established, 
its role in T cell activation is less certain. Previous studies using human T cells 
indicated that cross-linking of CD59 on human T cells in vitro induced cell activation 
and proliferation. The aim of the work described in this Chapter was to determine 
whether this finding could be recapitulated using mouse T cells and to study the effect 
of CD59a deficiency on T cells using Cd59a -/- mice.
Whilst CD59 is highly expressed in all human circulating cells (Meri and 
Lachmann, 1991; Nose et a l , 1990), expression of CD59a on mouse lymphocytes is 
low but detectable by WB and RT-PCR. Cross-linking of CD59a on T cells failed to 
induce T cell activation measured by IL-2 release, probably as a consequence of low 
levels of CD59 expression. Indeed, in order to reproduce the cross-linking experiments 
previously performed using human T cells, mouse T cell lines had to be transfected in 
order to increase the expression level of CD59a. In this chapter, we took advantage of 
mice deficient for the human homologue of CD59 (CD59a), to better understand the 
effect of CD59 in T cell activation in vivo and in vitro.
In order to gain more insight into the effect of CD59a on T cell activation,
Cd59a -/- and WT mice were infected with a rVV expressing the GP of LCMV. 
Cd59a-/- mice demonstrated significant increases in CD4+ T cell proliferation to 
rVVG2 compared to WT. This was not due to a poor control of the virus since VV
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titres measured in the ovary after day 3 post-infection were reduced compared to WT 
mice.
CD4+ T cells have been shown to play a crucial role in clearance of vaccinia 
virus by both humoral and cell-mediated mechanisms (Xu et al., 2004b). CD4+ T cells 
provide the cognate signals to B cells for production of protective virus-neutralizing 
IgG and, upon activation, they produce IFN-y which exhibits a direct anti-viral effect 
(Belyakov et al., 2003; Galmiche et al., 1999; Harris et al., 1995; Karupiah et al., 
1993). The high numbers of CD4+ T cells infiltrating the ovaries of Cd59a-/- infected 
mice parallels the increase in proliferation of the virus-specific CD4+ T cells, resulting 
in increased local production of IFN-y and more efficient virus clearance.
An alternative explanation for enhanced CD4+ T cell responses in Cd59a-/- mice 
involves complement. CD59a protects cells from complement mediated cell lysis 
inhibiting the formation of the MAC. Infection with rVVG2 may lead to complement 
activation that will be amplified in the absence of CD59a. Formation and deposition of 
MAC could induce cell activation as previously shown with mesangial cells (Lovett et 
al., 1987). However, our data demonstrate that the enhanced proliferation of Cd59a -/- 
CD4+ T cells is complement independent. In vivo inhibition of complement with sCRl 
did not alter rVV-specific CD4+ T cell proliferation in Cd59a-/- mice responses 
remained higher than in WT mice. To confirm this result, Cd59a-/- mice were back- 
crossed into C3-/-mice. VV-infection of Cd59a-/- C3-/- mice induced increased virus- 
specific CD4+ T cell activity similar to Cd59a-/- mice.
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Finally, in contrast to the cross-linking experiments performed in vitro, these 
data indicate that CD59a downmodulates anti-viral CD4+ T cell responses induced in 
vivo. These data are similar to those reported recently using CD55-deficient mice 
(Dafl-/- mice) where lymphocytes from these mice were found to proliferate more 
vigorously in response to a range of antigens compared to wild-type mice (Heeger et 
al., 2005; Liu et al., 2005). However, enhanced proliferation of Cd59a -/- CD4+ T 
cells is complement independent, contrasting with the recent data reported for Dafl-/- 
mice (Heeger et al., 2005; Liu et a l, 2005). In the case of CD55, the investigators 
found that the enhanced proliferative responses observed in Dafl-/- mice were largely, 
although not exclusively, complement dependent. Thus, while CD55 affects T cell 
activity in both a complement dependent and independent fashion, this study suggests 
that the effect of CD59a is complement independent. Another study reported that T 
cells isolated from Ly-6 A -  deficient animals also proliferate more vigorously than 
those isolated from their wild-type counterparts (Stanford et al., 1997). Interestingly 
Ly-6 A, CD59 and CD55 are all GPI-anchored molecules localized in lipid rafts, and 
all have previously been found in cross-linking studies to promote T cell activation in 
vitro (Davis et al., 1988b; Korty et a l, 1991; Stanford et al., 1997). Despite this, all 
three molecules negatively regulate T cell activity in vivo. Since GPI-linked proteins 
weakly associate with protein tyrosine kinases, it is possible that they can act either as 
positive or negative regulators of T cell activation by sequestering signalling 
molecules or interfering with assembly of signalling complexes in lipid rafts, the net 
effect dependent upon the trigger.
In vitro
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Significantly, in vitro studies of T cell responses in Cd59a-/- mice recapitulate the in 
vivo data. Stimulation of CD4+ T cells with CD3- specific antibodies and APCs 
induced increased cell proliferation in CD59a-/- compared to WT, though they 
responded in a similar way to CD3- and CD28- specific stimulation. These data 
suggest the presence of a ligand on APCs which, upon engagement with CD59a, 
down-modulates CD4+ T cell proliferation. APCs have been shown to express different 
complement component that may lead to MAC formation (Morgan and Gasque, 1997). 
Inhibiting complement had no effect on the enhanced proliferation observed in CD59a 
-/- T cells indicating that the ligand is not part of the complement cascade. The nature 
of the ligand is uncertain although several investigators have proposed that the natural 
ligand for human CD59 is CD2 (Deckert et al., 1992; Hahn et al., 1992). In one study, 
it was shown that radiolabelled CD59 bound to CD2-transfected CHO cells and that 
CD2-specific antibodies blocked binding (Deckert et a l, 1992). Using surface plasmon 
resonance analyses however, no interaction could be detected between the two 
molecules (Van der Merwe et al., 1994). The identity of a natural, non-complement 
ligand for CD59a will be further discussed in Chapter 5.
TCR engagement triggers a series of events, including early events such as TCR 
down-regulation, cytokine release, and late events such as proliferation. The results 
presented in this Chapter indicate that both early and late events are affected by 
CD59a. Activated CD4+ T cells lacking the expression of CD59a produce higher levels 
of IL-2 compared to WT CD4+ T cells and show more rapid and extensive TCR down- 
regulation. The biological significance of TCR downregulation is still unclear. TCR 
ligation is associated with receptor downregulation and this dynamic regulation of 
TCR cell surface expression is thought to be an important mechanism for T cells to
99
calibrate their response to different levels of stimuli. A more rapid TCR 
downregulation may be a consequence of a lower activation threshold on CD59a- 
deficient CD4+ T cells or may protect the cells from over-stimulation and anergy 
induction. It has been proposed that TCR downregulation is essential for T cell 
activation (Valitutti et al., 1995; Viola and Lanzavecchia, 1996). TCR internalization 
may serve as a focus for kinase association promoting or facilitating intracellular 
signaling (reviewed in Rothenberg, 1996). An alternative explanation for TCR 
downregulation is that internalization of the receptors limits prolonged contact with 
antigen, and thereby prevents tolerance by excessive TCR signalling. Together, these 
data suggest that CD59a modulates the early events of T cell activation.
In summary, the experiments described in this chapter identify a role for the 
GPI-anchored complement regulator protein, CD59a, in negative modulation of T cell 
activity in vivo and in vitro. Some key questions arise from this data. Firstly, is 
negative modulation of T cells by CD59a important for limiting the extent of T cell 
proliferation and therefore any pathological consequences of a T cell response? 
Secondly, what is the mechanism through which CD59a exerts its T cell modulating 
effect? Lastly, is the effect of CD59 on human T cells similar to that observed on 
mouse cells? These questions will be addressed in the following three chapters.
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Chapter 4 -  Influenza-induced immunopathology in 
Cd59a-/- mice
4.1. Introduction
Influenza virus infection represents a significant health problem, causing high 
morbidity and mortality worldwide. As described in detail in Chapter 1, influenza virus 
infection induces a massive pulmonary inflammatory response involving cells of the 
innate and adaptive immune system that can result in lung pathology. In studies of 
asthma in mice, complement activation has been shown to promote infiltration of 
inflammatory cells into the lungs (Krug et al., 2001; Marc et al., 2004). In addition, 
lack of complement component C3, results in reduced T cell infiltration into the lungs 
of influenza-infected mice. These findings imply that complement activation could 
contribute to virus-induced immunopathology and it is possible that the protective 
effects of CReg such as CD59a limit this process. The results presented in the previous 
chapter showed that CD59a modulated the CD4+ T cell response to rVV in a 
complement-independent manner. It is possible therefore that CD59 also modulates the 
CD4+ T cell response following infection with influenza virus, thereby limiting the 
extent of T cell-mediated immunopathology in a complement independent fashion. 
Based on this information, it was hypothesized that a deficiency in Cd59a would result 
in enhanced innate and adaptive immune responses to influenza virus and therefore 
enhanced immunopathology, mediated by complement dependent and independent 
mechanisms. This chapter describes experiments that address this hypothesis.
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4.2. Results
4.2.1. Cd59a-/- Mice Exhibit Increased Lung Inflammation Compared to WT 
Mice
Experimental influenza infection results in significant lung injury that can be detected 
by histological study of infected lungs. Cd59a-/- and WT mice were infected with 
influenza virus (HI7, H3N2) (Townsend and Skehel, 1984) intra-nasally and lungs 
were evaluated for evidence of pathology at day 8  post-infection. H&E stained 
sections of a non-infected lung and influenza-infected lungs of Cd59a-/- and WT mice 
are shown in Figures 4.1 A-C. Lung pathology was scored by an independent observer 
who examined the lungs for evidence of alveolar exudates, (score 0 to 3); 
haemorrhages (score 0 to 4); interstitial inflammatory infiltrate (macrophages and 
lymphocytes, score 0 to 4) and fibrosis (score 0 to 5) (see Figure 4.ID). Low levels of 
alveolar exudates were observed in both groups of mice. Areas of haemorrhage and 
areas of inflammatory infiltration were more extensive in Cd59a -/- mice compared to 
WT mice. Areas of fibrosis were observed only in Cd59a-/- mice. Each score were 
added together for every individual mouse to compile a final histological score (0-16). 
As shown in Figure 4. IE, the final histological score, and therefore the extent of lung 
pathology was significantly greater in Cd59a -/- mice.
4.2.2. Innate Immune Response to Influenza Virus
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Figure 4.1. Cd59a-/- Mice Exhibit Increased Lung Inflammation Compared to 
WT Mice
Mice were infected with influenza virus and lungs removed 8 days after infection 
(n=6/ group). (A) represent a healthy lung. Lungs from Cd59a -/- (B) or WT (C) mice 
were fixed in Zinc fixative, sectioned and staining with H & E. Representative 
histological score of lungs H&E staining are shown in (D). Histological score was 
evaluated by an independent observer (E). Statistical significant was evaluated by 
Mann-Whitney U test.
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Several reports indicate that the extent of influenza-induced lung pathology correlates 
with the extent of cellular infiltration in the lungs of infected mice. In order to 
compare cellular infiltrates in the lungs of WT and Cd59a -/- mice, lungs were 
harvested 3  and 8  days post infection with influenza virus and the different cell types 
were analysed by flow cytometry. Neutrophils were identified as 
SSChlghCDl lb+Grlhlgh F4/80' cells while macrophages and eosinophils were detected 
as SSChi8hCDl lb+G rlmed F4/80+ and SSC|0WCD1 l ^ G r l ^  F4/80+ respectively (Figure 
4.2). No difference was observed in the extent of macrophage and eosinophil 
recruitment between groups of mice (Figure 4.3A and B) but higher numbers of 
neutrophils were observed in the lungs of Cd59a-/- compared to WT mice (Figure 
4.3C).
NK cells are activated in response to infection with influenza virus (see 
Chapter 1). In order to assess NK cytotoxicity, Cd59a-/- and WT mice were infected 
with influenza virus and a killing assay was performed at day 3 post-infection. The NK 
cytolytic activity against YAC-1 cells was low but similar for both groups of mice 
(Figure 4.4A). Total numbers of NK cells recruited to infected lungs was analysed by 
flow cytometry at day 3 and 8  after infection. High numbers of NK cells were found in 
lungs of infected mice but numbers were similar between Cd59a-/- and WT mice 
(Figure 4.4B)
4.2.3. Cd59a-/- Mice Exhibit Increased Numbers of Lung-Infiltrating 
Lymphocytes after Influenza Infection
Influenza infection of mice induces a rapid release of cytokines by infected cells and 
recruitment of lymphocytes within the lung (Enelow et al., 1998). Total numbers of
105
103 10* 
F4/80
1 10 -  103 10 * 
F4/80
Eosinophils
10°  1 0 '  10 -  103 10 * 
F4/80
' Neutrophils
Figure 4.2. Identification of Neutrophil, Eosinophil and Macrophage populations
Presence of neutrophils, eosinophils and macrophages in influenza-infected lungs was 
analyzed by flow cytometry. Cells were identified by forward (FSC) side (SSC) scatter 
and antibody binding to CD1 lb, Gr-1 and F4/80: SSChlghCDl lb+G rlhi6h F4/80' 
(neutrophils), SSChighCDl lb+Grlmed F4/80+ (eosinophils) and SSC|0WCD1 lb+G rlmed 
F4/80+ (macrophages).
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Figure 4.3. Increased Neutrophil Recruitment into Lungs of Cd59a-/- Mice
Mice were infected with influenza virus and lung-infiltrating macrophages (A), 
eosinophils (B) and neutrophils (C) were analyzed by flow cytometry as explained in 
Figure 4.2. Each symbol represents an individual mouse and similar data was observed 
in two independent experiments. Means are also indicated in each graph. Statistical 
significance was evaluated using Student’s t test.
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Figure 4.4. Cd59a-/- Mice Have Unaltered NK Cytotoxicity
NK cytotoxic activity was analyzed at day 3 after Influenza vims infection. Spleen 
cells were incubated with YAC-1 and cell lysis was mesured by 51Cr release (A). Total 
numbers of lung-infiltrated NK cells were analyzed by flow cytometry (B). Mice were 
analyzed individually and values shown are the mean ± SEM (A) and each symbol 
represents an individual mouse (B). Similar data was observed in two independent 
experiments. Statistical significance was evaluated using Student’s t test.
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lung-infiltrating lymphocytes were analysed by flow cytometry at day 3, 8  and 12 post­
infection. Both, Cd59a-/- and WT mice showed a maximal T cell expansion at day 8  
post-infection that decreased significantly by day 12 (Figure 4.5A and B). The number 
of CD4+ T cells recovered from the lungs at day 3 post-infection was strikingly higher 
in Cd59a-/- compared to WT mice. Similar results were observed at day 8  post­
infection and by day 12, numbers of CD4+ T cells in lungs were similar for both 
groups of mice (Figure 4.5A). Total numbers of CD8 + T cells infiltrating the lungs 
were reduced compared to CD4+T cells peaking at day 8  post-infection. Slightly higher 
numbers of CD8 + T cells were observed in the lungs of Cd59a-/- mice compared to 
WT mice but the difference between the two groups was not statistically significant 
except at day 12 post-infection (Figure 4.5B). The trend for higher numbers of CD8 + T 
cells in the lungs of Cd59a-/- mice compared to wt mice may reflect enhanced helper 
CD4+ T cell activity in the Cd59a -/- mice (Figure 4.5B). Antigen-specific CD8 + T cell 
numbers in the lungs of both groups of mice was also analysed on days 8  and 1 2  post­
infection by tetramer staining for the inmunodominant peptide np6 8 . No significant 
difference was observed between the mouse groups (Figure 4.5C).
Functional assays were performed to assess the activity of the infiltrating 
lymphocytes in Cd59a -/- and wt mice. IFN-y production by T cells recovered from the 
lungs was assessed by intracellular staining and flow cytometry following stimulation 
of the cells with PMA/ionomycin. IFN-y-producing cells were mainly detected at day 
8 post-infection. The number of IFN-y producing CD4+ T cells in Cd59a-/- mice was 
significantly higher than WT mice (Figure 4.5D). No difference was found in the 
number of IFN-y-producing CD8 + T cells (Figure 4.5E).
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Figure 4.5. Cd59a-/- Mice Present Increased Numbers of Lung-infiltrated 
Lymphocytes after Influenza Infection
Cd59a-/- and WT mice (n=3/ group) were infected with 20HAU of influenza virus. 
Three, 8  and 12 days after infection, lungs were harvested and stained for CD4+ and 
CD8 + T cells. Naive mice were used for day 0. Total numbers of CD4+ (A) and CD8 + 
(B) T cells were determined by flow cytometry. Total number of np6 8 -specific CD8 + T 
cells was determined by tetramer staining (C). Lung homogenates were stimulated 
with PMA/ionomycin for 4 h and CD4+ (D) and CD8 + (E) IFN-y producing T cells 
were determined by antibody intracellular staining. All results represent mean values ± 
SEM from at least 2 independent experiments.
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4.2.4. Enhanced Influenza-specific CD4+ T Cell Proliferation in Cd59a-/- Mice
To determine whether the increase in the number of CD4+ T cells in the lungs of 
Cd59a-/- mice was due to better priming of antigen-specific T cells, influenza-specific 
CD4+ T cell proliferation was examined. Cd59a-/- and WT mice were infected with 
influenza virus and CD4+ T cells were purified from spleens at day 8 , 12 and 42 after 
infection. Influenza-specific proliferation of CD4+ T cells was increased in Cd59a-/- 
mice compared to WT mice at all time points tested (Figure 4.6A and B). The 
stimulation index (SI) was calculated by dividing the mean counts per minute (cpm) for 
T cells plus antigen by the mean cpm for T cells alone. A SI of 2 or more was 
considered positive. Cd59a-/- mice exhibited an SI > 3 for primary and memory 
responses (Figure 4.6C and D respectively). In WT mice, a positive SI was observed 
only at 12 days after infection (Figure 4.6C and D), indicating that influenza-specific T 
cell proliferation is more readily observed in Cd59a-/- mice.
4.2.5. CD59 Expression Does Not Affect CD8+ T Cell Cytotoxicity
As described above, total numbers of influenza-specific CD8 + T cells recovered from 
influenza-infected lungs were similar in Cd59a-/- mice and WT mice. IFN-y 
production by the CD8 + T cells was also similar in both mouse groups. To confirm that 
the CD8 + T cell response to influenza was comparable in Cd59a -/- and WT mice, CTL 
cultures were set up from infected mice at days 8 , 12 and 42 post-infection and five 
days later tested for killing of peptide-pulsed target cells. As expected, influenza virus 
induced a strong CTL response and, as expected, the lytic activity of Cd59-/- mice was 
comparable to WT mice (Figure 4.7).
4.2.6. Infection with Influenza Virus Induces Weight Loss in Balb/c.Cd59a-/- Mice
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Figure 4.6. Enhanced Influenza-specific CD4+ T Cell Proliferation in Cd59a-/- 
Mice
Cd59a-/- and WT mice were infected with 20HAU of influenza virus. After 8, 12 (A) 
and 42 days (B), CD4+ T cells were purified from splenocytes and stimulated with 
APCs loaded with UV-inactivated virus. Influenza-specific proliferation was detected 
by 3H-Thymidine incorporation at day 6. Stimulation index (SI) was calculated by 
dividing specific cpm by the background (C, D). Mice were analyzed individually and 
values shown are the means ± SEM (n= 3 mice/group). The results are representative 
of two independent experiments. Statistical significance was evaluated using Student’s 
t test
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Figure 4.7. Influenza-specific CTLs in Cd59a-/- Mice
Cd59a-/- and WT mice were infected with 20HAU of influenza virus. After 8  (A), 12 
(B) and 42 days (C) of influenza virus infection, CD8 + T cell cytotoxic activity was 
analyzed. Mice were analyzed individually and values shown are the mean ± SEM (n= 
3 mice/group). The results are representative of two independent experiments. 
Statistical significance was evaluated using Student’s t test (> 0.05 for all conditions 
tested)
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Despite histological evidence of increased lung pathology in Cd59a-/- compared to 
WT mice, no clinical symptoms of influenza infection were observed in either group of 
mice. Indeed it has been reported that C57BL/6 mice such as those used in these 
experiments rarely display obvious signs of influenza-induced pathology such as 
weight loss whereas excessive Thl-type influenza-specific CD4+ T cell responses in 
Balb/c mice correlate with measurable weight loss which is dose dependent and 
correlates with the extent of lung pathology (Hussell et a l , 2001). Experiments were 
therefore performed to determine whether influenza-induced weight loss in Balb/c 
mice was exacerbated as a result of CD59a deficiency.
For this purpose, Balb/c mice lacking CD59a (Balb/c.CD59a -/-) were obtained. 
Prior to analysing the response of these mice to influenza virus infection, experiments 
were performed to confirm that the phenotype of Balb/c.CD59a -/- mice was similar to 
those on the B6  background. Specifically, the mice were tested to determine whether 
deletion of CD59 caused spontaneous vascular haemolysis and haemoglobinuria (Holt 
et a l , 2001) as observed in B6  mice. Plasma and urine from Balb/c.Cd59a-/- mice 
contained increased amounts of haemoglobin when compared to Balb/c. WT mice 
indicating intravascular haemolysis and haemoglobinuria as reported previously for 
B6.Cd59a-/- mice (Figure 4.8).
Balb/c WT and Balb/c.Cd59a-/- mice were infected with a low dose of 
influenza virus and weight loss was monitored daily. Infection resulted in rapid weight 
loss in Balb/c.Cd59a-/- mice while body weight in Balb/c.WT mice remained almost 
constant (Figure 4.9). Since weight loss correlates with the extent of cellular
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Figure 4.8. Intravascular Haemolysis and Haemoglobinuria in Cd59a-/- Mice
Urine from Balb/c.Cd59a-/- and Balb/c. WT mice was collected and haemoglobinuria 
was measured by absorbance at 415 nm (A). Mice were bled into EDTA tubes and 
haemoglobin concentration was measured in plasma as described in material and 
methods (B). Each symbol represents an individual mouse. Statistical significance was 
evaluated using Student’s t test.
115
110-,
o>
|  1 0 0-
(0c
O)
O  90-  
0s
80
0 2 4 6 8
Cd59a-/- 
WT
Days
Figure 4.9. Influenza Infection Induces Weight Loss in Cd59a-/- Mice
Mice on the Balb/c background were infected with influenza virus and weight was 
monitored daily. Results represent mean values ± SEM of 5 mice per group. Statistic 
significance was evaluated by student’s T test. P value was < 0.02 at all time points 
measured after infection.
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infiltration into the infected lungs total numbers of macrophages, eosinophils and 
neutrophils were evaluated in both groups of mice by flow cytometry. Similar numbers 
of macrophages and eosinophils recruited to the lungs of both Balb/c.Cd59a-/- and 
Balb/c. WT (Figure 4.10A and B) however, numbers of neutrophils were elevated in 
Balb/c.Cd59a-/- mice at day 3 post infection (Figure 4.IOC). T cell responses were also 
assessed. As expected, Balb/c.Cd59a-/- mice exhibited increased total numbers of 
lung-infiltrating CD4+T cells compared to WT mice (Figure 4.10D). Total numbers of 
infiltrating CD8 + T cells were similar in both groups in line with the previous results 
obtained using B6  mice (Figure 4.10E). Overall, influenza infection of Balb/c.Cd59a-/- 
mice replicated the previous findings with B6.Cd59a-/- although total numbers of 
infiltrating cells in Balb/c.Cd59a-/- mice were greater than B6.Cd59a-/- mice, 
corresponding to the weight loss observed in the former group of mice.
4.2.7. Enhanced Cellular Infiltration in the Lungs of Cd59a-/- mice is Mediated 
by Complement Dependent and Independent Mechanisms.
In order to assess the effect of complement activation on lung infiltration in Cd59a -/- 
mice, complement was inhibit by daily injection of sCRl (i.v.) for the first 3 days of 
influenza infection. After 3 days, lungs were harvested and total numbers of infiltrating 
cells were analysed by flow cytometry. No difference was observed in numbers of 
CD8 + T cells, NK cells, macrophages and eosinophils after sCRl administration 
(Figure 4.11A, B, C and D) although the increase in neutrophil number found in 
Cd59a-/- mice was normalised and comparable to WT mice after complement 
inhibition (Figure 4.1 IE). Similar to previous findings in mice infected with rVVG2 
(Chapter 3), numbers of total infiltrating-CD4+ T cell remained unchanged after sCRl
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Figure 4.10. Enhanced Lung Inflammation in Balb/cCd59a-/- Mice
Cd59a-/- and WT mice (n=5/ group) on a Balb/c background were infected with 
influenza virus. Three and 8  days after infection, lungs were harvested and infiltrating 
cells were identified by flow cytometry. Total numbers of macrophages (A), 
eosinophils (B) and neutrophils (C) were identified as described in Figure 4.3. Lung- 
infiltrating cells were also stained for CD4+ (D) and CD8 + T (E). Each symbol 
represents an individual mouse. Means are represented in all graphs. Statistical 
significance was evaluated using Student’s t test
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Figure 4.11. Enhanced Influenza-induced Lung Inflammation in Cd59a-/- mice is 
Mediated by Complement Dependent and Independent Mechanisms
Complement was inhibited in vivo by administration of sCRl (i.v.) daily and mice 
were infected with influenza virus. After 3 days, lungs were harvested and total 
numbers lung-infiltrating cells were determined by flow cytometry. Total numbers 
CD8 + T cells (A) NK cells (B), macrophages (C), eosinophils (D), and neutrophils (E) 
were identified as described in Figure 3. Infiltrating-CD4+ T cells (F) were also 
identified by flow cytometry. Each symbol represents an individual mouse. Means are 
represented in all graphs. Statistical significance was evaluated using Student’s t test.
♦ Cd59a-/- 
o Cd59a-/-sCI 
□ W T  
■ W T sCR1
♦  Cd59a-/- 
o CD59a-/-sCF  
□ W T  
■ W T sCR1
♦ Cd59a-/- 
o Cd59a-/-sCR1 
□ WT 
■ WT sCR1
119
administration, indicating that modulation of the CD4+ T cell response by CD59a in 
experimental influenza infection is complement independent (Figure 4.1 IF). Overall, 
these data indicate that CD59a modulates the immune response to influenza virus by 
complement dependent (neutrophils) and independent (CD4+ T cells) mechanisms.
4.2.8. CD4+CD8+ double positive cells in the lungs of infected mice
Phenotypic analyses of the cells infiltrating the lungs of influenza- infected mice 
revealed a novel population of CD4/CD8 double positive (DP) lymphocytes. These 
cells were analysed by two-colour flow cytometry at day 3 and 8  post-infection. At 
three days post-infection (Figure 4.12A), CD4/CD8 DP cells were observed in the 
lungs of both WT and Cd59a -/- mice but higher percentages were observed in Cd59a- 
/- mice. No DP cells were observed in either group by day 8  post-infection or naive 
mice (Figure 4.12B). The percentages of the DP cells varied between 1% to almost 80 
% in Cd59a-/- mice but did not exceed 40% in wt mice (Figure 4.13 A). Surprisingly, 
CD4/CD8 DP cells were found only in the draining lymph nodes of Cd59a-/- mice 
(Figure 4.13B).
It is broadly accepted that the expression of CD4 and CD8  is mutually exclusive 
in mature lymphocytes. CD4/CD8 DP cells are present in the thymus where they 
differentiate into either CD4 or CD8  single-positive (SP) cells before emigrating into 
the periphery. Further characterisation of the cells by flow cytometry revealed that the 
DP cells were CD4in<ermediaKCD8high and did not express CD 11 c, CD lib , NK 1.1 or 
Grl (Figure 4.14). Expression of TCR and various T cell activation markers was then 
analyzed. The CD4/CD8 DP cells from isolated from both lungs and draining lymph-
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Figure 4.12. CD4/CD8 DP Cells in Lungs from Infected Mice
Mice were infected with influenza vims. At day 3 (A) and 8  (B) post infection, lungs 
were harvested and infiltrating cells stained for CD4 and CD8 . Representative Dot 
plots of CD4/CD8 expression are shown.
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Figure 4.13. Increased Frequency of CD4+CD8+ DP Cells in Cd59a-/- Mice
Mice were infected with influenza virus. Three days post-infection, lungs and LN were 
harvested and analyzed for the expression of CD4 and CD8  by flow cytometry. Each 
symbol represents an individual mouse. Means are indicated in both graphs. Statistical 
significance was evaluated by Student’s t test.
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Figure 4.14. Phenotype Characterization of CD4/CD8 DP Cells
Gated CD4+/CD8+ DP cells from infected lungs were analyzed for the expression of 
NK1.1, CD lib , Gr-1, CD llc and B220. Lung homogenates were stimulated with 
PMA/ionomycin for 4 h and CD4+/CD8+ DP cells producing IFN-y and IL-4 were 
determined by antibody intracellular staining
nodes of the infected mice did not express TCR, CD25, CD62L or CD44 (Figure 4.15). 
DP cells have been found previously in mice infected with Chlamydia pneumoniae and 
influenza virus. These cells, which were found in the lung within days of infection, 
were CD4mtermediateCD8 hlgh DP cells that did not express TCR and did not produce IFN- 
y upon stimulation (Pentilla et al., 1998). Parallel staining of thymocytes showed a 
similar phenotypic profile (Figure 4.15). This was an intriguing observation revealing 
a possible thymic origin for CD4/CD8 DP cells.
To explore this possibility, mice were thymectomized, infected two weeks later 
with influenza virus and lungs harvested 3 days post-infection. The experiment was 
performed in Cd59a-/- mice due to the higher numbers and frequency of CD4/CD8 DP 
cells in these mice compared to WT mice. Figure 16 shows the percentage of 
CD4/CD8 DP cells infiltrating the lungs of thymectomized and control mice. Whilst 
CD4/CD8 DP cells were found in 70% of control mice, DP cells were not found in any 
of the thymectomized mice, indicating that the DP cells come from the thymus. The 
functional significance, if any, of the cells remains unclear since the cells were unable 
to produce IL-4 and IFN-y after stimulation with PMA and ionomycin.
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Figure 4.15. Characterization of CD4/CD8 DP Cells
Gated CD4/CD8 DP cells from infected lungs and draining LN were analyzed for the 
expression of T cell (TCR) and activation markers (CD25, CD44 and CD62L). Cells 
were stained in parallel with CD4/CD8 DP thymocytes.
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Figure 4.16. Origin of CD4/CD8 DP Cells
Cd59a-/- mice were thymectomized and, after two weeks, mice were infected with 
influenza virus. Presence of CD4/CD8 DP Cells was analyzed in lungs 3 days after 
infection. Non-thymectomized mice were used as controls. Representative dot plots of 
CD4/CD8 DP Cells in thymectomized and control mice are shown in (A). Percentages 
of CD4/CD8 DP Cells were calculated by flow cytometry (B). Each symbol represents 
an individual mouse and similar data was observed in two independent experiments. 
Mean are also indicated in each graph. Statistical significance was evaluated using 
Student’s t test.
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4.3. Discussion
The use of Influenza infection in mice provides a good model to study the immune 
response in Cd59a-/- mice. Clearance of influenza virus is mediated by a concerted 
activity of the innate immune system followed by antigen-specific T cells.
As discussed previously the complement system impacts on both innate and adaptive 
immune responses to pathogens including influenza virus. The aim of the work 
presented in this Chapter was to determine whether the complement regulator, CD59a, 
plays an important role in limiting complement activation after influenza infection 
thereby limiting the immunopathological consequences of infection with the virus. 
Firstly, experiments were performed to determine whether the extent of 
imunopathology was greater in the lungs of influenza-infected Cd59a -/- mice 
compared to WT mice. Although lungs from infected mice were grossly normal in 
terms of colour and size with only small red foci, a closer examination by histological 
studies of H&E lung sections revealed increased lung injury in the Cd59a-/- mice 
compared to WT mice. An important feature of Cd59a-/- infected lungs was the 
prominent number of infiltrating cells. Characterization of the infiltrate revealed 
greater numbers of neutrophils in Cd59a-/- than WT mice. Neutrophils are considered 
a first line of defence against infection with pathogens. Their role has been well 
investigated in terms of their importance in early protection against bacterial infection 
(Mayer-Scholl et a i, 2004; Tatsukawa et al., 1979; reviewed in Mayer-Scholl et al., 
2004; Segal, 2005). The relative contribution to virus clearance has not been intensely 
investigated; however it has been suggested that neutrophils are important for 
controlling virus replication in influenza-infected mice after antibody depletion
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(Fujisawa, 2001; Ratcliffe et al., 1988; Tumpey et al., 1996; Tumpey et a l, 2005). 
Simultaneously, they may also contribute to the overall pathogenesis by release of 
immune mediators and subsequent T cell recruitment (Kobasa et al., 2004; Mulligan et 
al., 1993; Tumpey et al., 2005). Accumulation of neutrophils in the lung was 
dramatically reduced in sCRl-treated Cd59a-/- mice indicating that the enhanced 
neutrophils response in the Cd59a -/- mice was due to enhanced complement activity 
in these mice. In Cd59a-/- mice, more MAC formation occurs and, this increased MAC 
deposition not may only generate more cell injury and lysis, but also serve to further 
amplify complement activation and therefore the inflammatory response. Complement 
fragments have been shown to induce neutrophils migration to lungs. Administration 
of cobra vena factor (CVF) has been used to generate lung injury. In this model, 
complement components generated as a consequence of systemic complement 
activation by CVF, caused neutrophil migration and sequestration in lungs (Doyle et 
al., 1997; Mulligan et al., 1993). In addition, C3b deposition in HSV-infected 
fibroblast enhanced neutrophil attachment to infected cells via receptor recognition 
(Von Herrath et al., 1996). As discussed in Chapter 1, the anaphylatoxins C3a and C5a 
can act as chemoattractants of neutrophils (Martin et al., 1997; reviewed in Guo and 
Ward, 2005). However, CD59a regulates MAC assembly, and does not directly 
influence production of C3a and C5a. It has been demonstrated that MAC formation 
can indirectly influence the recruitment of inflammatory cells. For example, deposition 
of sub-lytic amounts of MAC on human endothelial cells in vitro has been shown to 
promote production of IL- 8  and MCP-1, chemotactic for neutrophils and monocytes 
respectively (Dobrina et al., 2002; Kilgore et al., 1997; Kilgore et al., 1995). 
Alternatively, absence of CD59a, by rendering cells more susceptible to MAC- 
mediated damage or killing, might indirectly cause local complement activation and
generation of chemoattractants. Overall, the results described here imply that the 
absence of CD59a increases deposition of MAC that, directly or indirectly enhances 
neutrophil recruitment to the lung. In the absence of complement, neutrophil numbers 
in Cd59a-/- mice were comparable to WT mice. Inhibition of complement had no 
effect on neutrophil numbers in WT mice probably due to the efficient natural 
regulation of complement activation in these mice. Conversely, inhibition of 
complement had a significant effect on neutrophil numbers in Cd59a -/- mice because 
in the absence of CD59a, complement activation is more pronounced.
Influenza viruses exhibit inter-strain variation, differing markedly in their 
virulence and in their ability to cause lung pathology ranging from mild to severe. The 
severity of the lung pathology also appears to depend on genetic background of the 
host and can differ markedly amongst different mouse strains. In the majority of the 
experiments described here, B6  mice were infected with 20 HAU of the HI 7 virus. 
Using this dose of virus, influenza-induce immunopathology observed in those mice 
was mild with no weight loss and relatively little damage to the lung structure. Mice 
were also infected mice with more virulent virus strains (PR8  and X31) and higher 
doses (200 HAU per mouse. Maximal dose allowed) with no evident clinical 
manifestations. To further analyze the effect of CD59a deficiency on lung pathology 
WT and CD59a-deficient mice on the Balb/c background were analysed. 
Balb/c.Cd59a-/- mice showed a rapid decrease in body weight that remained low until 
day 8  post-infection. Body weight in Balb/c. WT mice was found to be constant 
through the duration of the experiment probably due to low dose of virus used. 
Increased numbers of neutrophils were also observed in lungs of Balb/c.Cd59a -/- mice 
compared to WT. Balb/c mice.
T cell responses were also analysed in WT and CD59a-deficient mice 
following infection with influenza virus. No difference was observed in the CD8 + T 
cell response induced following infection of Cd59a -/- and WT mice with influenza 
virus, consistent with previous findings made using rVVG2 infected mice described in 
Chapter 3. Higher numbers of lung-infiltrating CD4+ T cells were, however observed 
in influenza virus infected Cd59a-/- mice on both the B6  and Balb/c backgrounds. The 
kinetics of CD4+T cell accumulation in lungs differed between Cd59a-/- mice and WT 
mice. The total number of CD4+T cells on day 3 post-infection was dramatically 
increased in Cd59a-/- mice compared to WT mice and remained almost equally high at 
day 8  post infection. By day 12 post-infection, similar numbers were observed in 
Cd59a-/- and WT mice. The CD4+ T cells from both groups of mice produced equal 
amounts of IFN-y on a per cell basis but increased numbers of lung-infiltrated CD4+ T 
cells in Cd59a-/- mice resulted in higher total levels of the cytokine, which is known to 
have direct anti-viral effects, at the site of virus replication. To determine whether 
increased CD4+T cell activity in Cd59a-/- mice facilitates more rapid virus clearance, 
virus titres were measured in the lungs by ELISA. Virus levels were undetectable at 
day 3 and 8  post-infection in Cd59a-/- and WT mice indicating that both groups of 
mice can efficiently control influenza virus infection (data not shown). In the previous 
chapter, rWG2-specific CD4+ T cell responses were enhanced in a complement 
independent manner in mice lacking CD59a. Since it has previously reported that 
complement activation promotes the activity of influenza-specific T cells in the lungs, 
it was possible that the effect of CD59a on T cell activity was an indirect effect 
attributable to complement (Baelder et al., 2005; Karp et al., 2001; Kopf et a l, 2002). 
However, the results presented in this chapter demonstrate that inhibition of 
complement activity using sCRl did not prevent the enhancement of CD4+ T cell
responses observed in the Cd59a -/- mice, indicating that the effect of CD59a- 
deficiency on CD4+ T cell activity is complement independent.
The analyses of cells infiltrating the lungs of influenza infected WT and Cd59a 
-/- mice revealed a population of CD4/CD8 DP cells in the lungs at day 3 but not day 8  
post-infection. Higher percentages of these cells were seen in the lungs of Cd59a -/- 
mice compared to WT, and DP cells were found only in the draining lymph nodes of 
the Cd59a -/- mice. Phenotypic examination of the cells indicated that they were 
similar to DP cells isolated from thymus. Indeed, DP cells were not found in mice 
thymectomised prior to influenza infection. It has been reported that a high proportion 
of peripheral CD4/CD8 DP cells are present during the neonatal period in mice and 
newborn humans (Bonomo et a l, 1994; Griffrths-Chu et al., 1984; Kotiranta-Ainamo 
et a l, 1999). In the mouse study, CD4/CD8 DP cells were detected in the lymph 
nodes but not spleens of 3- to 4-day-old mice, the percentage of which was found to 
vary greatly from mouse to mouse and which disappeared by 10 days of life (Bonomo 
et a l, 1994). The results of the study presented here imply that DP thymocytes can 
also escape from the thymus of adult mice, following infection. The mice used in this 
study were 4 - 6  weeks old, and it is possible that in older mice where thymic output is 
considerably reduced (usually at around six month of life), these cells would no longer 
be apparent (Scollay et a l, 1980). In adult rats, premature thymocytes can escape into 
the periphery as demonstrated by intrathymic injection of FITC and subsequent 
tracking of the FITC-labelled cells in the periphery (Hosseinzadeh and Goldschneider, 
1993; Jimenez et a l, 2002). The increased incidence of DP cells in influenza-infected 
Cd59a-/- mice compared to WT mice may be a consequence of the more profound 
inflammatory response to influenza observed in these mice. The fate of the cells in the
influenza-infected mice described here is unclear. It is possible that the cells are not 
evident at day 8  post-infection due to cell death by apoptosis following export from the 
thymus. Intrathymic injection of FITC previous to influenza infection would allow the 
fate of the cells to be followed after export from the thymus into peripheral sites.
Several previous studies have also identified CD4/CD8 DP cells in the context 
of virus infection. In mice, presence of CD4/CD8 DP cell has been described after 
reovirus, adenovirus and influenza virus infection (Hillemeyer et al., 2002; Pentilla et 
al., 1998; Periwal and Cebra, 1999). CD4/CD8 DP cells have also been found in 
peripheral blood from healthy humans, although the frequency of the cells is 
reportedly increased during infections with e.g. human immunodeficiency virus (HIV) 
and Epstein-Barr virus (EBV) (Imlach et a l, 2001; Ortolani et a l, 1993; Tonutti et a l, 
1994; Weiss et a l, 1998).The latter study demonstrated that circulating CD4loCD8hlgh 
DP cells were mature cells that had lost CDla-expression and were positive for the 
activation-memory marker CD45RO (Imlach et a l, 2001; Nascimbeni et a l, 2004; 
Ortolani et a l, 1993). In hepatitis C virus (HCV)-infected patients, CD4/CD8 DP cells 
were shown to specifically respond to MHC class II- and MHC class I-restricted HCV 
antigens by IFN-y production and were found in the liver, the site of infection 
(Nascimbeni et a l, 2004). The authors of this study suggested that CD4/CD8 DP cells 
are fully activated T cells that have acquired the expression of the other co-receptor. 
Indeed, experiments performed in vitro have shown that expression of CD4 on CD8 + T 
cells can be induced after stimulation with CD3- and CD28-specific antibodies, 
mitogens or DCs (Kitchen et a l, 2004; Sullivan et a l, 2001). Furthermore, purified 
CD4+ T cells activated and cultured in the presence of IL-4 have been shown to
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express the a-chain of CD8 , an effect that is accompanied by increased cell 
proliferation and IFN-y release by the cells (Molteni et al., 2002; Paliard et a l, 1988). 
Recently Baba and colleagues identified a population of CD4/CD8 DP cells at sites of 
myosin-induced myocarditis, which were derived from monocyte-macrophage 
precursors and exhibited cytotoxic activity (Baba et a l, 2005). Overall, these studies, 
performed both in rodents and humans, indicate that CD4/CD8 DP cells with different 
phenotypic and functional characteristics have been identified implying that several 
different types of DP cells exist. Whether any of these cells play an important role 
within the immune system is yet to be established.
In summary the results of the experiments described in this Chapter indicate that 
influenza-induced immunopathology, defined by scoring lung pathology, is 
exacerbated in mice lacking CD59a. Increased pathology correlated with an increase in 
the number of lung-infiltrating neutrophils and CD4+ T cells. Higher CD4+T cell 
infiltration displayed in the Cd59a-/- mice was complement independent while 
accumulation of neutrophils in the lung was dramatically reduced in sCRl-treated 
Cd59a-/- mice implying a dependence on complement activation. These findings 
clearly demonstrate that CD59a impinges on the immune response to influenza by at 
least two mechanisms: complement-dependent (neutrophils) and independent (CD4+T 
cells).
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Chapter 5- Investigating Mechanisms of CD4+ T Cell 
Modulation by CD59a
5.1. Introduction
As discussed in previous chapters, deficiency of CD59a significantly enhanced the 
CD4+ T cell response to virus infection via a complement-independent mechanism 
raising the possibility that CD59a functions as a negative regulator of adaptive 
immunity in vivo.
There is clearly a need to regulate T cell responses in vivo. Clonal expansion of 
CD4+ T cells is tightly regulated, as unchecked growth can result in expansion of 
autoreactive effector cells leading to autoimmune disease; or over-exuberant immune 
responses to foreign antigens leading to immunopathology. Several mechanisms are 
known to contribute to the regulation of T cell growth including activation-induced 
cell death (AICD), suppression by regulatory T cells and the delivery of negative 
signals via signalling molecules expressed on the cell surface (reviewed in Frauwirth 
and Thompson, 2002; Parijs and Abbas, 1998; Sakaguchi, 2004).
5.1.1. Activation Induced Cell Death (AICD)
Fas (CD95/APO-1) is a transmembrane receptor which belongs to the tumor necrosis 
factor receptor superfamily. Fas expression is upregulated on activated T cells and 
upon engagement with its ligand, FasL, mediates AICD, whereby the T cell dies by 
apoptosis (Nagata, 1997). Surface expression of Fas/APO-1 is known to play a critical 
role in regulation of CD4+ T cell growth (reviewed in Parijs and Abbas, 1998) since
134
mice lacking expression of Fas, exhibit lymphoproliferative disease illustrating the 
importance of the Fas -  FasL pathway in regulating homeostasis of naive T cells and 
restricting the growth of activated T cells (Adachi et a l, 1995; Watanabe-Fukunaga et 
al, 1992).
As mentioned in Chapter 1, patients with PNH exhibit clonal expansion of 
abnormal haematopoietic cells expressing a mutated form of the PIG-A gene that is 
involved in the biosynthesis of GPI-anchors. As a result, a proportion of blood cells 
from all lineages (myeloid, erythroid, mega-karyocytic and lymphoid) are deficient in 
surface expression of GPI-anchored proteins such as CD59 (Johnson and Hillmen, 
2002; Parker, 1996).It has been observed that patient cells lacking CD59 proliferate 
more extensively than CD59+ cells from the same patient. The proliferative advantage 
of the CD59- cells has been attributed to the relatively low expression of Fas in the 
membrane of the CD59- cells compared to those that express CD59 (Brodsky et a l , 
1997; Chen et a l, 2000). It is conceivable therefore that CD4+ T cells lacking CD59a 
also express lower levels of Fas, are therefore less susceptible to AICD and proliferate 
more extensively in response to antigen as described in Chapters 3 and 4.
5.1.2. Regulatory T Cells
There is accumulating evidence that T-cell-mediated regulation represents another 
mechanism for controlling T cell growth in vivo. It is now apparent that a population of 
CD4+ T cells called regulatory T cells (Treg) have the ability to control immune 
responses in vivo (Sakaguchi et a l, 1995). Based on intense research during the last 
decade, naturally occurring Treg cells (CD4+CD25+ Treg) have emerged as an 
important T cell population for preserving peripheral tolerance to self-antigens.
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CD4+CD25+ Treg develop in the thymus and are characterised by expression of CD25, 
CTLA4, GITR or the transcription factor, Foxp3 (reviewed in Fehervari and 
Sakaguchi, 2004; Jonuleit and Schmitt, 2003). The cells do not proliferate following 
stimulation through their T cell receptor but can inhibit the proliferation of 
conventional T cells (Sakaguchi et al., 1995; Thornton and Shevach, 1998) and 
reviewed in (reviewed in Sakaguchi, 2004). Tregs with the same phenotypic and 
functional characteristics have been identified in mice and humans (reviewed in 
Jonuleit and Schmitt, 2003). Although the cells have been studied mainly in the 
context of their ability to inhibit the activity of autoreactive T cells, there is also a 
strong body of evidence to support a role for naturally occurring Tregs in modulation 
of immune responses to pathogens (Groux et al., 1997; Takahashi et al., 1998; 
reviewed in Rouse and Suvas, 2004). As well as naturally occurring Tregs that arise in 
the thymus, Tregs can also be induced in the periphery. These cells, which exhibit 
phenotypic and functional characteristics that overlap with naturally occurring Tregs, 
have been termed adaptive Tregs and also suppress the activity of conventional T cells 
(reviewed in Roncarolo et a l , 2001; Weiner, 2001). The possibility that enhanced 
CD4+ T cell responses in Cd59a -/- mice are due to defective Treg activity was 
therefore tested as described in this chapter.
5.1.3. Negative Cell Signalling
Engagement of the Ag receptor on T lymphocytes triggers a complex signalling 
network that culminates in cell activation and differentiation. T cells require at least 
two signals for full activation. One signal is delivered by the binding of the 
antigen/MHC complex on the APC to an antigen-specific receptor on the T-cell 
surface. The best characterized second or costimulatory signal is delivered by the
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interaction between a cell-surface receptor on the T cell (CD28) with its ligands, CD80 
(B7-1) and CD8 6  (B7-2) on the APC. When T cells are triggered through the TCR in 
the absence of an appropriate costimulation signal, they may enter a quiescent state 
known as anergy. Multiple costimulation pathways both positively (CD40/CD40L and 
ICOS/ICOS-L) and negatively (B7.2 / CTLA4, PD-1/PD-1L) regulate T-cell function 
(reviewed in Frauwirth and Thompson, 2002; Greenwald et al., 2002). Thus T cell 
activation is regulated by a balance of positive and negative signals mediated by a 
series of costimulatory ligand-receptor pairs. In addition, T cell responses can be 
modulated by inadequate cell priming by APCs. Ligation of ILT3 (Immunoglobulin­
like transcript 3) with an as yet unidentified ligand or the MyD-1 (CD 172) receptor 
with CD47 on APCs has been shown to inhibit APC activation affecting antigen 
presentation and T cell priming (Brooke et al., 1998; Celia et a l, 1997; Smith et a l, 
2003) Whether CD59a delivers a negative signal to the T cell either directly or via the 
APC will be explored in this chapter.
Overall therefore, the objectives of the work described in this Chapter were to 
investigate 1) whether CD4+ T cells from Cd59a -/- mice were less susceptible to 
AICD, 2) whether suppression of T cell responses by Treg cells is defective in Cd59a - 
/- mice and 3) whether CD59a delivers a negative signal to the T cells directly or 
indirectly via effects on APCs.
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5.2. Results
5.2.1. Susceptibility to Fas-mediated Apoptosis
As shown previously in Chapter 3 (Figure 3.6B), CD4+ T cells from Cd59a-/- mice 
divided more extensively in response to stimulation with APCs and CD3-specific 
antibodies compared to WT mice. In order to determine whether this was due to less 
apoptosis in T cells isolated from the Cd59a -/- mice, three days after stimulation the 
cells were stained for annexin V expression. The percentage of proliferating cells that 
were annexin V positive was similar between the groups (Figure 5.1). Also, expression 
of Fas on CD4+ T cells was equally up-regulated upon activation of CD4+ T cells from 
Cd59a-/- and WT mice (Figure 3.11).
In order to confirm that CD59a+CD4+ T cells were not more susceptible to Fas- 
mediated killing than CD59a“CD4+ T cells, purified CD4+ T cells from Cd59a-/- and 
WT mice were activated with CD3- and CD2 8 -specific antibodies and cultured for 24 
hours with soluble FasL (sFasL) containing a Flag tag plus Flag-specific antibodies 
necessary to cross-link sFasL for induction of Fas-mediated killing. Addition of 1/50 
dilution of sFasL induced apoptosis in the majority of CD4+ T cells as measured by 
annexin V and PI staining and both groups of cells displayed a similar response to 
increasing concentrations of cross-linked sFasL (Figure 5.2A).
Results obtained in Chapter 3 showed that modulation of CD4+ T cell activation 
by CD59a requires the presence of APCs. Susceptibility of the CD4+ T cells to Fas- 
mediated apoptosis was therefore investigated in the presence of APCs. Total 
splenocytes were activated with CD3-specific antibodies and apoptosis was induced 
with cross-linked sFasL. The level of apoptosis induced by sFasL was comparable in
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Figure 5.1. CD59-CD4+ T Cells Are not More Resistant to Apoptosis
Purified CD4+T cells were activated with CD3-specific antibodies in the presence of 
APCs. After 3 days, proliferated cells were stained for annexin and analyzed by flow 
cytometry. Histograms are representative of two independent experiments.
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CD59a' and CD59+ CD4+ T cells (Figure 5.2 B and C). Together this data indicates 
that CD59a-expressing T cells are not more susceptible to Fas-mediated apoptosis.
5.2.2. An Evaluation of CD4+CD25+ Regulatory T Cells in Cd59a-/- Mice.
As discussed previously, Treg play an important role in controlling immune responses. 
The most striking property of CD4+CD25+ Treg cells is their ability to suppress the 
proliferative responses of CD4+CD25"T cells (Takahashi et al., 1998; Thornton and 
Shevach, 1998; Thornton and Shevach, 2000). A relative defect, in terms of number or 
function, of these Tregs could be responsible for CD4+ hyper-responses in Cd59a-/-.
To test this hypothesis, CD4+CD25+ T cells from naive Cd59a-/- and WT mice were 
enumerated. As shown previously in Figure 3.11 (Chapter 3) (day 0), no significant 
difference in the percentage of CD4+CD25+ T cells from naive Cd59a-/- and WT mice 
was found. Next, the suppressive capacity of CD4+CD25+ Treg was tested in vitro. 
When co-cultured with CD4+CD25+ Tregs, proliferation of CD4+CD25 ~ T cells upon 
incubation with CD3-specific antibodies and APCs was reduced in a dose dependent 
manner (Figure 5.3). However, no significant difference was observed in the capacity 
of CD4+CD25+ Tregs isolated from WT and Cd59a -/- mice to mediate suppression. 
Furthermore, CD59a-/- or WT responder cells were equally susceptible to the 
suppressive effects of CD4+CD25+ Tregs (Figure 5.3). These findings indicate that 
CD4+CD25+ Tregs in CD59a-/- mice are similar in number and function to those in 
WT mice.
T cells, whose immunosuppressive activity is induced/acquired in the periphery, 
have also been identified. Inducible Treg subsets include Trl and Th3 cells, whose 
major effector molecules are the immunosuppressive cytokines IL-10 and TGF-B,
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Figure 5.2. Induction of Apoptosis on CD4+ T Cells
Cells were incubated 24 h with sFasL and cross-linked with Flag-specific antibodies to 
induce apoptosis. Purified CD4+T cells were incubated with CD3- and CD28-specific 
antibodies for 24 h. Apoptosis was detected by annexin and PI specific staining (A). 
Total splenocytes were stimulated with CD3-specific antibodies. Apoptosis was 
analyzed by annexin staining in total cells (B) or in the CD4+-gated population (C). 
Histograms and dot-plots shown are representative of two independent experiments.
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Figure 5.3. Suppression Effect of CD4+CD25+ Regulatory T Cells in Cd59a-/- 
Mice.
CD25’ and CD25+ CD4+ T cells were purified from Cd59a-/- and WT mice. CD25' 
CD4+ T cells were stimulated with APCs and CD3-specific antibodies and CD25+ 
CD4+ T cells were added at 1:1 and 5:1 ratios. Proliferation was measured by 3H- 
Thymidine incorporation. Values shown are the mean ± SD Statistical significance (*) 
was evaluated using Student’s T test (p<0.01).
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respectively (reviewed in Fehervari and Sakaguchi, 2004; Steinman et al., 2003). It is 
possible that there is a defect in the generation of these cells in Cd59a -/- mice. This 
hypothesis is based on the idea that Treg cells are induced in WT mice following 
infection with influenza virus that serve to limit the expansion of the virus-specific T 
cell response. Thus, in the case of Cd59a-/- mice, an inability to generate these Treg 
cells would result in greater expansion of influenza-specific CD4+ T cells as described 
in Chapter 4. If this is true, the expansion of influenza-specific CD59a'CD4+ T cells 
should be limited in the presence of influenza-primed CD4+ T cells from WT mice. An 
experiment was therefore performed whereby purified CD4+ T cells from Cd59a-/- and 
WT mice were labelled with the fluorescent, membrane-intercalating dyes PKH26 
(red) or PKH67 (green) respectively and cotransferred into T cell deficient Rag-/- 
mice. One day after cell transfer, mice were either left uninfected or challenged with 
influenza virus and three days later, the mice were sacrificed and lungs were evaluated 
for the presence of fluorescent cells by flow cytometry. No infiltrating cells were 
observed in the lungs of uninfected mice however, an increased percentage of CD59a‘ 
CD4+T cells was found (2 fold increase, Figure 5.4) indicating that, under similar 
conditions of cell priming, CD4+ T cells from Cd59a-/- mice showed enhanced cell 
proliferation that was not due to impaired generation of inducible Tregs. If that had 
been the case, Tregs generated from WT CD4+ T cells should have equally suppressed 
both cell types.
5.2.3. CD59a ligand on APCs
Cd59a-/- mice, as discussed in previous chapters, exhibited enhanced CD4+ T cell 
responses in vivo and in vitro compared to CD4+ T cell from WT mice. This effect was 
shown to be complement-independent and required the presence of APCs implying
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Figure 5.4. Co-transfer of Fluorescently Labelled CD59a+ and CD59a' CD4+T 
Cells.
CD59a' (PKH26, red) and CD59a+ (PKH67, green) labelled T cells from naive mice, 
were transferred to recipient mice by intravenous injection. One day later, the mice 
were challenged with Influenza virus. After an additional 3 days, mice were sacrificed, 
and fluorescence cells were identified by flow cytometry. Representative dot plot of 
two independent experiments are shown.
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that CD59a on T cells interacts with a ligand, other than a complement component, on 
APCs. To test this hypothesis a fluorescently labelled CD5 9 a-IgG2a fusion protein 
(made in the laboratory by Dr B. Sivasankar) was used to examine whether all or a 
subset of murine splenocytes bound CD59a. The CD5 9 a-IgG2a fusion protein did not 
bind neutrophils, NK cells, CD8 + and CD4+ T cells but did bind to macrophages, DCs 
and B cells (Figure 5.5). Interestingly therefore, it appears that a ligand for CD59a is 
selectively expressed on cells attributed with antigen presentation capacity.
5.2.4. Effect of CD59a ligation on APC
CD59a is anchored to the cellular membrane through a GPI linkage and, due to the 
lack of a cytoplasmic domain, is unable to activate signalling pathways directly. The 
data presented in previous chapters seems to indicate the existence of a ligand for 
CD59a on APCs, which may be signalling competent. The possibility that engagement 
of CD59a does not modulate the CD4+ T cell response directly, but rather indirectly 
through CD59a-ligand signalling on APCs was therefore considered (Figure 5.6). In 
order to test this hypothesis, proliferation of CD4+ T cell from Cd59a-/- mice was 
assessed in the presence of irradiated CD59a+CD4+ T cells. The reasoning behind this 
experiment was that CD59a expressed on irradiated WT CD4+ T cells would engage 
with its ligand on the APC and, if this interaction resulted in delivery of a negative 
signal to the APCs, this would prevent the enhanced proliferation normally observed 
for CD4+ T cells purified from Cd59a -/- mice. Proliferation of CD59a'CD4+ T cells 
was not affected by the presence of irradiated CD59a+CD4+T cells suggesting that 
engagement of CD59a does not affect APC function (Figure 5.7).
To further explore the effect of CD59a engagement on APC function, effects of 
CD59a engagement on DC maturation and antigen presentation were analysed. DCs
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Figure 5.5. CD59a-Fc fusion Protein Binds to APCs
Splenocytes were double staining with biotinilated- CD59a-IgG2a fusion protein (y 
axis) and antibodies to CD4, CD8, Gr-1 (granulocytes), B220 ( B cells), CD1 lb ( 
Macrophages), CD1 lc (DCs) and NK1.1 (NK cells) (x axis) (A). As a control for non­
specific staining, cells were staining with a biotynilated-mouse IgG2a antibody 
(MEM-43).Stains are representative of two independent experiments.
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Figure 5.6. CD59 Delivers a Negative Signal to the APC
Direct interaction of CD59 on the T cell and a specific ligand on the APC results in an 
inhibitory signal being transmitted to the APC resulting in down modulation of APC 
activity and consequently, T cell.
Figure 5.7. Ligation of CD59a Does not Affect APC Function.
CD4+ T cells from Cd59a-/- or WT mice were incubated with APCs or CD3-specific 
antibodies. To assess a possible regulatory effect of CD59a binding to APCs, irradiated 
CD4+ T cells from both groups of mice were added to the well. Proliferation was 
measured by 3H-Thymidine incorporation. Values shown are the mean ± SD and 
statistical significance (*) was evaluated using Student’s T test (p<0.05). Data is 
representative of two independent experiments.
are the most potent APCs and possess the ability to stimulate naive T cells. Immature 
DCs (iCDs) are characterized by high endocytic activity and low T-cell activation 
potential and, when stimulated, DCs differentiate into mature DCs (mDCs) 
upregulating MHC class II and co-receptors such as CD86, greatly enhancing their 
ability to activate T-cells (Mclntire and Hunt, 2005). Infection with influenza virus has 
been shown to mature DCs (Celia et al., 1999). In order to test if ligation of CD59a 
ligand impinges on DCs maturation, immature DCs were incubated with CD4+ T cells 
from Cd59a-/- and WT mice and influenza virus when applicable. DC maturation was 
assessed by up-regulation of MHC class II and CD86. No difference was observed on 
maturation of DCs recovered after CD59a-/- or WT CD4+ T cell-DC co-culture (Figure 
5.8). The antigen presenting capacity of these cells were then tested in an influenza- 
specific proliferation assay. DCs, previously incubated with either CD59a -/- or WT T 
cells and influenza virus, were used to prime influenza specific-CD4+ T cell purified 
from an infected WT mouse. As shown in figure 5.9, no difference was observed in T 
cell priming by DCs cocultured with either CD59a-/- or WT CD4+ T cells, indicating 
that expression of CD59a on CD4+ T cells does not alter the antigen presentation 
capacity of DCs (Figure 5.9).
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Figure 5.8. CD59a Binding Does not Affect DCs Maturation
Immature BM-derived DCs were infected with 0.01 HAU/cell for 24 h to induce 
maturation. To study the effect of CD59a binding on DCs, purified naive CD4+ T cells 
from Cd59a-/- or WT mice were added to DCs during maturation stimulus (ratio 3:1). 
DCs maturation was analyzed by up-regulation of CD86 and MHC-II expression. 
Representative histograms from two independent experiments are shown.
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Figure 5.9. CD59a Binding Does not Affect Antigen Presentation on DCs
DCs previously incubated with Influenza virus and CD4+ T cells from Cd59a-/- or WT 
mice, were used as APCs for influenza-specific CD4+ T cells proliferation. WT mice 
were infected with 20 HAU of influenza virus. After 12 days, splenocytes CD4+ T 
cells were purified and used as responders. 105 responder cells were incubated with 
3x104 (A) or 104 (B)DCs for 6 days. Uninfected-DCs were used as negative control. 
Proliferation was measured by 3H-Thymidyne incorporation. Values shown are the 
mean ± SD and statistical significance (*) was evaluated using Student’s T test 
(p<0.05). Data is representative of two independent experiments.
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5.3. Discussion
The experiments described in this Chapter aimed to investigate the potential 
mechanisms through which CD59a modulates CD4+ T cell activity in vitro and in vivo. 
The possibility that CD59a -/- T cells were less susceptible to AICD was investigated 
since previous reports indicate an anti-apoptotic role for human CD59. Co-ligation of 
both CD59 and Fas in Jurkat cells using cross linking antibodies dramatically 
decreased cell death mediated by Fas while co-ligation of both CD28 and Fas 
dramatically increased Fas-mediated apoptosis (Legembre et al., 2006). The authors of 
the study attributed the finding to CD59-mediated translocation of Fas into a specific 
lipid microdomain causing modulation of its signalling pathway. Whether this 
represents a physiological pathway through which CD59 and Fas interact is not 
known. Other reports have indicated that clones from PNH patients, sorted based on 
CD59 expression, exhibit reduced Fas expression and are therefore more resistant to 
apoptosis. Whilst this finding implies a link between CD59 expression and resistance 
to apoptosis, those cells lacking CD59 lack expression of all GPI-anchored proteins 
therefore the effect on apoptosis is not necessarily due to lack of CD59 (Horikawa et 
al., 1997; Ware et al., 1998). The findings of the experiments presented in this Chapter 
do not support a role for CD59a in modulating the sensitivity of mouse CD4+ T cells to 
FasL-induced apopotosis.
Next, experiments were performed to determine whether regulatory T cell activity was 
impaired in Cd59a -/- mice. Similar numbers and suppressive activity of CD25+CD4+ 
Tregs was found in Cd59a-/- mice compared to WT ruling out the hypothesis that the 
level or activity of naturally occurring Tregs is impaired in the Cd59a -/- mice. The 
possibility that Tregs are differentially induced in response to antigen stimulation in
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WT and Cd59a -/- mice was also investigated. A recent study showed engagement of 
the human CReg, CD46, on human CD4+ T cells induced a regulatory T cell phenotype 
in the cells. In these experiments, co-engagement of CD46 and CD3, in the presence of 
IL-2, induced an IL-10-secreting Treg cell phenotype characteristic of Trl cells 
(Kemper et a l, 2003). Trl cells differentiate in the periphery from naive precursors, 
typically in the presence of interleukin-10 (IL-10), and regulate T-cell responses 
through their ability to produce IL-10 and TGF-p. The hyperactivity of CD59a- 
deficient T cells cannot however be attributed to a defect in generation of Trl cells 
since the hyperactvitiy was still evident after mixing the cells with WT T cells. Co­
transfer of CD4+ T cells from Cd59a-/- and WT mice also showed that the difference 
in cell proliferation was intrinsic to the CD59a-deficient CD4+ T cell. However, the 
nature of this experiment does not rule out a difference in cell migration of CD4+ T 
cells from Cd59a-/- and WT mice. In response to influenza-infection, CD59-CD4+T 
cells may express integrins or chemokine receptors conferring increased migratory 
capacity to the lung.
5.3.2. Negative Cell Signalling 
Indirect Effects via APCs
Signalling by GPI-anchored proteins is intriguing, because these proteins have no 
transmembrane or cytoplasmic domains. Therefore, it is possible that CD59a binding 
initiates intracellular signalling that is transduced through the CD59 ligand. Several 
receptors have recently been shown to modulate the activity of myeloid cells. Ligation 
of the CD200R with a recombinant protein and specific antibodies inhibited IFN-y- 
induced TNF-a and IL-6 secretion by macrophages and was also shown to induce 
production of IL-10 and TGF-p by DCs resulting in generation of Tregs (Gorczynski et
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al., 2005; Jenmalm et al., 2006). The expression of the ligand CD200 was shown to be 
upregulated on T cells upon activation (reviewed in Barclay et al., 2002). Similar 
effects were reported as a result of CD47-CD172 interacting on APCs and T cells. 
Engagement of CD47 on DCs results in impaired maturation of the DCs and decreased 
production of inflammatory cytokines (Demeure et al., 2000), ultimately affecting 
their ability to stimulate T cells. No such effect was observed for CD59a expressing T 
cells since in the presence of T cell expressing CD59a, no defect in antigen 
presentation or maturation was observed.
Direct Effects on T Cells
It is possible that engagement of CD59a on T cells downmodulates the signal delivered 
to the T cells upon activation through the TCR (Figure 5.10). Antibody cross-linking 
of CD59 on human T cells induces protein phosphorylation and, in 
immunoprecipitation studies, CD59 was found to be associated with src kinases. This 
finding implies that CD59 modulates T cell activation by associating with signalling 
molecules found in the cell membrane. Indeed, CD59 is a GPI-anchored protein found 
in lipid rafts and may therefore modulate T cell signalling by associating with other 
proteins also found in lipid rafts. Translocation of signalling molecules in and out of 
lipid rafts can control the ability of cells to respond to various stimuli. For example, 
CD28 engagement has been shown to induce redistribution and polarization of GPI 
microdomains at the site of TCR engagement and increases the presence of the linker 
of activated T cells (LAT) in membrane rafts while CTLA-4 ligation effectively blocks 
this increase and reduces raft expression (Margarita Martin 2001)
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Figure 5.10. CD59 Negative Modulates Signal to the T Cell
Direct interaction of CD59 on the T cell and a specific ligand on the APC results in an 
inhibitory signal being transmitted to the T cell reducing the strength of the positive 
signal delivered through the TCR.
In an attempt to test the effect of CD59a on T cell activation, analyses of Ca2+ 
flux and protein tyrosine phosphorylation were performed on WT T cells and T cells 
lacking CD59a upon stimulation with CD3-specific antibodies and APCs. 
Unexpectedly, no signal could be detected after stimulation of WT or CD59a-deficient 
T cells using either method. Several technical difficulties came to light. Firstly, naive 
lymphocytes were used in these assays and stimulation with soluble antibodies and 
APCs may not induce a strong enough stimulation to allow a signal to be detected 
within the short time-frame of the experiments (protein tyrosine phosphorylation = 
minutes, Ca2+ flux = seconds). In general, using either antigen-pulsed APCs or T cell 
clones or by CD3 and CD28 cross linking, other investigators have investigated T cell 
signalling (Donnadieu et al., 1992; Geiger et a l , 1999). In the experiments described 
here, no antigen-specific T cell clones were available and it was not possible to 
perform the experiments by cross linking CD3 and CD28 because APCs were required 
in the assays to provide the ligand for CD59a. TCR activation using CD3-specific 
antibodies and APCs may not provide a sufficiently strong signal for detection. In 
addition, CD59a binding to its ligand might not occur simultaneously posing another 
limitation for assays described here. Additional work will therefore be required to 
explore in more detail the effect of CD59a on T cell activation. It may be possible to 
improve the experiments by back-crossing Cd59a-/- mice with CD4+ TCR transgenic 
mice (eg. OTII, ovalbumin-specific) which will provide a source of antigen-specific 
CD4+CD59" T cells that can be easily activated with peptide-loaded APCs. In this 
context, CD59a engagement and TCR activation will occur simultaneously and 
potentially solve the problems described above. Another possibility may involve 
activation of the T cells with beads coated with CD3-specific antibodies and the
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CD59a ligand. Identification of the ligand for CD59a will be required for this 
approach to succeed.
In summary, the results of this Chapter rule out the possibility that CD59a 
modulates T cell activity through affecting Fas-FasL interactions, through regulatory 
cell activity or through delivery of a negative signal to APCs. Unfortunately due to the 
technical limitations discussed above, it has not yet proven possible to determine 
whether CD59a affects the strength of a signal delivered to a T cell upon TCR 
engagement. As mentioned above, it may be possible to address this issue in more 
detail using experimental systems whereby better strategies for detecting signalling 
events within T cells can be employed.
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Chapter 6- CD59 Modulates Human CD4+ T Cell 
Proliferation
6.1. Introduction
CD59 is highly expressed on human T cells and, although several studies imply that 
CD59 is involved in T cell activation, its specific function has not been well defined. 
Studies have shown that antibody cross-linking of CD59 induces a series of events 
including the activation of protein-tyrosine kinases, Ca2+ flux, IL-2 release and cell 
proliferation (Korty et al., 1991; Stefanova, 1991). These events are not unique to 
CD59, since many other GPI-anchored proteins induce a series of similar events when 
cross-linked with specific antibodies (Gunter et al., 1984; Kroczek et al., 1986; Reiser, 
1990; Thompson et al., 1989). Controversy exists regarding the physiological 
relevance of these experiments. Since the GPI anchor proteins only transverses the 
outer leaflet of the membrane bilayer, it is likely T cell activation by cross-linking 
antibodies is the result of protein aggregation and association of CD59 with signalling 
molecules.
Studies in vivo with CD59a deficient mice, showed contradictory results. While 
antibody cross-linking of CD59 induced T cell activation, mice deficient in CD59a 
exhibited CD4+ T cell hyperactivity as discussed in Chapter 3 and 4. The same 
findings were made in studies of other GPI-anchored proteins like CD55 and Ly6A 
(Heeger et al., 2005; Liu et al., 2005; Stanford et al., 1997).
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The purpose of this study was to investigate the effect of CD59 on human T cell 
activation. The aim was to conduct these experiments by blocking CD59 and 
measuring the effect of loss of CD59 function rather than to perform antibody cross- 
linking experiments as described above. The first part of this Chapter describes 
production of Fab fragments of CD59-specific antibodies and the latter part describes 
the impact of antibody binding on the activity of human T cells.
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6.2. Results
6.2.1. Differential Expression of CD59 on Human CD4+ T Cell Subsets
CD59 is widely distributed on most tissues and circulating cells including lymphocytes 
(Meri and Lachmann, 1991). In order to determine whether CD59 expression differs 
amongst different populations of CD4+ T lymphocytes, CD4+ T cells from healthy 
donors were purified using magnetic beads and phenotypically characterized using 
antibodies specific for T cell activation and memory markers.
Two isoforms of CD45 have been described that are differentially expressed on 
T cells upon stimulation (Clement et al., 1988). While the low molecular weight 
isoform CD45RO is expressed primarily on memory T cells, CD45RA is expressed on 
cells with a resting/naive phenotype (Akbar et al., 1988). All CD4+ T cells expressed 
high levels of CD59 (Figure 6.1 A) but increased expression of CD59 was detected on 
CD4+CD45RO+ T cells compared to CD4+CD45RA+ T cells (Figure 6.1 A and B). 
These data indicate that recently or previously activated T cells up-regulate expression 
of CD59. To further investigate this possibility, CD4+ T cells were activated with 
CD3-specific antibodies and APCs, and expression of CD59 was compared in 
unactivated and activated cells. Upon stimulation, expression of CD59 was up- 
regulated on CD4+ T cells as measured by an increase in mean fluorescence (Figure 
6.2A). Moreover, acquisition of the activation marker CD25 by activated cells was 
accompanied by up-regulation of CD59 expression (Figure 6.2B). Thus, CD4+ T cells 
appear to up-regulate CD59 expression upon activation but whether CD59 is involved 
in the process of T cell activation or whether it is upregulated simply to protect 
activated cells from complement attack remains to be clarified.
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Figure 6.1. Expression of CD59 on Human CD4+ T Cells
CD4+ T cells were purified from human PBMCs. Cells were stained with CD59-, 
CD45RA- and CD45RO-specific antibodies (A). Expression of CD59 was analyzed on 
CD45RA (B) and CD45RO (C) gated cells. One representative dot plot and histograms 
from 3 different experiments are shown.
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Figure 6.2. Expression of CD59 on Activated Human CD4+ T Cells
CD4+ T cells were activated with CD3-specific antibodies and APCs. 24 hours post­
activation, expression of CD59 was analyzed (A). Expression of CD59 was analyzed 
on recently activated cells, detected by CD25 expression (B) gated cells. One 
representative dot plot and histograms from 2 different experiments are shown.
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6.2.2. Generation of Fab Fragments
Cross-linking of CD59 induces activation of human T cells however, lack of CD59a 
expression results in hyperactivity of mouse T cells. In order to reconcile these 
observations, Fab fragments from CD59-specific antibodies were generated to block 
CD59 expressed on human T cells. Removal of the antibody Fc portion was necessary 
to avoid antibody cross-linking by Fc receptors binding on APCs.
IgG antibodies have a molecular weight (MW) of approximately 150 KDa and 
are formed of two identical heavy chains and two light chains of 50 and 25 KDa 
respectively. The two heavy chains are linked to each other by disulfide bonds and the 
heavy chains are bound to a light chain also by a disulfide bond (Edelman et al., 1969). 
IgG antibodies were papain digested, a cut in the hinge region that joins the heavy 
chains to yield two antigen-binding fragments (Fab) and one dimer of the C-terminal 
half of the heavy chain (Fc) (Porter, 1959). The Fab portion contains the antigen 
binding specificity. The three fragments have similar molecular weights of 50 kD each.
Antibodies to human CD59 were selected based on their epitope binding 
regions. Antibodies MEM43 and HC1 bind to non-identical epitopes on CD59. In 
addition, previous work has shown that MEM43 blocks the ability of CD59 to protect 
against complement-mediated cell lysis while HC1 does not (Bodian et al., 1997) 
(Figure 6.3). The antibodies, both IgG2a, were incubated with papain at a 1:25 ratio 
(w/w) for 18 hours. Aliquots were taken every hour and samples were analysed on a 
10% SDS gel. Good antibody digestion to 50 KDa bands (Fab + Fc) was observed 
after ON incubation (Figure 6.4A) and was unchanged with increased concentration of 
enzyme (Figure 6.4B). Fab fragments were finally generated by papain incubation ON
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Figure 6.3. Epitope binding site of CD59-specific antibodies
Picture extracted from Bodian et al (1997) showing antibody binding site of different 
monoclonal antibodies for human CD59. Residues whose mutation disrupted the 
binding of each antibody are shaded black and those whose mutation led to reduce 
levels of binding are shaded grey. MEM43 and HC1 mAbs were selected for Fab 
fragment generation.
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Figure 6.4. Generation of Fab Fragments
Monoclonal antibodies were incubated for different times with papain (1/25 w/w). 
Complete antibody fragmentation was obtained after ON incubation (A). Optimal 
concentration of papain was evaluated by ON antibody incubation with 1/25 w/w (IX) 
or 1/12.5 w/w (2X) of papain (B). Ab were incubated ON with 1/25 w/w of papain (C) 
and Fab fragments were purified with Hi-Trap Sepharose (D). Abs were run in 10% 
SDS gel to visualize the Fab band ( 25 KDa with and 50KDa without (3-ME). As a 
control, untreated antibody was loaded into the gel.
169
at 37°C at a final concentration of 1 enzyme: 25 antibody (w/w). The Fab fragment, 
together with the Fc fragment, were identified as a 50 KDa band (no p-ME) or 25 KDa 
band (with p-ME) on a 10% SDS gel (Figure 6.4C). P-ME cleaves the disulfide bonds 
that link the heavy and light chains generating two bands of approximately 25 KDa. 
The Fc fragment was removed using a protein A column leading to a pure population 
of Fab fragments (Figure 6.4D).
6.2.3. Characterization of Fab Fragments
Enzymatic digestion of CD59-specific antibodies could affect their capacity to bind 
CD59. Fab CD59-binding was tested on human CD4+T cells by flow cytometry 
(Figure 6.5A). As explained above, MEM43 but not HC1 antibody blocks CD59 
binding to the MAC. To functionally test the Fab fragments, complement-mediated 
lysis of human E was analysed in the presence of the intact antibodies or the Fab 
fragments. As predicted, incubation with the MEM43 antibody considerably increased 
complement mediated-E lysis (Figure 6.5B). Fab fragments of MEM43 were able to 
block E lysis, but this effect was not as pronounced as with the intact antibody. This is 
probably because intact antibodies are multivalent and the binding of two adjacent 
antigens increases the functional affinity and avidity of the antibody. Conversely, Fab 
fragments are monovalent and can exhibit fast off-rates and poor retention time on 
their targets.
As reported previously HC1 only moderately enhanced cell lysis (Figure 6.5B). 
The small increase observed in complement mediated lysis using HC1 may reflect the 
fact that CD59 is a very small molecule and bivalent HC1 antibody binding might 
therefore partially block the active site. Indeed, the monovalent Fab fragment of HC1
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Figure 6.5. Functional Characterization of Fab Fragments
Binding of Fab fragments o f CD59-specific antibodies was detected on CD4+ T by 
flow cytometry (A). E from healthy donors were sensitized with CD55-specific 
antibodies and incubated with human serum (control, B). Intact and Fab fragment 
antibodies were added to the serum where applicable (B). E haemolysis was measured 
by absorbance at 415 nm. Values shown are the mean ± SD (triplicates).
171
did not enhance complement mediated lysis.
6.2.4. Antibody Cross-linking of Human CD59 Induces T Cell Proliferation
Antibody cross-linking of CD59, using MEM-43, has been shown to induce T cell 
proliferation (Korty et al., 1991). Experiments were therefore performed to confirm 
this finding and to determine whether cross-linking HC1 also affects T cell 
proliferation. Thus, human CD4+ T cells were stimulated with CD3-specific 
antibodies, CD59-specific antibodies and cross-linking anti-Ig. Cross-linking of CD59 
with MEM43 antibody induced T cell proliferation confirming published reports. 
Interestingly, the use of HC1 also increased CD4+ T cells proliferation implying that 
the effect of CD59 cross-linking is independent of the antibody-binding site (Figure 
6.6).
6.2.5. Blocking of CD59 Increases CD4+T Cell Proliferation
To address whether CD59 modulates T cell activation, CD4+ T cells were incubated 
with the Fab fragments and T cells were activated with CD3-specific antibodies and 
APCs. A macrophage cell line U937 that does not express CD59, was used as an APC. 
CD4+ T cells were incubated with the Fab fragments, washed and then activated with 
increasing concentrations of CD3-specific antibodies in the presence of APCs. 
Incubation with the MEM-43 Fab fragments had no effect on T cell proliferation 
whereas the HC1 Fab fragments resulted in a modest increase in proliferation at all 
concentrations of CD3-specific antibodies used (Figure 6.7A). Similar results were 
obtained with the use of PBMCs as APCs (Figure 6.7 B) although the effect was 
significant only at low concentrations of CD3-specific antibodies. Dividing cells
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Figure 6.6. CD59 Cross-linking Induces T Cell Proliferation
Purified CD4+ T cells from healthy donors were incubated with MEM43 and HC1 
antibodies followed by an anti-Ig antibody. T cells were activated with CD3-specific 
antibodies. Values shown are the mean ± SD and statistical significance (*) was 
evaluated using Student’s T test (p<0.05).
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express de novo CD59 molecules that would escape binding to the Fab fragments 
which were washed off prior to setting up the T cell proliferation assay. It is possible 
therefore that these cells continue to bind to the CD59 ligand on APCs, thereby 
reducing the effect of the Fab fragments. To test this possibility, CD4+ T cells were 
stimulated in the continuous presence of antibody fragments for 3 days. Again, T cell 
proliferation was not affected by inclusion of the MEM-43 Fab fragments. In contrast, 
the proliferative response was significantly increased by the HC1 Fab fragments in a 
concentration-dependent manner (Figure 6.7C). As explained before, MEM-43 and 
HC1 antibodies bind to non-identical epitopes on CD59 suggesting that HC1 but not 
MEM-43 binds the active site of CD59 responsible for modulation of T cell activity. 
Interestingly, the HC1 binding site is not implicated in MAC regulation
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Figure 6.7. Blocking of CD59 Expression Increase CD4+ T Cell Proliferation
Purified CD4+ T (2xl04) cells from PBMCs were incubated with CD3-specific 
antibodies and irradiated U937 cells (A) or PBMCs (B) as APCs (lxlO5). CD59 
expression was blocked with CD59-specific Fab antibodies. CD4+ T were incubated 
with Fab antibodies previous activation (A and B). Fab antibodies were added to the 
wells at different concentrations (C). Proliferation was measured by 3H-thymidine 
incorporation at day 3. Values shown are the mean ± SD and statistical significance (*) 
was evaluated using Student’s T test (p<0.05).
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6.3. Discussion
CD59 is expressed on most tissues and on all circulating cells. Unlike mouse T cells 
where CD59a expression is barely detectable by flow cytometry (Harris et al., 2003), 
high levels of expression were detected on human CD4+ T cells. Interestingly, CD4+ T 
cells expressing the memory marker CD45RO+, expressed higher levels of CD59 than 
CD45RA+ cells. In addition, recently activated cells expressing CD25 also up- 
regulated expression of CD59. This may be necessary to protect T cells from 
complement attack, especially activated cells present at a site of inflammation. 
However, based on the data described in previous chapters, up-regulation of CD59 
expression may play a role in influencing T cell activation. To study this further, the 
capacity of selected antibodies to CD59 to modulate activation of CD4+ T cells was 
analyzed. Two mAbs were tested, MEM-43 that targets the putative active site for 
complement inhibition and HC1 that binds an epitope remote from this site. 
Interestingly, CD59 cross-linking with both intact antibodies (MEM43 and HC1), in 
association with CD3 stimulation, induced T cell activation. During cross-linking 
experiments, activation is not induced directly by antibody binding but by protein 
aggregation. CD59 is a GPI-anchored protein that cannot directly trigger cell 
activation, but interaction with protein kinases has been proposed as a mechanism of 
CD59-induced T cell activation (Stefanova and Horejsi, 1991; Stefanova, 1991). 
Antibody cross-linking of GPI-anchored proteins generates large clusters of lipid rafts 
sequestering a range of surface proteins and signalling molecules that may never 
associate in a physiological antigen-ligand interaction. The physiological relevance of 
these observations is therefore questionable and raises doubts over the use of antibody 
cross-linking to study T cell activation.
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Munne CD59a negatively modulates CD4+ T cell responses in vivo as discussed 
in previous chapters. In order to recapitulate these findings in humans, Fab antibodies 
were generated to block the expression of CD59 on human T cells. Of the two 
antibodies tested, only H C1 Fab fragments enhanced T cell activation. Increased cell 
proliferation was moderate and only reached a 2 -fold increase with a low 
concentration of CD3-specific antibodies. One plausible explanation is de novo 
synthesis of CD59 molecules on dividing cells that are no longer blocked by 
antibodies. To eliminate this possibility, CD4+ T cell proliferation assays were 
performed in the continuous presence of Fab antibodies. An increase in CD4+ T cell 
proliferation was observed in the presence of the HC1 Fab compared to control wells 
and those containing the MEM-43 Fab and this difference was enhanced with 
increasing concentrations o f the HC1 Fab. However, the increase in cell proliferation is 
minor compared to that observed in Cd59a-/- mice, and may reflect technical 
limitations concerning the use of antibodies in in vitro assays. Interestingly, HC1 
binding to CD59 does not compromise its function as a CReg suggesting that the 
active site of CD59 required for T cell modulation, differs from the active site for 
MAC binding. Ligand binding to different domains of CD55 elicits different biological 
effects. CD55 possess 4 SCR domains and each o f these modules has a specific 
biological function. Brodbeck and colleagues, using recombinant DAF proteins devoid 
of individual SCRs, demonstrated that the regulation of the classical pathway of 
complement resides in the SCR2, SCR3 domains while, blocking of the alternative 
pathway, also requires the SCR4 domain (Brodbeck et al., 1996). The SCR1 domain 
has recently been described to bind the CD97 molecule, a non-complement ligand for 
CD55.
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The Effect of Antibody Binding. Activation vs Blocking?
As discussed above, Fab binding to CD59 enhances T cell activation depending on the 
antibody clone used. Fragmented HC1 antibody-binding to the non-complement 
related active site o f CD59, enhances CD4+ T cells proliferation while Fab fragment 
binding to the complement related active site of CD59 (MEM-43) has no effect. 
Antibody Fab fragments have been successfully used by several investigators to 
modulate T cell responses (Brown et al., 2003; Haspot et al., 2002; Krummel et a l, 
1996; Perrin et al., 1999; Vanhove et al., 2003). Fab antibodies to CD28 have been 
shown to reduce T cell proliferation by blocking its costimulatory function (Haspot et 
al., 2002; Krummel et al., 1996; Perrin et al., 1999; Vanhove et al., 2003). However, 
the effect o f Fab binding may differ with distinct antibody clones. While Fab 
fragments with high affinity blocked CD28 function, Fab fragments with low binding 
affinity showed little or no effect on T cell proliferation (Vanhove et al., 2003). In the 
studies performed here, a low binding affinity to CD59 could explain the moderate 
effect on CD4+ T cell proliferation observed with HC1 Fab fragments. Thus, it 
becomes impossible to discriminate between blocking and activating effects of HC1 
and MEM43 binding. There is a general consensus that Fab antibodies block protein 
function however, it appears that inhibition depends on the antibody binding site rather 
than the antibody valence. Monovalent binding (Fab) as well as intact antibodies to 
CD3 has been shown to induce T cell activation and IL-2 production in human T cell 
clones (Ledbetter et a l ,  1986; Peacock et al., 1991; Tamura and Nariuchi, 1992). This 
suggests that, when the function o f the molecule is unknown, it becomes difficult to 
predict the effect o f the antibody binding. Thus, while the data presented in this 
chapter imply that blocking CD59 does indeed promote T cell activation, solid 
conclusions cannot be drawn using the methods (incubation with intact antibodies and
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Fab fragments) utilised so far. Better methods for blocking CD59 expression on human 
T cells are now needed. With this in mind, silencing of CD59 using siRNA offers an 
alternative to antibody blocking. The use of siRNA has proven to be a valid approach 
for sequence-specific suppression of gene expression and therefore for loss of function 
studies. Such experiments should allow solid conclusions to be drawn over whether 
CD59 negatively or positively modulates human T cell responses.
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Chapter 7- Final Discussion
7.1. CD59a Modulates Immune Responses
Complement plays a key role in linking innate and adaptive immunity. While 
complement activation during the early events of the immune response provides a 
rapid and efficient means for opsonising or killing pathogens and triggers 
inflammation, it also plays a role in adaptive immunity, particularly in the humoral 
immune response. Seminal studies by Pepys and colleagues showed that C3 played a 
role in antibody production (Feldmann and Pepys, 1974; reviewed in Pepys, 1972). 
This link between complement and adaptive immunity was further investigated and 
defined by several groups some twenty years later, who demonstrated that antigen 
opsonised with C3 fragments potentiated the immune response by crosslinking 
complement receptor 2 and surface IgM in a signalling complex on the B cell 
(Matsumoto et al., 1991; reviewed in Carroll, 2004). Complement activation is a 
potentially dangerous system and is therefore very strictly regulated by CReg. MAC 
has been implicated in the pathogenesis o f several autoimmune and inflammatory 
diseases (reviewed in Nangaku, 2003). Over-activation of complement in the absence 
of CD59a, has been shown to exacerbate tubulointerstitial damage after renal 
Ischemia-reperfusion injury (IRI) (Tumberg et al., 2004). In this model, Cd59a-/- mice 
exhibited increased tubular injury, neutrophil recruitment and MAC deposition in 
tubular epithelial cells. Inhibition of the terminal pathway of complement protected 
mice from renal IRI injury suggesting that MAC is critical in complement mediated 
renal post-ischemic injury (Zhou et al., 2000). A similar role for CD59a and MAC was 
suggested in a mouse model o f accelerated nephrotoxic nephritis (ANTN) (Tumberg et
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a l 2003). In a model of antigen-induced arthritis (AIA), Cd59a-/- mice exhibited high 
MAC deposition and joint pathology with increased cartage destruction, bone erosion 
and cellular infiltration compared to control mice (Williams et a l , 2004). In addition, 
expression of human CD59 in inflamed joints in rheumatoid arthritis was reduced 
compared with non-inflamed tissues suggesting that reduced regulation of the MAC is 
relevant for the development o f arthritis (Konttinen et al., 1996). Thus, CD59a can 
modulate immune responses by controlling complement activation and MAC 
formation. CD59a, by blocking the formation of the MAC, will impinge on the 
magnitude of the immune response generated. MAC deposition has been shown to 
amplify inflammatory responses by direct and indirect mechanisms. A number of 
studies have shown that the deposition of a sub-lytic concentration of MAC on 
endothelial cells triggers cell activation and the release of inflammatory mediators such 
as MCP-1, IL-8, and RANTES (Kilgore et a l , 1995; Ward, 1996). Simultaneously, 
MAC can create complete transmembrane channels leading to osmotic lysis of the cell. 
Necrotic cells and the intracellular material released from them can bind complement 
components (e.g. C lq, C3 and C4) and amplify complement activation and the 
inflammatory response (Jiang et a l ,  1992; Gaipl et a l , 2001) (Figure 7.1 A, B and C). 
The work presented in this thesis indicates that CD59a, which serves to downregulate 
activation of the complement cascade, also has the effect of downregulating T cell 
responses (Figure 7.ID)
The studies described in this thesis, demonstrate a novel role for the membrane 
CReg CD59a in modulation o f T cell responses. Virus- specific CD4+ T cell responses 
were increased in Cd59a-/- mice compared to control mice. In addition, higher
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Figure 7.1. Interplay Between the Innate and Adaptive Immune System in the 
Absence of CD59a
CD59a protects cells from MAC formation and cell lysis (A). Lack of CD59a increases 
MAC deposition on cell membrane. (B) MAC opens a pore in the membrane of 
targeted cells resulting in cell lysis. Deposition of complement C3, C4 and C lq on 
necrotic cells exacerbates complement activation and formation of complement 
component that can play important roles in the inflammatory response. Ligation of 
CD1 lb with C3b/iC3b leads to increased adhesion, chemotaxis, and phagocytosis of 
both neutrophils and macrophages whereas C3a and C5a can enhance expression of 
neutrophil-adhesion molecules induce vascular permeability and attract leukocytes by 
chemotaxis. (C) Sub-lytic concentration of MAC on the cell surface of endothelial 
cells increases expression of adhesion molecules and induces secretion of IL-8, 
RANTES and MCP-1 chemoattractant for neutrophils, T cells and monocytes 
respectively. (D) Expression of CD59a on CD4+ T cells negatively modulates T cell 
activation in a complement independent manner.
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frequencies of lymphocytes were present at the main site of primary infection in Cd59a 
-/- mice. The effect of CD59a deficiency on CD4+ T cell proliferation was complement 
independent since inhibition of complement using sCRl did not reverse the effect of 
CD59a-deficiency on CD4+ T cell proliferation. Furthermore, enhanced virus-specific 
CD4+ T cell proliferation was also observed in Cd59a-/- mice backcrossed onto a C3- 
deficient background. These experiments rule out the possibility that a complement 
component ligates CD59a on T cells to mediate this effect.
It is likely that the complement dependent and independent effects of CD59a 
expression act in conjunction to negatively modulate the immune response. In the 
influenza virus model described in Chapter 4, increased lung inflammation in Cd59a-/- 
mice correlated with a complement-dependent infiltration of neutrophils and a 
complement-independent infiltration of IFNy-producing CD4+ T cells. Activated 
neutrophils that have been recruited at the site of inflammation by complement 
component derived and MAC-mediated inflammatory mediators release cytokines and 
chemokines that induce recruitment o f T cells as well as other immune cells (Bonder et 
al., 2004; reviewed in Scapini et al., 2000). Thus, absence of CD59a may boost the 
CD4+ T cell response in two ways; Firstly, a more robust innate immune response 
induced in the absence of CD59a could serve to amplify the subsequent T cell response 
and, secondly removal o f the inhibitory effect of CD59a expression on the T cells 
themselves would also promote their expansion. In Cd59a-/- mice, enhanced 
neutrophil recruitment will therefore result in more T cells and, simultaneously, these 
T cells will proliferate more by CD59a complement-independent mechanism. It is 
notable that, in the models of renal IRI, ANTN and IAI discussed above, high cellular 
infiltration was observed in Cd59a-/- mice (Tumberg et al., 2004; Tumberg et al.,
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2003; Williams et al., 2004). This could be due, in part, to the lack of T cell 
modulation by CD59a. In neither of these studies was cellular infiltration assessed in 
the absence of complement activation. In order to discriminate the indirect effect of 
CD59a deficiency on T cell responses which might result from amplification of 
complement activation and direct effects of CD59a on T cell activation, transgenic 
mice where CD59a is expressed only on T cells would be useful. This technique has 
been successfully performed to generate several transgenic mice (Carrasco et a l , 1997; 
Galkina et al., 2003) and could be used to provide a better understanding of the role of 
CD59a in modulating CD4+ T cell responses.
7.2. Possible Mechanisms for Modulation of T Cell Responses by 
CD59a
In this thesis, Cd59a-/- mice have been shown to exhibit enhanced CD4+ T cell 
responses to virus. T cell hyper-response was not abrogated by complement inhibition 
suggesting that CD59a negatively modulates CD4+ T cell activity in a complement- 
independent manner. As discussed previously, the role of CD59a as a CReg is well 
described but little is known about its direct role on T cell activation. As shown in 
Chapter 3, proliferation assays performed in vitro demonstrated that CD4+ T cells, 
lacking CD59a expression, proliferated more vigorously in response to stimulation 
with CD3 specific antibodies and APCs. Interestingly, no difference was observed in 
proliferation when the T cells were stimulated with CD3- and CD28-specific 
antibodies indicating that APCs were required to observe the enhanced proliferation in 
Cd59a -/- T cells. These data implied that CD59a on T cells normally engages with a 
ligand on APCs, a hypothesis that was supported by the observation that a CD59a-
IgG2a fusion protein bound to macrophages, DCs and B cells. Experiments performed 
in this thesis could not find any negative effect of CD59a engagement on APC 
function; thus downmodulation of T cell activity by CD59a engagement appears to be 
through inducing a negative signal in the T cell rather by transmitting a negative signal 
that results in downmodulation of the APC. The question of how a GPI-anchored 
protein modulates T cell activation therefore arises.
The mechanism with which CD59, as well as other GPI-anchored proteins, 
delivers intracellular signals is not yet clear. Since the GPI anchor only transverses the 
outer leaflet of the membrane bilayer, it is likely that signalling will depend on 
association with other molecules. GPI-anchored proteins co-precipitate with p561ck 
and p59Fyn kinases (Shenoy-Scaria, 1992; Stefanova et al., 1991). Thus it is possible 
that association of GPI protein with the Src family o f protein kinases leads to cell 
signalling. The effect of GPI-anchored proteins on T cell activation may be a reflection 
of their presence in lipid rafts and their accumulation in the immunological synapse. 
Engagement of the TCR with MHC-peptide complex results in macromolecular 
rearrangements of the T cell membrane resulting in the formation o f an organized 
structure called the “immunological synapse” (IS). This structure is formed within 5- 
30 minutes of TCR engagement and is associated with reorganization of the actin 
cytoskeleton and segregation of adhesion and TCR-associated molecules into two 
major components, a central and peripheral supramolecular activation cluster (cSMAC 
and pSMAC). The TCR-CD3 complex, together with CD28, PKC0, Lck and Fyn, are 
found in the cSMAC while LFA-1, talin and CD4 are present in the pSMAC. Upon 
TCR stimulation, many signalling proteins selectively concentrate in membrane 
microdomains called lipid rafts e.g. ZAP-70, phospholipase Cyl (PLCyl), Vav
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Rac/CDC42 exchange factor and the protein kinase Cq (PKCq), and these rafts are 
thought to accumulate mainly within the cSMAC (Burack et a l , 2002; Montix et a l , 
1998; reviewed in Alonso and Millan, 2001). If rafts do indeed act as platforms for T 
cell signalling, then it is possible that this represents a way through which GPI- 
anchored proteins could positively or negatively influence T cell activation. It is 
believed that maintaining signalling molecules in distinct heterogeneous microdomains 
within the plasma membrane is a mechanism through which T cells orchestrate a 
diverse and controlled response (Gomez-Mouton et a l , 2001; reviewed in Germain 
and Stefanova, 1999). In other words, a protein A is separated from protein B and 
protein C in lipid rafts. Upon T cell activation, changes in the organization of the 
plasma membrane and its constituents, facilitate the rearrangement and redistribution 
of raft-associated proteins, thereby allowing contact o f protein A with protein B but 
remaining separated from protein C. Heterogeneity in lipid rafts composition may be a 
mechanism by which discrete signalling pathways can be differentially activated 
during an immune response by changes in the lateral mobility of enzymes, substrates, 
and adaptor proteins within the plasma membrane. Marmor and colleagues showed that 
activation of T cells with immobilized specific antibodies to TCR and GPI-anchored 
proteins (CD48, Thy-1, Ly6-A, TSA-1 and Qa-2) suppressed cell proliferation but not 
IL-2 release or cytotoxicity. Despite the production of IL-2, GPI-immobilized cells 
failed to signal through the IL-2R resulting in a profound reduction of IL-2-induced 
cell growth. Three chains participate in the formation of the IL-2R (IL-2Ra, (3 and y) 
and are mainly partitioned into lipid rafts. Investigators found that IL-2R on these cells 
lacked the expression of the IL-2RP that is known to be associated to the protein 
tyrosine kinase JAK1. GPI-anchored proteins may participate in the lateral mobility of 
IL-2R chains necessary for hetero-trimerization of the IL-2R. Immobilization of GPI-
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anchored proteins with antibodies could prevent the trafficking of some of the chains 
and, therefore, the assembly of the subunits. This last hypothesis of raft heterogeneity 
and lateral mobility of GPI-anchored proteins may explain why both cross-linking 
CD59 or CD59a and deleting CD59a expression on T cells promotes T cell 
proliferation. When cross-linked mouse CD59a or human CD59 proteins are not freely 
and selectively migrating within the plasma membrane but are forced to aggregate and 
associate with other proteins eliciting dramatically different immunological effector 
functions compared to natural ligand binding.
Based on the discussion above, expression of CD59 in membrane microdomains 
raises the possibility that CD59 may interfere with the formation o f the immunological 
synapse. No studies exploring this role have been described. Expression of CD59a on 
T cells is very low and cannot be easily detected by immuno-fluorescence techniques. 
In an attempt to study CD59a distribution during formation of the immunological 
synapse, murine T cell lines were transfected to over-express CD59a. As a result, 
expression of CD59 was not restricted to lipid rafts but also was expressed in non-rafts 
fractions making interpretation difficult. On human T cells, cross-linking of CD59 
showed patchy distribution o f CD59 by confocal microscopy, co-localization with 
actin filaments and phosphotyrosine enrichment in the lipid raft patches (Deckert et a l , 
1996; Harder and Simons, 1999). At the moment, no studies of membrane CD59 
distribution under physiological condition of T cell stimulation have been reported.
Clearly, many questions regarding the role of CD59 on T cells remain to be 
answered. As discussed in Chapter 5, CD59a appears to have a direct negative effect 
on T cell activation. However, due to technical limitations, it was impossible to
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confirm this theory. To induce stronger signals for measurement of very early events in 
T cell activation (Ca flux and protein phosphorylation) it will be useful to cross 
Cd59a-/- mice with CD4+ TCR transgenic in order to allow the experiments to be 
carried out using high frequencies of antigen-specific T cells. This methodology will 
give A) a stronger signal following T cell activation and B) simultaneous T cell 
activation through TCR and CD59a ligand. Identification o f the natural ligand for 
CD59a will also prove extremely useful for studying modulation of T cell activity by 
CD59a. At the moment this is an area of intense research in the laboratory.
7.3. Human CD59 as a Therapeutic Target
7.3.1. Manipulation of immune responses
Appropriate stimulation of the immune system is crucial for successful resolution of 
infection/ damage. Turning the immune response off after an infection is controlled is 
equally important since hyper-stimulation of the immune system can lead to 
uncontrolled inflammation. Due to the complex and multigenic processes underlying T 
cell activation, several pathways can be targeted to reduce T cell responses such as 
antigen recognition, co-stimulation and regulation (Daoussis et a l , 2004; Krinzman et 
a l, 1996; Latchman et a l ,  2001). Glucocorticoids and anti-histamines are currently 
used for controlling immune responses but they are largely palliative and non-specific 
potentially causing immunosuppression. CD59 prevents complement-mediated cell 
lysis but does not block opsonisation or anaphylatoxin production. In addition, CD59 
negatively modulates T cell responses but still allows the mounting of an adequate 
immune response. Thus the use of CD59 as a therapeutic target may be advantageous 
since the effects on the immune responses would be expected to be subtle, allowing 
modulation of the immune response without completely switching off host defenses.
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Administration of membrane-targeted recombinant rat CD59 (sCD59-APT542) in 
mouse and rat, was successfully used as a therapeutic agent for AIA. Animals treated 
with sCD59-APT542 showed a significant decrease in joint inflammation with 
minimal synovial hyperplasia, cartilagenous/bony erosions and less mononuclear cell 
infiltration (Fraser et a l, 2003; Williams et a l, 2004). It is important to note however, 
that this recombinant protein is missing the GPI-anchored portion that may be relevant 
for direct modulation of the T cell response.
Recently, a novel recombinant human CD59 soluble protein (rhCD59-P) has 
been described to protect the erythrocytes of patients with PNH from complement- 
mediated cell lysis (Hill et a l,  2006). In this study, CD59 was modified with a novel 
synthetic membrane-anchored peptide that efficiently attaches to cell membranes for at 
least 3 days in vitro. This new recombinant CD59 protein might also have potential for 
the treatment of uncontrolled inflammatory responses.
7.3.2. Recombinant CD59 as a strategy for immune-modulation
Inhibition of immune responses during virus infection may result in poor control of 
virus replication and persistence o f disease. At the same time, over-reaction o f the 
host’s immune system may be accompanied with pathology as described for influenza 
virus infection. In this case, the use of recombinant CD59 (rCD59) may be beneficial 
to the host by reducing lung inflammation but still allowing the generation of an 
adequate immune response. Infection of Cd59a-/- mice with influenza virus resulted in 
high lung inflammation with increased numbers of infiltrating neutrophils and CD4 T 
cells compared to WT mice. It will be of interest to test whether administration of 
rCD59 can limit the immunopathological consequence of complement activation and T
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cell hyperactivity in these mice after influenza infection. For this purpose, rCD59 
could be administrated intranasally to target the respiratory tract.
7.3.3. Recombinant CD59 for Tumor Immunotherapeutic
The strategy employed to treat a particular disease will depend on whether the 
mounting of an immune response is beneficial or detrimental to the patient. In the case 
of tumour immunotherapy, it is clearly beneficial to promote tumour-specific immune 
responses. Adoptive transfer of T cells has been intensively investigated for treatment 
of cancer (Rosenberg et al., 1988a; Rosenberg et al., 1988b; reviewed in Dudley and 
Rosenberg, 2003). Adoptive T-cell therapy using antigen-specific CD8+ T cells for 
cancer treatment has been attempted with some degree of success (reviewed in Dudley 
and Rosenberg, 2003). The trials performed so far indicate that a major obstacle to the 
success of effective lymphocyte transfer therapies for cancer is failure o f the 
transferred cells to persist in the recipient (reviewed in Dudley and Rosenberg, 2003).
It may be possible to enhance anti-tumor T cell survival / persistence by silencing 
molecules known to have a negative effect on T cell proliferation / survival. CD59 
may represent one such molecule. RNA interference using short, double-stranded RNA 
(small interfering RNA, or siRNA) is currently used for suppressing gene expression in 
mammalian cells and, since siRNA has already been shown to effectively silence 
expression of different genes on PBMCs (Cobum and Cullen, 2002; Qureshi et al., 
2006), it may prove possible to use this technology for the silencing of CD59 
expression on T cells (Elbashir et al., 2001; Ge et al., 2003; reviewed in Dorsett and 
Tuschl, 2004; Dykxhoom et a l ,  2003). Lymphocytes have several features which 
make them attractive for gene therapy. The cells are readily available from peripheral 
blood as a single cell suspension and are easily manipulated in tissue culture, expanded
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by IL-2 allowing gene insertion, selection and testing prior to their return to the 
patient. In summary, the strategy of silencing CD59 expression on T cells to enhance 
immunity has of great potential for the treatment of different diseases.
7.4. Conclusion
In this thesis, I demonstrated a new role for CD59a distinct from its common role as a 
CReg. The novel finding that CD59a has a role in CD4+ T cell activation is of utmost 
importance to the field o f immunology. I showed that murine CD59a modulates 
antivirus CD4+ T cells responses, an effect that was independent o f complement 
activation. The exact mechanism by which CD59a controls CD4+ T cells activity 
remains unclear but it is believed that, upon binding to an unknown ligand on APCs, 
CD59a directly modulates T cell activation. This study also demonstrated that CD59a 
can modulate immune responses in a complement-dependent manner. Influenza- 
infected Cd59a-/- mice exhibited enhanced numbers of lung-infiltrating neutrophils 
compared to WT mice. This effect was complement-dependent suggesting that CD59a, 
by blocking MAC deposition, also modulates the innate immune response to virus. 
Several questions however, remain to be answered. Identification of the ligand is 
imperative for full understanding of the mechanism by which CD59a modulates CD4+ 
T cell responses. In addition, in order to recapitulate the mouse findings in the human 
system, more appropriate methodology will have to be implemented as discussed in 
Chapter 6. The results o f these studies will enable the possibility of manipulating 
immune activity through targeting CD59 to be more fully explored.
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C utting Edge: M urine C D 59a M odu lates A n tiv ira l C D 4+ T 
C ell A ctiv ity  in  a C o m p lem en t-In d ep en d en t M anner1
M. Paula Longhi,2 Baalasubramanian Sivasankar,
Awen Gallimore
CD59 blocks form ation o f the membrane attack complex 
o f complement by inhibiting binding o f C9 to the C5b-8 
complex. To investigate a role fo r  CD59 in promoting T  
cell responses, we compared T  cell activation in CD59a- 
deficient (Cd59a~'~) and wild-type (W T) mice after in 
vitro stimulation and after infection with rW . Virus-spe­
cific CD4+ Tcell responses were significantly enhanced in 
Cd59a~'~ mice compared with W T  mice. Similarly, 
Cd59a / T  cells responded more vigorously to in vitro 
stimulation with CD3-specific Abs compared with W T  
mice. This effect o f CD59a on T  cell proliferation was 
found to be complement-independent. Collectively, these 
results demonstrate that CD59a down-modulates CD4+ 
T  cell activity in vitro and in vivo, thereby revealing an­
other link between complement regulators and T  cell 
activation. The Journal o f Immunology, 2005, 175: 
7098-7102.
H uman CD59 is a 18—20 kDa GPI-anchored protein expressed in all circulating cells and in most tissues (1). In common with other GPI-anchored proteins, it 
is found in membrane microdomains, lipid rafts, which serve as 
platforms for Ag receptor signaling complexes in lymphocytes. 
CD59 acts as a complement (C)3 regulator by inhibiting the 
formation of the membrane attack complex (2). Others have 
suggested that CD59 also acts as a costimulatory molecule for T 
cell activation. Ab-mediated cross-linking of CD59 on PMA- 
treated human T cells caused enhanced proliferation and IL-2 
production (3).
To explore the role of CD59 in T cell activation in vivo, we 
examined T cell function in mice lacking the species analog, 
CD59a (4). T cell activity was compared in Cd59a~/_ and 
Cd59a+/+ (wild-type; WT) mice after in vitro stimulation and 
after infection of mice with recombinant vaccinia virus (rW). 
CD8 T cell responses were unaltered in the absence of 
CD59a; however, CD4+ T cells displayed enhanced prolifera­
tion to several stimuli both in vivo and in vitro. C inhibition did
not influence the enhanced responses, indicating that CD59a 
modulates CD4+ T cell activation independent of C.
Materials and Methods
Mice
C57BL/6^ (H-2b) mice (WT) were obtained from Harlan. B6.129- 
Cd59a prn (Cd59a 1 ) mice were generated as described previously (4) and 
backcrossed onto the C57BL/6 background for eight generations. Cd59a- /~ 
mice were intercrossed with the B6.129S4-C3,mlCrr (C3_/_) mice (5) also on 
the C57BL/6 background. Experiments were performed in compliance with 
Home Office regulations.
Cell culture
Yac-1 cells, T cells, and V8E, a mouse CD4+ T cell hybridoma (6) (provided by 
Dr. Annette Oxenius, University of Zurich, Zurich, Switzerland), were main­
tained in RPMI 1640 medium supplemented with 10% FCS, penicillin-strep- 
tomycin, L-glutamine, and 2-ME. V8E cells were transfected with CD59a using 
standard methods.
Infection with r W  and determination o f antivirus response
rW  expressing the gp of lymphocytic choriomeningitis vims (LCMV) has been 
described previously (7). Mice received injections i.p. with 50 p. 1 of rW GP at 
10® PFU/ml. At day 3 and 8 after infection, ovaries were harvested for vims 
titers, and immunostaining and spleens were harvested for CTL assays and T 
cell proliferation assays. For memory responses, spleens were harvested 6 wk 
after infection, and CTL assays and CD4+ T cell proliferation assays were per­
formed.
Fluorescence staining
Cy5-conjugated Abs were used for CD4 staining (Caltag Laboratories). Cells 
were incubated with 5 /u.g/ml mAb for 30 min, washed, and resuspended in 
FACS buffer. IFN-y staining was performed using IFN-y-FITC mAbs (BD 
Pharmingen) after incubating ovary-derived lymphocytes for 4 h at 37°C in the 
presence of ionomycin (1 /xg/ml), PMA (20 ng/ml), and monensin (3 pM) 
(Sigma-Aldrich). CFSE staining (Molecular Probes) was conducted by incubat­
ing the cells for 10 min at 37°C with 0.5 p.M CFSE. In all cases, cells were 
resuspended in FACS buffer and analyzed by FACS (FACSCalibur; BD Bio­
sciences).
Immunoprecipitation and Western blotting
Immunoprecipitation was performed as described previously (8). Lysates of 
mouse CD4+ or CD8+ T cells were incubated with 10 p.g of mouse mAb 
against CD59a (mCD59.4) (9) and 50 p,l of protein A-Sepharose beads for 2 h 
at 4°C. The immunoprecipitates were washed in lysis buffer and boiled in non­
reducing SDS-PAGE sample buffer. Beads were removed by centrifugation,
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and supernatants were resolved on nonreducing 12% SDS-PAGE and trans­
ferred to nitrocellulose. The membrane was probed with the CD59a-specific 
mAb mCD59.1 as described previously (9).
T cell proliferation
CD4 * and CD8 T cells from single-cell suspensions of splenocytes were pu­
rified by positive MACS MicroBcads selection (Miltenyi Biotec). To produce 
APCs, spleen cells were panT depleted (Dynabeads; Dynal Biotech) and irra­
diated with 2400 cGy CD4 + , or CDS cells (2 X 104 cells) were incubated 
with 1 O' APCs and 1 /xg/ml anti-CD3 mAb in a 96-multiwell (MW) plate. Cell 
proliferation was assessed by thymidine incorporation or CFSE FACS analysis 
at day 3. For anti-CD28 and anti-CD3 mAb stimulation, 105 CD4+ T cells 
were incubated in a 96-MW plate with 2 /xg/ml anti-CD28 and 2 /xg/ml anti- 
CD3 (Leinco Technologies). Vaccinia-specific CD4^ T cell proliferation was 
performed by incubation of 10' CD4+ T cells with 6 X 105-irradiated spleno­
cytes and 2.5 /xg/ml P i3 peptide (GLNGPDIYKGVYQFKSVEFD) (LCMV- 
GP, I-Ab) or P61 peptide (SGEGWPYIACRTSWGRAWE) (LCMV-NP, 
I-Ab). CD8+ T cell proliferation was conducted against the Derestricted pep­
tide gp33. Cells were incubated for 6 days, and thymidine was added for the last 
18 h.
Exogenous incorporation o f CD59a
CD59a was purified as described previously (10). CD4 r T cells (5 X  106 cells) 
were incubated with 5 fig of CD59a for 20 min at 37°C to permit incorpora­
tion via the GPI anchor. Cells were then washed and incubated for another 2 h 
to allow migration of CD59a into lipid rafts (11).
CTL assay
Spleen cells (4 X 106 cells) were stimulated in vitro with 1 X 106 gp33 
(KAVYNFATM) (LCMV-GP, Db) peptide-loaded (10“ 5 M) splenocytes, and 
IL-2 was added at day 2. After 1 wk, cells were restimulated with 1 X  10*’ gp33 
splenocytes and IL-2 (10 U/ml). rW-specific CTL activity was measured 5 
days later as described previously (12).
Virus titers
rW GP titers were determined in ovaries at day 3 and 8 postinfection. Ovaries 
were homogenized and incubated on a monolayer of TK-  cells as described 
previously (13).
CD59a cross-linking and IL-2 ELISA
V8E, a mouse CD4+ T cell hybridoma negative for CD59a expression by 
FACS, was transfected with CD59a as described (9). Purified CD4 T cells 
from Cd59a~ / or WT mice or V8E cells, untransfected or transfected with 
CD59a, were incubated with mCD59.1 or isotype-control mAb for 15 min at 
4°C. After washing, cells were plated at 105 cells/well in triplicate in a 96-MW 
plate. Where appropriate, 5 /xg/ml F(ab')2 rabbit anti-rat IgG Ab (Serotec) was 
added to the wells to cross-link (3). Cells were activated with 0.5 ng/ml PMA 
and incubated at 37°C. After 18 h, IL-2 was measured by ELISA according to 
the manufacturer’s instructions (BD Pharmingen).
C inhibition
For inhibition of C activity in vitro, 1 /xg/ml recombinant human soluble CR1 
(sCRl; gift from T Cell Sciences) was added to each well of a 96-MW plate. Cell 
proliferation was assayed after 3 days by thymidine incorporation. For in vivo 
inhibition, mice received injections i.v. daily with 20 mg/kg sCRl. To confirm 
C inhibition, mice were bled daily, and serum was tested for C hemolytic ac­
tivity using rabbit erythrocytes (RbE) sensitized with mouse anti-RbE anti- 
serum. Serial dilutions of test or control sera were incubated with 2% RbE. 
Hemolysis was measured by absorbance in supernatants at 415 nm ([A4,5 (sam­
ple) -  A4l5 (min)]/[A4I5 (max) — A4I5 (min)] X100). Hemolytic activity in 
samples taken 24 h posttreatment was always <15% of controls.
Results and Discussion
Induction o f IL-2 production by anti-CD59 mAb
Previous cross-linking experiments indicate that human CD59 
acts as an accessory molecule for T cell activation (3). To con­
firm this finding in the mouse system, we stimulated purified 
splenic CD4+ T cells with PMA, CD59a-specific mAb and 
cross-linking anti-Ig. CD59a cross-linking on mouse CD4+ T 
cells did not induce IL-2 production (Fig. I A). Because this 
may be due to the low level of CD59a on mouse lymphocytes 
(as assessed by FACS; Ref. 9), we overexpressed CD59a in a
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FIGURE 1. CD59a cross-linking induces secretion of IL-2. Expression of 
CD59a in VE8 and VE8-CD59a cells was detected by flow cytometry (Q. Pu­
rified CD4+ splenic T cells from WT and Cd59a-/_  mice (A) or VE8 and 
VE8-CD59a cells (B) were incubated with mCD59.1 mAb followed by an anti- 
Ig Ab. After 18 h, IL-2 production was detected by ELISA. Values shown are 
mean ±  SD. The results are representative of two experiments. Statistical sig­
nificance (*) was evaluated using the Student’s t test {p <  0.001).
murine CD44 T cell hybridoma (V8E) (6). Transfected cells 
expressed CD59a (Fig. 1C), and, when stimulated with PMA, 
cross-linking of CD59a yielded enhanced IL-2 production in 
comparison to untransfected cells subjected to the same stimuli 
(Fig. IB). These data indicate that when CD59a is expressed at 
a sufficient level on murine T cells, cross-linking CD59a does 
enhance IL-2 production in a manner similar to that described 
for human T cells.
Mouse T  cells express CD59a
CD59a expression is not detectable on murine lymphocytes by 
FACS (9). More sensitive methods were therefore used to de­
termine whether primary murine CD4+ and CD8+ T cells ex­
press CD59a. CD59a expression was detectable by RT-PCR 
(data not shown) and immunoprecipitation, followed by West­
ern blotting (Fig. 2A) in both CD4+ and CD8+ T cells from 
WT but not Cd59a-/_  mice.
Immune responses in Cd59aT/~ mice following infection with r W
To determine whether physiological levels of CD59a plays any 
role in modulation of murine T cell activation in vivo, T cell 
responses were compared in WT and Cd59a_/_ mice after 
rW G P infection. rW GP contains several MHC-restricted 
peptide epitopes recognized by T cells in WT mice. One pep­
tide, gp33, derived from the gp, is presented by H2-D to 
CD8+ T cells (14), whereas another epitope, pl3, is presented 
by H2-I-Ab to CD4+ T cells (12). No significant difference in 
CTL activity (Fig. 2B) or Ag-specific CD8+ T cell proliferation 
(Fig. 2Q  was observed between groups of mice at 8 days after 
infection. There was also no significant difference in CTL ac­
tivity measured at day 42 after infection (data not shown). Vi­
rus-specific CD4+ T cell proliferation assays performed at the 
same time points revealed stronger proliferative responses to the 
specific peptide, p i3, in Cd59a_/_ mice compared with WT 
mice, whereas no differences were observed in background pro­
liferation to an irrelevant peptide, p6l (Figs. 2, Dan&E). These 
data are similar to those reported recently using CD55-deficient 
mice, where CD4+ T lymphocytes from these mice were found
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FIGURE 2. rW GP-specific CD8+ T cell activity and CD4+ T cell prolif­
eration. CD59a expression was analyzed from immunoprecipitates of purified 
CD4+ T and CD8+ T cells from WT and control T  cells from Cd59a- / ~ mice. 
Expression was detected using specific Abs in Western blotting (A). CD8+ T 
cell cytotoxic activity (B) and cell CD8+ T cell proliferation (Q  was analyzed at 
day 8 after rW GP infection. Nonspecific lysis in the experiment shown in (5) 
was <10%. CD4+ T cells purified from rWGP-infected mice were tested for 
proliferation against peptides p6l and pl3 8 days (D) and 6 wk (£) postinfec­
tion. Mice were analyzed individually, and values shown are the mean ±  SEM 
(n = 3 mice/group). The results are representative of three independent exper­
iments. Statistical significance was evaluated using the Student’s t test.
to proliferate more vigorously in response to a range of Ags 
compared with WT mice (15, 16). Another study reported that 
T cells isolated from Ly-6A-deficient animals also proliferate 
more vigorously than those isolated from their WT counter­
parts (17). Interestingly, Ly-6A, CD59, and CD55 are all GPI- 
anchored molecules localized in lipid rafts, and all have previ­
ously been found in cross-linking studies to promote T cell 
activation in vitro (3, 17, 18). Despite this, all three molecules 
negatively regulate T cell activity in vivo. Because GPI-linked 
proteins weakly associate with protein tyrosine kinases, it is pos­
sible that they can act either as positive or negative regulators of 
T cell activation by sequestering signaling molecules or inter­
fering with assembly of signaling complexes in lipid rafts, the 
net effect dependent upon the trigger.
Immune responses in ovaries and virus titers
To determine whether the enhanced proliferation of gp-specific 
CD4+ T cells observed after in vitro stimulation reflected a 
stronger anti-viral CD4+ T cell response in vivo, numbers of 
CD4+ T cells at the site of rW G P infection (ovary) were com­
pared in WT and Cd59a_/_ mice at day 8 after infection. 
Higher numbers of infiltrating CD4+ T  cells (Fig. 3^ 4) and 
IFN-y-producing CD4+ T cells (Fig. 3B) were observed in the 
ovaries of Cd59a 7 mice compared with WT mice. The same 
analysis was performed for ovary-infiltrating CD8 + T cells 
(Figs. 3, Cand D). Although higher numbers of C D 8( T cells 
were observed in the ovaries of Cd59a 1 mice compared with 
WT mice, this difference was not statistically significant and 
may reflect enhanced helper CD4+ T cell activity rather than a 
direct effect of CD59a on CD8+ T  activity. Virus titers were 
also compared in both groups of mice at days 3 and 8 postin­
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FIGURE 3- rW G P clearance in Cd59a_/_ mice. Ovary-infiltrating lym­
phocytes were stained for intracellular IFN-y, CD4, and CD8 expression at day 
8 postinfection and analyzed by FACS. Total numbers of infiltrating CD4 + 
and CD8+ T cells are shown in A and C, respectively, and total numbers of 
IFN-y producing CD4+ and CD8 + T cells are shown in B and D, respectively. 
Virus titers in the ovaries of infected mice were determined at day 3 and 8 
postinfection (£). Each symbol represents an individual mouse, and similar data 
were observed in two independent experiments. Mean titers are also indicated 
in each graph. Statistical significance was evaluated using the Student’s t test.
fection. Virus titers were significantly lower in Cd59a~/_ mice 
compared with WT mice at day 3 postinfection, whereas both 
groups of mice had controlled the infection by day 8 (Fig. 3E). 
These data indicate that the more robust CD4+ T cell response 
observed in Cd59a_/_ mice does not reflect an inability to clear 
the virus efficiendy but may rather contribute to more rapid 
control of the infection.
Analysis o f  C D 4+ T  cell proliferation in vitro
We next compared proliferation of T cells from WT mice and 
Cd59a~/_ mice after in vitro stimulation with CD3-specific 
mAb and APCs. Although no difference was observed in pro­
liferation of CD8+ T cells (Fig. 45), CD4+ T cells from 
Cd59a_/_ mice exhibited more proliferation in vitro compared 
with T cells from WT mice (2.5-fold increase; Fig. 4^ 4). The 
increase in proliferation of CD4+ T cells from Cd59a_/ mice 
compared with WT mice was only apparent when CD3-spe- 
cific mAb and APCs were used for in vitro stimulation and not 
when CD3- and CD28-specific Abs were used (compare Figs. 
4, B and Q .T o determine whether CD59a expression on APCs 
affected proliferation of the responding T cells, CD4+ T cells 
were incubated with APCs from WT or Cd59a / mice. 
CD4+ T cell proliferation was not influenced by the presence 
or absence of CD59a on APCs, indicating that the difference in 
proliferation of CD4+ T cells from WT and Cd59a_/_ mice is 
due to expression of CD59a on the T cells (data shown). Incor­
poration of GPI-anchored CD59a into CD4+ T cells from 
Cd59a_/_ mice (Fig. 4D) caused a reduction in proliferation to 
levels the same as cells from WT mice (Fig. 45). Together, these
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FIGURE 4. In vitro proliferation assays. Purified CD4+ or CD8+ T cells 
(>90%) were CFSE labeled and incubated with anti-CD3 mAb and APCs (A 
and B) or anti-CD28 mAb (C). Calculation of  the number of mitotic events was 
performed as described previously (22). One representative result of at least 
three independent experiments is shown. Values indicating mitotic events are 
the means of three experiments ±  SD. To confirm that lack of CD59a expres­
sion was responsible for enhanced proliferation of T cells from Cd59a- / ~ mice, 
lymphocytes were incubated with GPI-anchored CD59a (CD59a-GPI) before 
the proliferation assay (E). Incorporation of CD59a-GPI on CD4~ T cells was 
confirmed by immunostaining (D). Values shown represent the mean ±  SD. 
The experiment was performed on three separate occasions. Statistical analysis 
was performed by the Student’s t test.
data imply that CD59a down-modulates CD4+ T cell prolif­
eration and requires the presence of APCs to exert this effect. It 
is possible that CD59a engages with a ligand on the APC or, 
alternatively, a soluble factor produced by the APC. To test the 
possibility that C activation and formation of the membrane 
attack complex mediates CD59a modulation of T cell activity, 
CD4+ T cells purified from both WT and Cd59a-/_  mice
were stimulated with CD3-specific mAb and APCs in the pres­
ence and absence of a soluble'inhibitor of C (sCRl). sCRl 
blocks activation of the classical and alternative pathways of C 
by binding C3b and C4b and mediating proteolytic degrada­
tion of these molecules (19). Inhibition of C in vitro did not 
affect the proliferative response of Cd59a“ /_ T cells, indicating 
that the enhanced proliferation was C independent (Fig. 5A). 
To determine whether this was also true in vivo, mice infected 
with rW G P received injections daily with sCRl, a treatment 
that efficiently inhibited C throughout the course of the exper­
iment. gp-specific CD4+ T cell responses were measured 9 days 
after infection, and no difference was observed in virus-specific 
proliferative responses induced in the presence or absence of C 
inhibition (Fig. 5B). To confirm this result, Cd59a_/~ mice 
were intercrossed with C3_/~ mice and then infected with 
rW G P. Virus-specific CD4 1 T cell responses were enhanced 
equally in Cd59a-/_  and Cd59a_/~C3“ /_ mice compared 
with WT and C3 1 mice (Fig. 5 Q. These data demonstrate 
that the enhanced proliferation of Cd59a_/_ CD4+ T cells is C 
independent and contrast with a recent report for the C regu­
lator CD55 (15). Enhanced CD4+ proliferative responses ob­
served in CD55-deficient mice were largely, although not ex­
clusively, C dependent.
In summary, this report identifies a role for the GPI-an­
chored C regulator CD59a in negative modulation of T cell 
activity in vivo. Due to the GPI anchor, CD59a is sequestered 
in membrane microdomains, which serve as platforms for Ag 
receptor signaling complexes in lymphocytes. CD59a may in­
fluence the rearrangement of lipid rafts after APC/CD4+ T cell 
association. T  cell activation induces a rapid compartmentaliza- 
tion of signaling machinery into lipid rafts. Costimulatory mol­
ecules are important for this redistribution (20), and it is pos­
sible that the presence of CD59a within rafts result in 
recruitment of different raft-associated kinases leading to mod­
ulation of T cell activity. No difference was found with 
CD8 f cells, possibly due to differences in lipid raft composition 
between CD4+ and CD8+ cells (21).
Further analyses of Cd59a- /  mice are required to provide 
insight into the precise nature of the molecular events underly­
ing the effect of CD59a on T cell activity. Such an understand­
ing will reveal pathways through which CD59a and its human
FIGURE 5- Role of C in CD4+ T  cell proliferation. C 
was inhibited in vitro in assays where CD4+ T  cells were 
stimulated with CD3-specific mAb and APCs {A). Data are 
representative of two experiments, and values are shown as 
mean ± SD. C was inhibited in vivo by administration of 
sCRl to mice for the first 9 days of infection with rW G P  
(B). In vivo experiments were repeated with Cd59a_/~ 
C3~/_ mice (C). Mice were individually analyzed, and the 
values shown indicate the mean ± SEM (« =  3 mice/ 
group). The results were analyzed statistically by the Stu­
dent’s t test.
g 2000 
2
£  1000j
■ ■ C d 5 9a '
!§§§ WT 
I p=0 005 p=0 005
antiCD3 antiC D3/sCR'
B
p=0 02 p=0 018
60000
r :  ■
IC d 5 9 ' 50 01
30 OC P=0.04
■iC d59a-'
® W T
■ IC d 5 9 a /-C3-/-
ES C 3A
7102 MODULATION OF T CELL ACTIVITY BY CD59
analog may be exploited for therapeutic approaches designed to 
either up-regulate beneficial T  cell responses or down-modulate 
those that are harmful.
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Holding T cells in check -  a new role 
for complement regulators?
M. Paula Longhi, Claire L. Harris, B. Paul Morgan and Awen Gallimore
M edical Biochem istry and Im m unology, Henry W ellcom e Building, Cardiff University, Heath Park, Cardiff, UK, CF14 4XN
Com plement is not only part of the innate immune 
system , but has also been im plicated in adaptive  
im munity. The role of complement and its regulatory 
proteins in modulating T cell activity has been the focus 
of several recent studies. These, which have included 
w ork on the membrane co-factor protein (MCP or CD46), 
decay accelerating factor (DAF or CD55) and CD59, 
indicate that complement regulators can influence the 
proliferative capacity of T cells and their ability to  
produce cytokines, influencing the outcome of a T cell 
response to  a given antigen. Here w e review these 
studies, which reveal another im portant link between 
the innate and the adaptive im mune system.
Regulation of complement
Complement (C) has long been considered an arm of the 
innate immune system, as it is activated immediately in 
the presence of pathogen and provides a rapid and efficient 
means for opsonising or killing pathogens and triggering 
inflammation. As far back as the 1970s, however, there 
were indicators that C might have a role in adaptive 
immunity, particularly in the humoral immune response 
(reviewed in [1]). C activation is triggered via either the 
alternative pathway, which ticks over constantly in 
plasma providing an immediate means of defence against 
pathogens, or the classical pathway, triggered by binding 
of Cl to antibody or of mannan-binding lectin (MBL) to 
bacterial carbohydrate moieties (Box 1). Products of 
activation include the pro-inflammatory fragments C3a 
and C5a, which recruit leukocytes to sites of infection and 
activate these and other cells, and the opsonic fragments 
C3b and C4b, which label targets for elimination by 
phagocytes. All routes of activation culminate in the 
formation of a lytic transmembrane pore, the membrane 
attack complex (MAC). The C system is in a constant state 
of low-level tick-over activation, poised to amplify on 
targets and pepper adjacent innocent bystander cells with 
C fragments and complexes. To survive this potent threat, 
an armoury of regulatory proteins has evolved that protect 
self cells from damage by homologous C. Some of these C 
regulators (CRegs) are soluble, plasma proteins, whereas 
others are expressed on cell membranes; the latter group 
is the subject of this review.
The activation pathways are controlled by several 
membrane CRegs that belong to the ‘regulators of C
activation’ gene family and include decay accelerating 
factor (DAF or CD55) and membrane co-factor protein 
(MCP or CD46; reviewed in [2,3]). In common with all 
members of this family, they contain a structural module 
comprising ~  60 amino acids, termed the short consensus 
repeat (SCR); the C3b-binding and functional activities of 
the proteins reside in this region [4]. CD46 and CD55 each 
contain four SCR modules (reviewed in [5]; Figure 1). On 
cell membranes, CD55 regulates C by binding to the C3 
and C5 convertases, accelerating the decay of the enzyme 
subunits (decay accelerating activity) and thereby inter­
fering with both the classical and alternative arms of the C 
cascade [(d) in Box 1] [6]. CD46 binds either C3b or C4b, 
freshly deposited or left on the membrane from decayed 
convertases, enabling a plasma serine protease, factor I 
(fl), to proteolytically cleave C3b or C4b (co-factor 
activity), preventing regeneration of the convertase 
(reviewed in [7]). In rodents, CD55 is broadly expressed 
and performs a similar CReg function [8,9]; by contrast, 
CD46 is absent from most murine tissues, expressed only 
in testis [10]. Instead, rodents have another broadly 
expressed membrane CReg, C receptor related protein-y 
(Crry) [11,12]. Crry is also built from SCR domains and 
performs the functions of both CD55 and CD46 [12,13], 
Although several proteins collaborate to regulate the 
activation pathways of C, only one membrane CReg, 
CD59, inhibits the terminal pathway [14]. CD59, a small, 
globular glycoprotein (~ 20 kDa), is broadly expressed in 
tissues in humans and rodents and associated with the 
plasma membrane through a glycosyl phosphatidyl- 
inositol (GPI) anchor [15]. CD59 blocks formation of the 
lytic MAC by binding C8 within the C5b-8 complex, 
preventing unfolding and polymerisation of the final 
component, C9 [(d) in Box 1] [16]. Here, we review novel 
roles of these Cregs in modulating adaptive 
immune responses.
Modulation of T cell activation by CRegs
CD46 and Crry
Several recent publications and reviews have highlighted 
a role for CD46 in modulating T cell activity ([17] and 
reviewed in [18-20]). Simultaneous antibody ligation of 
CD3 and CD46 triggers induction of T cells showing 
characteristics of T regulatory 1-type cells (Trl cells). 
These cells secrete large amounts of interleukin-10 (IL-10) 
and inhibit proliferation of conventional CD4+ T cells. 
Later studies revealed that CD46-induced Trl cells 
express high levels of granzyme B and perforin and canCorresponding author: Gallimore, A. (gallimoream@cardiffac.uk). 
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directly kill autologous targets [21]. Collectively, these 
observations suggest that Trl cells impinge upon other 
immune responses either through cell lysis or through 
immunosuppressive effects of IL-10. Importantly, these 
and other studies also showed that triggering with 
physiologically relevant ligand, such as C3b dimer or 
pathogen, induced the same phenotype [22,23].
As noted above, CD46 expression in rodents is 
restricted to testis and its C regulatory function is 
subsinned by the rodent-specific CReg, Crry. Like CD46, 
Crry might also influence T cell activation. Although 
studies using natural ligands to ligate Crry have not been 
performed, antibody crosslinking of Crry on murine T cells 
promotes T cell activation and the production of Th2 
cytokines [24,251.
CD55 and CD59
There are two genes for CD59 in the mouse, encoding the 
widely distributed CD59a (the homologue of human 
CD59) and the testis-restricted CD59b [26,27]. Similarly, 
two genes for CD55 have been characterised in mice 
(named Dafl and Daf2). Dafl is GPI anchored, widely 
distributed and is the human homologue of CD55, 
whereas Daf2 is transmembrane anchored and is 
expressed only in testis and spleen [28,29]. Mice deficient 
in Dafl or CD59a have been engineered and used to 
examine the influence of these proteins on T cell activity 
in vitro and in vivo.
Deficiency of D afl on T cells increases responses 
to antigen
Two recent studies describe T cell responses in CD55- 
deficient (Do/7“ /_ ) mice. The first study by Liu et al. [30] 
showed that recall responses measured using spleen cells 
from mice immunised with ovalbumin (OVA) or an MHC 
class II restricted myelin oligodendrocyte glycoprotein 
(MOG)-derived peptide were more vigorous in D afl~ '~  
mice than in controls. T cells from the Dafl~*~ mice 
produced more interferon y (IFNy) and IL-2 upon antigen 
re-stimulation than their wild-type counterparts, whereas 
production of the immunosuppressive cytokine IL-10 was 
reduced. This hyper-responsiveness of T cells from the
Box 1. C activation and regulation
C is activated via two pathways. The alternative pathway (Figure la, see 
next page) ticks over spontaneously in plasma (left), generating C3b-like 
molecules or C3b that can deposit on cell membranes. Membrane- 
bound C3b binds factor B (fB), which is cleaved and activated by factor D 
(fD) to form the C3 convertase (cleaving enzyme), C3bBb. This enzyme 
cleaves multiple molecules of C3 to C3b, which deposit on the 
membrane and form fresh C3 convertase enzymes or associate with 
the initiating enzyme to form C3bBbC3b, the C5 convertase. The C5 
convertase cleaves multiple molecules of C5 to C5a and C5b, initiating 
the terminal pathway. The classical pathway (Figure lb) is activated by 
antibody. The first component of the classical pathway. C1, binds 
antibody and becomes activated, leading to cleavage of C4 and 
deposition of C4b on the membrane. C2 associates with C4b and is 
cleaved and activated by C1 to form the C3 convertase, C4b2a. As with
the alternative pathway, multiple molecules ofC3b are cleaved and these
associate with C4b2a to form the C5 convertase, C4b2a3b. The lectin 
pathway is identical to the classical pathway except that it is initiated by 
m annan-binding lectin (MBL) binding to carbohydrate moieties. 
Enzymes associated with MBL (MBL-associated serine proteases;
D afl~ , ~ mice was due to lack of CD55 on the T cells 
themselves because antigen presenting cells (APCs) 
purified from D a f l mice stimulated Tcells to produce 
IFNy to the same degree as those purified from Dafl+ / + 
mice. The more vigorous response observed in Dafl~ '~  T 
cells was not due to a global increase in sensitivity of T 
cells to antigen stimulation because no difference was 
observed in the response of Dafl and D afl+ /+ T cells 
to stimulation with superantigen. A key finding was that 
the enhanced production of IL-2 and IFNy by Dafl ~ / ~ T 
cells after re-stimulation with antigen was largely 
dependent upon a functional C system because the effect 
was lost when D afl~ '~  mice were backcrossed onto C3- 
deficient (C3~/ ~) mice in which C activity is abolished. A 
residual, C-independent effect of Dafl deficiency on T cell 
function was suggested by the observation that T cell 
responses were more vigorous in C3~/ ~Dafl~/ ~ mice 
than in C3~'~Dafl + ,+ mice. The C-independent effect 
was minor and unlikely to be of physiological relevance, as 
shown by studies in a T cell-driven experimental 
autoimmune encephalomyelitis model. Here disease was 
exacerbated in D a f l mice, but not in Dafl ' C3 1 
mice. Importantly, the increased T cell activity upon 
antigen re-stimulation in vitro was lost in D afl~ '~  mice 
after neutralisation of C5 in vivo. This finding implies that 
C products downstream of C5, that is, the anaphylatoxin 
C5a or the MAC, are responsible for the observed 
phenotype in D a f l mice.
Heeger et al. [31] independently reported similar 
findings in a different line of D afl~ '~  mice. In this 
study, the authors observed that D afl~ '~  spleen cells 
proliferated more vigorously following in vitro stimulation 
with allogeneic cells. In addition, more D afl~ '~  spleen 
cells from female mice immunised with the male antigen 
(HYDby) produced IFNy upon restimulation in vitro than 
in controls. D afl~ / ~ female mice also rejected male skin 
grafts more efficiently than controls and had more HY- 
specific T cell activity in IFNy ELISpot assays.
Although results described in these two studies are 
superficially similar and support a role for Dafl in 
modulating T cell response, there are important 
differences. Liu et al. [30] reported that D afl~ /_ and
MASPs) then cleave C4 and C2 in a manner similar to C1. The activation 
pathways converge at the point of C5 cleavage (Figure Ic). C5b remains 
associated with the C5 convertase, where it binds C6 and C7. The C5b67 
complex releases from the convertase and binds loosely to the 
membrane; it rapidly binds C8, forming the C5b678 complex. C9 binds 
to this complex and polymerises to form a lytic pore, termed the 
membrane attack complex (MAC). Regulation of the activation and 
terminal pathways is brought about through the actions of the 
membrane associated CReg: CD55, CD46 and CD59 (Figure Id). CD55 
has decay accelerating activity and acts by binding the C3 and C5 
convertases of all activation pathways (the alternative pathway C3 
convertase is illustrated here). Binding of CD55 accelerates the decay of 
the enzyme by promoting the release of the enzyme subunit Bb or C2a. 
By dissociating the enzymes CD55 prevents amplification of the cascade 
by further C3 cleavage and enzyme formation. CD46has cofactor activity: 
it binds C3b or C4b following decay of the convertase and enables a 
plasma serine protease, factor I (fl), to cleave and inactivate the protein. 
CD59 regulates the terminal pathway by binding the C5b678 complex, 
preventing correct C9 polymerisation and pore formation.
www.sciencedirect.com
Review TRENDS in Immunology Vol.xx No.xx Monthxxxx
(a) Q& O
f i g  O  < g  < s >  /
f i g -
C3 convertase
C3a C3bB C3bBb C3bBbC3b
(b) ©
Activated C1 
(classical pathway)
Antibody
C4a&
C3a
Oh ©
C4b2a
©  
CD
C4b2a3b
o % C5a
(c)
MAC
(d )
Bb (inactive)
C3 convertase 
(e.g. C3bBb)
C3b
CD46CD55
C3f
(7
(Box 1) Rgure I.
iC3b
(inactive) C5b678 C9
\
CD59
TRENDS in Immunology
control APCs pulsed with OVA or MOG peptide 
stimulated T cells with equal efficiency and concluded
that enhanced T cell proliferation in the Dafl mice 
was exclusively a result of CD55 deficiency on the T
cells. By contrast, Heeger et al. [31] showed that the 
response of HY antigen-specific D afl+/+ T cells to 
D a fl~ '~  APCs was greater than that to control 
APCs. HY-specific transgenic T cells also proliferated
www.sciencedirect.com
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Figure 1. Structure of CRegs. CD46, CD55 and Crry are all composed of a structural 
module termed the short consensus repeat (SCR), which are linked 'end-to-end' in 
the molecule resulting in the elongated structures shown. Crry is only present in 
rodents and is formed from five SCR domains in mice (shown here) and six or seven 
SCR dom ains in rat. All molecules contain variable am ounts of N-linked 
carbohydrate (light grey). Both CD55 and CD46 have membrane-proximal regions 
rich in serine/threonine residues that are heavily O-glycosylated (dark grey). CD59 is 
a small highly glycosylated molecule and, like CD55, is attached to the membrane 
via a GPI anchor.
more vigorously after transfer into male Dafl~'~  mice 
compared with controls. These observations indicate a 
role for Dafl on both partners in the interaction. A 
possible explanation for the disparity is that in the first 
study [30] the T cells had already been primed in vivo, 
whereas in the second [31] the T cells were naive to the 
triggering antigen. It is possible that the well known 
differences in activation requirements for secondary 
versus primary T cell responses overcome the influence 
of CD55 expression on APCs.
Is increased C activation the cause of T cell activation 
in D a f ~ / ~  mice?
Liu et al. [30] showed that the effects of Dafl deficiency on 
T cell activity are lost when C activity is removed, either 
b y backcrossing to C3~/ ~ mice or by inhibition of C5. 
Heeger et al. [31] reported similar findings, although in 
these experiments, neutralisation of C5 only partially 
abrogated the effect of Dafl deficiency. They also showed 
that T cell responses were partially normalized in 
Dafl- 1 - Factor D ~ , ~ mice, thereby implicating the 
alternative C pathway.
Taken together, a model begins to emerge from these 
studies in which C activation has a central role. C 
components, generated locally either by APCs or T cells, 
form a functional alternative pathway that activates C, 
generating opsonic and chemotactic fragments and other 
active products. In the presence of Dafl, amplification on 
T cells is restricted; when Dafl is missing, however, 
amplification proceeds with more deposition of C3b, more 
stimulation by C5a and more triggering by MAC 
(Figure 2a,b). Although other CRegs such as Crry and 
CD59 are present on these cells, it is known that co­
ordinated actions of multiple CRegs are required for 
efficient C regulation [32,33]; for example, deletion of 
CD59a in the mouse is sufficient to cause in vivo 
haemolysis [34].
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Figure 2. Interaction of C activation products with T cells and APC. (a) C ticks over 
spontaneously in plasma resulting in low level production of C3b. In wild-type 
animals, in which expression of CRegs is normal, levels of active complement are 
low and tick-over amplification is kept in check. The source of C is primarily from 
plasma. At sites of infection or inflammation (illustrated here) activation of the C 
cascade and production of active mediators is increased. These products (C3b, C3a, 
C5b, C5a and MAC) might have stimulatory effects on both APCs and T cells, 
resulting in enhanced T cell activation and proliferation (red arrow). Local C 
biosynthesis also occurs following APC/T cell interaction and contributes to the 
pool of C. Solid black arrows indicate cleavage events and/or progression of the C 
cascade; dashed black arrows indicate putative binding of activation products to 
receptors (only C3b, C3b, C5a and MAC are shown here), (b) When C regulation is 
deficient, for example in the Daf1~y~ mouse, C tick over is more efficient there is 
enhanced cleavage of C3 to C3b, particularly at sites of inflammation or infection, 
and C amplifies more readily on cell membranes. This results in C3b deposition and 
production of downstream C activation products. Following APC-T cell interaction, 
local C biosynthesis further contributes to the pool of C. Enhanced C activation, 
production of active mediators and subsequent cell stimulation occurs in the 
absence of CD55 resulting in the hyper-responsive phenotype seen in the Daf1~ '~  
mice. This phenotype is absent in C-deficient (C3, fD) animals or can be reversed in 
C-sufficient animals by blocking activation products (which are in red) using 
antibodies.
Key to the model is the observation that APCs and T 
cells involved in cognate interactions synthesize the 
alternative pathway C components C3, IB and fD [31]. 
The model is analogous to that proposed for adipose tissue 
where local production of alternative pathway C com­
ponents and local C activation is a physiological drive to 
lipid turnover [35]. The nature of the C activation 
products driving T cell activation is still a matter for 
conjecture. The observed inhibition by blocking C5
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implicates C5a and/or MAC. C5a, a potent anaphylatoxin, 
promotes and perpetuates inflammatory reactions by 
facilitating chemotaxis of neutrophils, eosinophils, mono­
cytes, macrophages and lymphocytes, and by inducing 
mast cells, neutrophils and macrophages to release 
inflammatory cytokines such as IL-12, TNFa and EL-6 
(reviewed in [361). C5a might therefore indirectly influ­
ence T cell function through promotion of inflammation 
and creation of a favourable environment for activation of 
antigen-specific T cells. Human T cells, however, express 
receptors for C5a and direct effects of C5a on T cell 
activation have been described [37]. It is not clear whether 
murine T cells express the C5a receptor, although virus- 
specific T cell responses are impaired in mice treated with 
a peptide antagonist of the C5a receptor [38].
MAC-induced cell activation has also been described in 
T cell lines. The relative contributions of C5a and MAC to 
the observed events should now be dissected using 
available inhibitors. Neutralisation of C5 did not com­
pletely abrogate the effect of Dafl deficiency in some of the 
experiments described above, and it is possible that C3a 
and/or C3b might play a role (Figure 2a,b). C3a (as well as 
C5a) stimulates proliferation of hepatocytes and promotes 
regeneration of damaged liver [39]. As activated T cells 
express the C3a receptor, a similar mechanism might be 
employed for stimulation of lymphocytes [40]. Kerekes 
et al. [41] showed that deposition of C3b on APCs 
facilitates T cell proliferation through improving cell-to- 
cell contact between APC and cognate T cell. Although T 
cells express a variety of C3 receptors, including the C3b 
receptor, CR1, a systematic study of the effects of C 
fragments on T cell activity has not yet been performed 
(reviewed in [42]). Dissection of these effects will help 
elucidate the extent to which C and C-regulators modify T 
cell responses in vivo.
Also worthy of consideration is the possibility that a 
C-independent component might contribute to the hyper­
activity of Dafl T cells because C3-deficient Dafl ~
T cells showed enhanced responses to recall antigens
compared with those purified from C3~‘~ mice [30]. One 
known non-C ligand for CD55 is CD97, a transmembrane 
(TM) protein, member of the epidermal growth factor 
(EGF)-TM7 family. It is constitutively expressed on 
granulocytes, monocytes and dendritic cells and is rapidly 
upregulated in lymphocytes upon activation. Heeger et al. 
[31], however, found no effect of antibody blocking of CD97 
on modulation of T cell responses.
Deficiency of CD59a enhances T cell activity in mice
T cell function has recently been examined in mice lacking 
CD59a (CD59a~/ ~) [43]. Virus specific T cell responses 
were measured in CD59a~' ~ mice and compared with 
those in control mice. Specifically, mice were infected with 
a recombinant vaccinia virus (rW ) expressing the 
glycoprotein (GP) of lymphocytic choriomeningitis virus 
(LCMV) and virus-specific CD4+ and CD8+ T cell 
responses were measured at various time points. Virus- 
specific CD4+ but not CD8+ Tcell responses were greater 
in CD59a~/ ~ mice than in controls. Higher numbers of 
lymphocytes were present at the main site of infection 
(ovaries) in CD59a~/ ~ mice and the infection was 
controlled more efficiently than in controls. Assays 
performed in vitro confirmed that CD4+ T cells lacking 
CD59a proliferated more vigorously in response to 
stimulation with CD3 specific antibodies and APCs. No 
difference was observed in proliferation when the T cells 
were stimulated with CD3- and CD28-specific antibodies 
indicating that APCs were required to trigger enhanced 
proliferation in C D 5 9 a T cells.
These data imply that CD59a on T cells engages a 
ligand on APCs, the effect of which is to down-modulate T 
cell activity. The down-modulation might occur directly 
through inducing a negative signal in the T cell or 
transmitting a negative signal via effects on the APC 
(Figure 3a,b), or indirectly by interfering with the 
recruitment of Src family kinases during T cell activation 
thereby reducing the strength of the positive signal 
delivered to the T cells (Figure 3c). In marked contrast
(a) CD59 delivers a negative signal 
directly to the T cell
T c e ll
Peptide
CD59
ligandMHC
APC
CD59
(b) CD59 delivers a negative 
signal to the APC
(c) CD59 ligation reduces strength of 
positive signal delivered through TCR
©
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Figure 3. Effects of CD59 on T-cell-APC interactions. Direct interaction between CD59 (or CD55) on the T cell and a specific receptor on the APC results in an inhibitory signal 
being transmitted (a) to the T cell or (b) to the APC, resulting in down-modulation of APC activity and consequently T cell activity, (c) Alternatively, engagement of CD59 on T 
cells might reduce the strength of the positive signal delivered through the T cell receptor (TCR).
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to the findings in Dafl ~ ' ~ mice, the effect of CD59a 
deficiency on CD4^ T cell proliferation was C indepen­
dent. Neither inhibition of C using soluble complement 
receptor type 1 (sCRl) nor removal of C by backcrossing 
onto C3- /_  mice reversed the effect of CD59a deficiency on 
C D 4' T cell proliferation in vitro or in vivo. These 
experiments effectively eliminate the possibility that a C 
component ligates CD59a on T cells to mediate the down- 
modulatory effect.
Concluding rem arks
The observations described here imply that CRegs, some­
times in collaboration with the C system, have key roles in 
regulating the adaptive immune system. It is notable that 
these CRegs, which serve to downregulate activation of 
the C cascade, also have the effect of downregulating T cell 
responses through several mechanisms. Engagement of 
CD46 by C component C3b results in induction of T rl cells 
th a t suppress the activity of other T cells and represents a 
mechanism through which C actively instructs the 
im m une system  to down-modulate antigen-specific 
responses. CD55 also holds T cell responses in check, 
although this occurs through limiting the stimulatory 
effects of C on both T cells and APCs rather than by 
altering the T cell phenotype. It is noteworthy, however, 
th a t antigen-stim ulated T cells from D a f l- / ~ mice 
produced more of the immunosuppressive cytokine IL-10 
than their wild-type counterparts.
Overall, it appears that under conditions of sustained C 
activation, such as tissue injury or chronic infection with a 
pathogen, CRegs serve not only to protect against the 
destructive effects of C but also to dampen down T cell 
response to avoid immunopathology and autoimmunity. It 
would now be informative to examine whether APCs 
and/or T cells modulate expression of CRegs according to 
their activation status as a means of fine-tuning their 
responses to C activation products. CD59, and perhaps 
also CD55, modulate T cell activation by processes 
independent of C activation. The discovery of CD59- 
binding ligands is urgently needed to aid the identification 
of the mechanism by which CD59 modulates T cell activity.
With the exception of studies of CD46, all the work 
described in this review has been in rodents. Several 
groups dem onstrated in early papers th a t antibody 
crosslinking of either CD55 or CD59 on human lympho­
cytes in association with stimulation through the T cell 
receptor or with phorbol esters induced re-organization of 
the  cytoskeleton [44,45], cell proliferation [46,47], 
enhanced tyrosine phosphorylation through p56lck and 
calcium mobilisation [48,49], As antibody crosslinking of 
GPI-anchored proteins generates clusters of lipid rafts 
sequestering a range of surface proteins and signalling 
molecules that might never associate in a physiological 
antigen-ligand interaction, the relevance of these cross- 
linking experiments is questionable. Studies to determine 
how modulation of CReg expression on human T cells 
affects their activity are now needed.
The rodent studies imply that CRegs represent a target 
for m anipulation of T cell function for therapy. For 
example, tumour-specific T cells are subjected to a 
spectrum of inhibitory influences and much effort is
being devoted to identifying ways to enhance the survival 
and proliferative capacity of anti-tumour T cell responses 
before re-infusion. If findings in mice are recapitulated in 
humans then the downregulation of CRegs would rep­
resent one such strategy.
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